

Complete Abstract Listing



International Parkinson and
Movement Disorder Society

Select a poster category to jump to the listing of abstracts in that category.

Monday Poster Categories

[Clinical Trials \(1 – 151\)](#)

[Parkinsonisms \(152 – 326\)](#)

[Cognition and Psychiatric Disturbances \(327 – 574\)](#)

[Functional Movement Disorders and Drug-Induced Movement Disorders \(576 – 605\)](#)

[Epidemiology and Rating Scales \(606 – 666\)](#)

Tuesday Poster Categories

[Hyperkinetic Movement Disorders I \(676 – 863\)](#)

[Hyperkinetic Movement Disorders II \(865 – 1030\)](#)

[Genetics and Metabolic Diseases \(1031 – 1180\)](#)

[Physiology \(1181 – 1324\)](#)

Wednesday Poster Categories

[Pharmacology and Therapy \(1329 – 1511\):](#)

[Surgery, Imaging and Technology \(1512 – 1810\):](#)

[Allied Healthcare, Physical Therapy, Rehabilitation and Quality of Life/Caregiver Burden \(1813 - 1930\):](#)

[Education, Other Topics \(1931 – 1986\)](#)

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Category: Clinical Trials (1 – 151):			
Monday, August 28	13:00 - 15:00	1	Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson's disease: A phase 2a, double-blind, placebo-controlled study
Monday, August 28	13:00 - 15:00	2	A randomized, phase 2a, double-blind, placebo-controlled clinical trial with NE3107 adjunctive to carbidopa/levodopa in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	3	A multiple-dose thorough QT study to evaluate the effect of amprelosetine on cardiac repolarization in healthy subjects
Monday, August 28	13:00 - 15:00	4	Circuit-based targeting for closed-loop deep brain stimulation for Tourette Syndrome
Monday, August 28	13:00 - 15:00	5	Effects of sling exercise in people with chronic stroke - the emphasis of core muscle control on gait
Monday, August 28	13:00 - 15:00	6	Efficacy and safety of Mexiletine versus Placebo in patients with myotonia: A Systematic Review and Meta-analysis
Monday, August 28	13:00 - 15:00	7	An Analysis of Subgroups of Multiple System Atrophy Patients from Amprelosetine Phase 3 Trials
Monday, August 28	13:00 - 15:00	8	Brain-behavior quantification and synchronization to drive closed-loop deep brain stimulation
Monday, August 28	13:00 - 15:00	9	Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube
Monday, August 28	13:00 - 15:00	10	Efficacy of perampanel in paroxysmal kinesigenic dyskinesia
Monday, August 28	13:00 - 15:00	11	Continuous Subcutaneous Levodopa/Carbidopa Infusion With ND0612 For Patients With Parkinson's Disease And Motor Fluctuations: Results From The Phase 3 Randomized, Active-
Monday, August 28	13:00 - 15:00	12	KINETIC 2: An ongoing phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor
Monday, August 28	13:00 - 15:00	13	Effectiveness of at home, repeated transcranial pulse current stimulation (tPCS) sessions for treatment of neurodegenerative ataxia.
Monday, August 28	13:00 - 15:00	14	Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti- α -synuclein monoclonal antibody Lu AF82422
Monday, August 28	13:00 - 15:00	15	SpeechATAX: A rater blinded randomized controlled trial of intensive home-based biofeedback therapy for dysarthria in progressive ataxia
Monday, August 28	13:00 - 15:00	16	Effects of mirror therapy on walking ability in patients with chronic stroke: a randomized controlled study
Monday, August 28	13:00 - 15:00	17	Questionnaire for the detection of Parkinson's disease
Monday, August 28	13:00 - 15:00	18	Investigating factors contributing to clinical trial recruitment in Parkinson's Disease within the Black community
Monday, August 28	13:00 - 15:00	19	Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	20	Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Monday, August 28	13:00 - 15:00	21	Challenges with oral anti-parkinsonian medications and opportunities with continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDP/CDP) for treatment of advanced
Monday, August 28	13:00 - 15:00	22	Results from IRL790C005 - A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in
Monday, August 28	13:00 - 15:00	23	Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson's disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion
Monday, August 28	13:00 - 15:00	24	Is there impairment in neuromuscular trunk control in Parkinson disease when compared to healthy elderly?
Monday, August 28	13:00 - 15:00	25	Placebo response in Parkinson's disease (PD) is predicted by expression levels of a specific brain network
Monday, August 28	13:00 - 15:00	26	Familial Parkinson's: Epidemiological data at Blida University Hospital.
Monday, August 28	13:00 - 15:00	27	IncobotulinumtoxinA to treat sialorrhea in Parkinson's disease: a real-life study: 4-year interim results
Monday, August 28	13:00 - 15:00	28	NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
Monday, August 28	13:00 - 15:00	29	Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson's disease: summary of phase 3 and real-world studies
Monday, August 28	13:00 - 15:00	30	Psilocybin therapy for depression and anxiety associated with Parkinson's disease: a pilot study (NCT04932434)
Monday, August 28	13:00 - 15:00	31	Why Me Why Not? Understanding the Perception of Research among African Americans with PD
Monday, August 28	13:00 - 15:00	32	Proof-of-concept clinical trial: Prevent cognitive decline in GBA-associated Parkinson's Disease
Monday, August 28	13:00 - 15:00	33	A staged screening paradigm to identify people at risk of Parkinson's disease in the Parkinson's Progression Markers Initiative

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	34	Recruiting people at risk of Parkinson's disease: comparative data from PPMI Online and HeBA Kassel
Monday, August 28	13:00 - 15:00	35	Development and acceptability testing of a patient decision aid on levodopa/carbidopa intestinal gel.
Monday, August 28	13:00 - 15:00	36	The feasibility and efficacy of speech therapy via video call in patients with Parkinson's disease: a preliminary study
Monday, August 28	13:00 - 15:00	37	Access-PD - a 'next generation' registry to accelerate Parkinson's disease research
Monday, August 28	13:00 - 15:00	39	Improvement of nocturia symptoms and associated quality of life in patients with Parkinson's disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Monday, August 28	13:00 - 15:00	40	Cost-effectiveness of Lee Silverman Voice Treatment LOUD (LSVT®) versus NHS Speech and Language Therapy versus control for dysarthria in Parkinson's disease: An economic evaluation alongside the 15-year effects of initiating treatment for Parkinson's disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease
Monday, August 28	13:00 - 15:00	41	Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson's disease uncontrolled by
Monday, August 28	13:00 - 15:00	42	Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease. The AMBITIOUS Study Protocol
Monday, August 28	13:00 - 15:00	43	Parkinson's Progression Markers Initiative (PPMI) prioritizes enrollment of individuals from diverse and underrepresented populations
Monday, August 28	13:00 - 15:00	44	Timed-up-and-go tests under dual-task conditions: Influence of different tasks on gait parameters in Parkinsonian patients
Monday, August 28	13:00 - 15:00	45	Reductions in OFF time with ND0612 for patients with Parkinson's disease experiencing motor fluctuations: Responder-analysis from an open-label Phase 2 study
Monday, August 28	13:00 - 15:00	46	Safety and efficacy of P2B001 (low dose combination of extended-release pramipexole and rasagiline) in patients with early Parkinson's disease: Subgroup analyses from a randomized,
Monday, August 28	13:00 - 15:00	47	Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson's Disease
Monday, August 28	13:00 - 15:00	48	Deep Brain Stimulation in Parkinson's Disease Patients: A One Year Follow-up in the Understudied Geography of Brazil
Monday, August 28	13:00 - 15:00	49	Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease
Monday, August 28	13:00 - 15:00	50	Characterisation of OFF-Time in Levodopa-Treated Parkinson's Patients: A Post-hoc Analysis of an Exploratory Trial
Monday, August 28	13:00 - 15:00	51	Randomized, waitlist-controlled trial of Karate Intervention to Change Kinematic Outcomes in PD (KICK OUT PD)
Monday, August 28	13:00 - 15:00	52	Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson's disease patients with GBA1 mutations
Monday, August 28	13:00 - 15:00	53	Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson's Disease
Monday, August 28	13:00 - 15:00	54	Substantia Nigra blood-brain barrier opening in Parkinson's disease: PET (18F-Choline) evidence of parenchymal penetration
Monday, August 28	13:00 - 15:00	55	Connectomic DBS informed multifocal transcranial direct current stimulation (tDCS) in Parkinson's Disease: a crossover double blinded study
Monday, August 28	13:00 - 15:00	56	Experience of the LARGE-PD protocol in a health center in Buenos Aires, Argentina
Monday, August 28	13:00 - 15:00	57	Ocular microtremor in Parkinson's Disease: Protocol for an observational pilot study
Monday, August 28	13:00 - 15:00	58	Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)
Monday, August 28	13:00 - 15:00	59	Eye tracking paradigm to identify disease-specific behavioral biomarkers in neurodegeneration
Monday, August 28	13:00 - 15:00	60	Psychosocial factors impacting participation in a time-intensive deep brain stimulation study of individuals with Parkinson's disease and dystonia
Monday, August 28	13:00 - 15:00	61	Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson's Disease
Monday, August 28	13:00 - 15:00	62	How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson's disease patients: Experience from the Phase 3 clinical trial
Monday, August 28	13:00 - 15:00	63	What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Monday, August 28	13:00 - 15:00	64	Dopaminergic neuronal cell therapy for Parkinson's Disease: results from a phase 1 study of Bemdaneprocel
Monday, August 28	13:00 - 15:00	65	Chinese medicine pattern diagnostic criteria in clinical and epidemiological studies of Parkinson's disease: a systematic review
Monday, August 28	13:00 - 15:00	66	Clinic versus home dose optimization of apomorphine sublingual film in Parkinson's Disease: cross-study comparison of safety
Monday, August 28	13:00 - 15:00	67	

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	68	Early onset of efficacy during titration in US phase 3 open-label InfusON trial of apomorphine subcutaneous infusion for Parkinson's disease motor fluctuations
Monday, August 28	13:00 - 15:00	69	Agreement between Parkinson disease Home Diary and observer assessments before and after structured patient training
Monday, August 28	13:00 - 15:00	70	Apomorphine sublingual film for OFF episodes in PD: Impact on orthostatic hypotension during dose-optimization
Monday, August 28	13:00 - 15:00	71	Intercultural differences in patient and clinician perceptions of MDS-UPDRS in Parkinson's disease
Monday, August 28	13:00 - 15:00	72	Dance for Parkinson's disease to improve gait and balance: clinical assessments vs. objective measures.
Monday, August 28	13:00 - 15:00	73	Effects of Boxing and conventional physiotherapy techniques in patients with PD: A randomized control study
Monday, August 28	13:00 - 15:00	74	Safety of foslevodopa/foscarbidopa during optimization and maintenance treatment: Post hoc analysis of a phase 3, single-arm trial
Monday, August 28	13:00 - 15:00	75	Repurposing the MDS-UPDRS part III for early-stage Parkinson's disease: Supportive evidence for a bradykinesia and rigidity specific sub-score
Monday, August 28	13:00 - 15:00	76	Improvements in Parkinson's disease motor complications after treatment with opicapone: results from the OPTI-ON study
Monday, August 28	13:00 - 15:00	77	Trial protocol: Randomized double blind controlled study to investigate disease modifying effect, safety and optimal dose of oral semaglutide tablet for patients with Parkinson's disease (MOST-ABLE)
Monday, August 28	13:00 - 15:00	78	In silico electrophysiology study reveals the modulating role of calcium channel on Subthalamic nucleus neuronal cells towards Parkinson's disease
Monday, August 28	13:00 - 15:00	79	Recruiting for Parkinson's disease risk: Successful engagement tactics to screen for hyposmia in undiagnosed individuals
Monday, August 28	13:00 - 15:00	80	Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson's Disease
Monday, August 28	13:00 - 15:00	81	Recruitment of Parkinson's disease patients with mild-to-moderate anxiety into a randomized controlled trial: Experience of a large Canadian tertiary movement disorders clinic
Monday, August 28	13:00 - 15:00	82	Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial
Monday, August 28	13:00 - 15:00	83	User Experience (UX): Successful Remote Engagement Strategy for Individuals at Risk for Parkinson's Disease in PPMI
Monday, August 28	13:00 - 15:00	84	Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson's disease: a multicentre randomised controlled trial
Monday, August 28	13:00 - 15:00	85	Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b
Monday, August 28	13:00 - 15:00	86	Using mediation analysis to account for the effect of Parkinson's Disease medications on disease progression
Monday, August 28	13:00 - 15:00	87	What do people with parkinsonism consider important and want to achieve?
Monday, August 28	13:00 - 15:00	89	Design of a time-to-event study in GBA Parkinson's Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase)
Monday, August 28	13:00 - 15:00	90	Arm swing deviations in patients with PD at different gait velocities
Monday, August 28	13:00 - 15:00	91	Long-term effects of a mobile technology-based brisk walking program on Parkinsonian symptoms in Parkinson's disease—a randomized controlled trial
Monday, August 28	13:00 - 15:00	92	Practice and outcome variation across Parkinson's Foundation Centers of Excellence
Monday, August 28	13:00 - 15:00	93	Parkinson's Progression Markers Initiative (PPMI): Defining PD biology to accelerate PD therapeutics
Monday, August 28	13:00 - 15:00	94	Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson's disease (PD): the LIXIPARK trial (NCT03439943)
Monday, August 28	13:00 - 15:00	95	iCARE-PD: a multinational multicenter feasibility study of Integrated Care Networks in Parkinson disease
Monday, August 28	13:00 - 15:00	96	Does baseline expectation of benefit predict outcome in SURE-PD3, a Randomized, Double-Blind, Placebo-Controlled, Phase III trial of Inosine in Parkinson's disease?
Monday, August 28	13:00 - 15:00	97	Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson's: The EJS ACT-PD Initiative
Monday, August 28	13:00 - 15:00	99	Dopamine transporter in the brain is linked to irritable bowel syndrome in Parkinson's disease
Monday, August 28	13:00 - 15:00	100	Long term effects of Deep Brain Stimulation on Camptocormia in Parkinson's disease
Monday, August 28	13:00 - 15:00	101	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA): Rationale, Design, and Baseline Data
Monday, August 28	13:00 - 15:00	102	Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	103	Istradefylline effect on Parkinson's Disease Tremor, Motor symptoms and non-Motor symptoms.
Monday, August 28	13:00 - 15:00	104	PASADENA 1-year open-label extension
Monday, August 28	13:00 - 15:00	105	Stability and predictability of motor symptom control in patients with advanced Parkinson's disease (aPD) receiving continuous subcutaneous foslevodopa/foscarbidopa (LDP/CDP)
Monday, August 28	13:00 - 15:00	106	A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson's disease dementia.
Monday, August 28	13:00 - 15:00	107	The PD-Ballet study: a randomised controlled, single-blinded trial of dance therapy for Parkinson's, baseline characteristics of the study cohort
Monday, August 28	13:00 - 15:00	108	Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson's disease: Three-year data from the open-label BeyoND study
Monday, August 28	13:00 - 15:00	109	Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial
Monday, August 28	13:00 - 15:00	110	Correlation between oculometric measures, disease severity, and clinical assessment in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	111	Trial site factor in Parkinson's disease (PD) diary non-compliance
Monday, August 28	13:00 - 15:00	112	Effect of dietary caffeine on brain dopamine transporter binding in Parkinson's disease
Monday, August 28	13:00 - 15:00	113	The effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson's disease patients; a randomized double-blinded placebo-controlled clinical trial
Monday, August 28	13:00 - 15:00	114	Zonisamide in advanced Parkinson's disease: a randomized placebo-controlled study in Egyptian population
Monday, August 28	13:00 - 15:00	115	Long-term evolution of advanced Parkinson's disease burden: second interim results from the international PROSPECT observational study
Monday, August 28	13:00 - 15:00	116	Validity and Reliability of the Turkish Version of the Radboud Oral Motor Inventory for Parkinson's Disease (ROMP)
Monday, August 28	13:00 - 15:00	117	Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson's disease: Phase IIa double-blind, randomized
Monday, August 28	13:00 - 15:00	118	Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	119	Enhancement of deep sleep in people with Parkinson disease using auditory stimulation of slow waves at home
Monday, August 28	13:00 - 15:00	120	Development and Validation of an Algorithm to Automatically Assess Motor Symptoms of Parkinson's Disease
Monday, August 28	13:00 - 15:00	121	Digital gait and turning impairments (quality but not quantity) during daily life are more severe in retrospective fallers compared to non-fallers with Parkinson's disease
Monday, August 28	13:00 - 15:00	122	Effect of Recognition of Vertical Posture on Forward Bending Posture in Patients with Parkinson's Disease: A Multicenter Observational Study
Monday, August 28	13:00 - 15:00	123	Path To Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson's Disease: Study Design
Monday, August 28	13:00 - 15:00	124	Foslevodopa/foscarbidopa in patients with advanced Parkinson's disease: subgroup analyses from a phase 3, randomized study
Monday, August 28	13:00 - 15:00	125	Effects on voice sound level and brain connectivity after HiCommunication: a novel speech and communication treatment for Parkinson's disease
Monday, August 28	13:00 - 15:00	126	STRAT-PARK: a biomarker and stratification initiative for Parkinson's disease
Monday, August 28	13:00 - 15:00	128	The impact of biographic factors and lifestyle on the symptoms of Parkinson's Disease – a five year follow-up
Monday, August 28	13:00 - 15:00	129	Rasagiline in Chinese patients with early-stage parkinson's disease: a randomized, double-blind, placebo-controlled, delayed-start trial
Monday, August 28	13:00 - 15:00	130	Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson's disease: Phase IIa double-blind,
Monday, August 28	13:00 - 15:00	131	Preliminary Report on Neuromelanin-Sensitive MRI Signal change after Allogeneic Bone marrow-derived Mesenchymal Stem Cells therapy: Phase IIa double-blind, randomized controlled trial
Monday, August 28	13:00 - 15:00	133	Online recruitment and retention in the Parkinson's Progression Markers Initiative (PPMI)
Monday, August 28	13:00 - 15:00	134	Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson's Disease and Movement Disorders Clinic
Monday, August 28	13:00 - 15:00	135	Operationalising goal setting as an outcome measure: Experience from the PRIME-UK randomised controlled trial
Monday, August 28	13:00 - 15:00	136	Why is HAL effective in improving gait and balance function in Parkinson's disease?
Monday, August 28	13:00 - 15:00	137	Impact of istradefylline on the onset of dyskinesia in Parkinson's Disease patients with wearing off: a randomized controlled study (ODYSSEI)

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	138	The effect of lumboperitoneal shunt surgery on patients with iNPH plus Parkinson's disease
Monday, August 28	13:00 - 15:00	139	Characterizing advanced Parkinson's disease: OBSERVE-PD observational study - results of the Belgian subgroup
Monday, August 28	13:00 - 15:00	140	ParkProReakt Study Protocol - A randomized controlled trial to evaluate a proactive approach to health care in Parkinson's disease
Monday, August 28	13:00 - 15:00	141	Randomized Controlled Trial comparing continuous intrajejunal levodopa infusion and deep brain stimulation for Parkinson's disease. Cost-effectiveness and cost-utility outcomes of the INVEST study
Monday, August 28	13:00 - 15:00	142	Exploring the Effects of Spinal Cord Stimulation for Gait Disturbances in Parkinson's Disease
Monday, August 28	13:00 - 15:00	143	A pilot, randomized, placebo controlled, double-blinded, delayed start trial of Modafinil for the treatment of Freezing of Gait in Parkinson's disease.
Monday, August 28	13:00 - 15:00	144	Montelukast as disease modifying treatment for Parkinson's disease: a pilot study.
Monday, August 28	13:00 - 15:00	145	Video-Based Motor Function Assessment by Professional Raters or by Software in Patients with Parkinson's Disease
Monday, August 28	13:00 - 15:00	146	Exploring the complementary approach of a standardized osteopathic treatment protocol on sleep quality in Parkinson's disease: A randomized controlled study
Monday, August 28	13:00 - 15:00	147	Impact of the severity of Parkinson's disease on skin elasticity
Monday, August 28	13:00 - 15:00	148	Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson's disease patients with wearing-off: a multicenter,
Monday, August 28	13:00 - 15:00	149	Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson's disease: interim analysis of a pilot add-on, randomized, controlled, pragmatic clinical
Monday, August 28	13:00 - 15:00	150	Chinese proprietary medicine as adjunct treatment for Parkinson's disease: a systematic review and meta-analysis
Monday, August 28	13:00 - 15:00	151	Unsupervised physical capacity testing at home: a systematic review
Category: Parkinsonisms (152 – 326)			
Monday, August 28	13:00 - 15:00	152	Expression profile of circRNA in peripheral blood mononuclear cells of patients with Parkinson's disease and atypical parkinsonian syndromes
Monday, August 28	13:00 - 15:00	153	Exosomal α -synuclein in Multiple system atrophy and parkinson's disease cause distinct synucleinopathies
Monday, August 28	13:00 - 15:00	154	In vivo proteomic investigation of deeply phenotyped parkinsonian syndromes for biomarkers of differential diagnosis
Monday, August 28	13:00 - 15:00	155	Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Monday, August 28	13:00 - 15:00	156	Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson's disease, THE YAMSA TRIAL
Monday, August 28	13:00 - 15:00	157	Pain in people with multiple system atrophy
Monday, August 28	13:00 - 15:00	158	LRRK2 G2019S mutation in Multiple System Atrophy, a case report
Monday, August 28	13:00 - 15:00	159	Blood NfL can track progression in multiple system atrophy
Monday, August 28	13:00 - 15:00	160	The pivotal difference in gut microbiota between multiple system atrophy and Parkinson's disease
Monday, August 28	13:00 - 15:00	161	Contribution of MRI and machine learning approaches to the diagnosis of patients with early-stage parkinsonism in a situation of clinical uncertainty
Monday, August 28	13:00 - 15:00	162	A multimodal approach for diagnosis of early Multiple System Atrophy (MSA)
Monday, August 28	13:00 - 15:00	163	An in-vivo study of regional synaptic density loss in patients with Multiple System Atrophy using [11C]UCB-J PET molecular imaging.
Monday, August 28	13:00 - 15:00	164	Natural history and disease progression biomarkers of multiple system atrophy: the ASPIRE-MSA study
Monday, August 28	13:00 - 15:00	165	UMSARS versus laryngoscopy-based assessment of dysphagia
Monday, August 28	13:00 - 15:00	166	Data-driven subtypes of multiple system atrophy and the implication on prognosis
Monday, August 28	13:00 - 15:00	167	Laryngeal clinical biomarkers in atypical Parkinsonism - results from an international multicenter study
Monday, August 28	13:00 - 15:00	168	Blood Pressure Monitoring in Multiple System Atrophy: Focused on Nocturnal Dipping Pattern
Monday, August 28	13:00 - 15:00	169	Prevalence of multiple system atrophy in Europe: literature review

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	170	Next-generation sequencing analysis of circulating microRNAs in multiple system atrophy
Monday, August 28	13:00 - 15:00	171	Short-term effect of continuous positive airway pressure in MSA patients with sleep disordered breathing
Monday, August 28	13:00 - 15:00	172	Brain metabolism associated with clinical feature in patients with multiple system atrophy
Monday, August 28	13:00 - 15:00	173	Evaluation of structural brain stem measurements for the differential diagnosis of MSA and IPD
Monday, August 28	13:00 - 15:00	174	The pivotal role of dual tracer (FDG + DOPA) PET MRI brain for diagnosis of MSA-C.
Monday, August 28	13:00 - 15:00	176	Autonomic dysfunction in the early stages of atypical Parkinsonism would have the first approach in the diagnosis: A report of fifteen cases in the Mexican population.
Monday, August 28	13:00 - 15:00	177	Disease progression in multiple system atrophy: the value of clinical cohorts with long follow-up
Monday, August 28	13:00 - 15:00	178	The diagnostic utility of the new MDS criteria for multiple system atrophy: a retrospective autopsy cohort study
Monday, August 28	13:00 - 15:00	179	Gender-specific differences of gait in parkinsonian syndromes
Monday, August 28	13:00 - 15:00	180	Investigation of usefulness of new MSA diagnostic criteria
Monday, August 28	13:00 - 15:00	181	Preliminary evidence for evolution of myoinositol and N-acetylaspartate as biomarkers of disease severity in early-stage multiple system atrophy
Monday, August 28	13:00 - 15:00	182	Use of levodopa-carbidopa intestinal gel to treat a patient with multiple system atrophy (MSA)
Monday, August 28	13:00 - 15:00	183	Clinical and radiological characteristics of a cohort of seventy-one Multiple System Atrophy patients
Monday, August 28	13:00 - 15:00	184	Acute laryngeal stridor in the emergency department: pandemic or additional sign?
Monday, August 28	13:00 - 15:00	185	Atypical parkinsonism syndromes: clinical presentations
Monday, August 28	13:00 - 15:00	186	An atypical presentation of Multiple System Atrophy (MSA)
Monday, August 28	13:00 - 15:00	187	A tau-directed monoclonal antibody could alter the tau pathology of progressive supranuclear palsy
Monday, August 28	13:00 - 15:00	188	Evaluation of a novel Phosphodiesterase 5 inhibitor as a potential therapeutic agent in P301S transgenic mouse model of tauopathy.
Monday, August 28	13:00 - 15:00	189	Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept
Monday, August 28	13:00 - 15:00	190	The value of volume of the subthalamic nucleus in diagnosis of progressive supranuclear palsy
Monday, August 28	13:00 - 15:00	191	Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA
Monday, August 28	13:00 - 15:00	192	TEP-PSP: preliminary results of a therapeutic education program in progressive supranuclear palsy
Monday, August 28	13:00 - 15:00	193	MRI morphometry and regional hypometabolism in the clinical predominance-types of Progressive Supranuclear Palsy
Monday, August 28	13:00 - 15:00	194	Regional Atrophy and Motor Speech in PSP
Monday, August 28	13:00 - 15:00	195	Creation of a biobank of patients with Progressive Supranuclear Palsy and Corticobasal Syndrome in Argentina
Monday, August 28	13:00 - 15:00	196	An acoustic-perceptual analysis of speech in clinical PSP phenotypes.
Monday, August 28	13:00 - 15:00	197	Localizing a brain network of progressive supranuclear palsy
Monday, August 28	13:00 - 15:00	198	Cell-specific MAPT gene expression is preserved in tau cytopathologies in Progressive Supranuclear Palsy
Monday, August 28	13:00 - 15:00	199	Clinico-pathological correlations in atypical parkinsonism
Monday, August 28	13:00 - 15:00	200	Differential effect of MAPT haplotype on survival in CBD and PSP-SCB phenotype
Monday, August 28	13:00 - 15:00	201	The Comorbidity and Comedication Profiles of Patients with Progressive Supranuclear Palsy in Two German, Multicenter Cohorts: A Systematic Cross-Sectional Analysis
Monday, August 28	13:00 - 15:00	202	Brain FDG-PET-MRI for early diagnosis of corticobasal syndrome
Monday, August 28	13:00 - 15:00	203	Amyloid status differentiates synaptic loss and atrophy in Corticobasal Syndrome.

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	204	Determinants of care partner burden in atypical parkinsonian syndromes
Monday, August 28	13:00 - 15:00	205	Topography of cholinergic vulnerability correlates of PIGD motor deficits in DLB and PSP: A [18F]-FEOBV PET study
Monday, August 28	13:00 - 15:00	206	Increased MD and decreased FA reflect cognitive impairment in PSP
Monday, August 28	13:00 - 15:00	207	Beyond Parkinson's disease and synucleinopathies: unexpected identification of prodromal corticobasal syndrome by the updated MDS research criteria for prodromal PD
Monday, August 28	13:00 - 15:00	208	Subjective cognitive complaints in patients with progressive supranuclear palsy and corticobasal syndrome
Monday, August 28	13:00 - 15:00	209	The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series
Monday, August 28	13:00 - 15:00	211	18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy
Monday, August 28	13:00 - 15:00	212	18F-Florzolotau PET imaging of tau pathology in the living brain of patients with corticobasal syndrome
Monday, August 28	13:00 - 15:00	213	Cognitive Interference in Postural Control as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders.
Monday, August 28	13:00 - 15:00	214	The Prevalence of Primary Tauopathies in Ireland; a Clinically-Defined Study in the Province of Leinster: design and initial data.
Monday, August 28	13:00 - 15:00	215	A Retrospective Review of Amantadine in Progressive Supranuclear Palsy
Monday, August 28	13:00 - 15:00	217	Data-driven Clustering of Neurodegenerative diseases based on EEG Spectrum power-law decay: the DaCNES Study.
Monday, August 28	13:00 - 15:00	218	Posturography as an objective measure of disease progression and prognostication in Progressive Supranuclear Palsy
Monday, August 28	13:00 - 15:00	219	PSP registry: preliminary cross-sectional results of the first 2 years of recruitment of a multicenter registry and biorepository.
Monday, August 28	13:00 - 15:00	220	Neurofilament light chain, tau-PET and microglia-PET predict clinical progression in amyloid-negative corticobasal syndrome
Monday, August 28	13:00 - 15:00	221	The prevalence and characteristics of REM sleep behavior disorder in progressive supranuclear palsy patients.
Monday, August 28	13:00 - 15:00	222	Prognostic impact of frontal-lobe clinical bedside signs in progressive supranuclear palsy
Monday, August 28	13:00 - 15:00	223	Describing the syndrome: a comprehensive analysis of a large cohort of corticobasal syndrome with pathological correlation
Monday, August 28	13:00 - 15:00	224	Remote monitoring of physical activity in Progressive Supranuclear Palsy (PSP) using wearable sensors
Monday, August 28	13:00 - 15:00	225	Progression of the Clinical Features of Progressive Supranuclear Palsy-Richardson Syndrome in Early and Advanced Stages
Monday, August 28	13:00 - 15:00	226	Atypical progression of motor symptoms in Facio-Scapulo-Humeral Dystrophy: clinical worsening or overlap?
Monday, August 28	13:00 - 15:00	227	Creutzfeldt-Jakob Disease misdiagnosed as Corticobasal degeneration
Monday, August 28	13:00 - 15:00	228	18f-PI-2620 tau PET neuroimaging, tau protein burden and 18f-PI-2620 tau autoradiography on human postmortem brain tissue in a PSP patient
Monday, August 28	13:00 - 15:00	229	Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP) Cohort in Central New York
Monday, August 28	13:00 - 15:00	230	Progressive Supranuclear Palsy: Review On Diagnostic Aspects Based On A Case
Monday, August 28	13:00 - 15:00	231	Effects of exergaming-based tai chi and eye movement training on balance and gait in progressive supranuclear palsy: a case report
Monday, August 28	13:00 - 15:00	232	p.Gln257Profs*27 mutation in progranulin gene in a patient with corticobasal syndrome - the importance of family history
Monday, August 28	13:00 - 15:00	233	Early-onset cortico-basal degeneration (CBD) due to a c.2092G>A MAPT mutation
Monday, August 28	13:00 - 15:00	234	CBS presenting rapidly progressive anterior operculum syndrome with suggested background pathology of 4-repeat tauopathy by tau PET: A case report
Monday, August 28	13:00 - 15:00	235	Impulse control disorder related to dopaminergic therapy in progressive supranuclear palsy
Monday, August 28	13:00 - 15:00	236	Phenotypic characterization of 104 patients with Progressive Supranuclear Palsy: A Tertiary care experience from South India
Monday, August 28	13:00 - 15:00	237	A vicious cycle of karyopherin abnormalities in synucleinopathies
Monday, August 28	13:00 - 15:00	238	Building a consensus conceptual model of meaningful symptoms and impacts in early Parkinson's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	239	Early versus late levodopa administration in Parkinson's disease: Comparative study
Monday, August 28	13:00 - 15:00	240	Chronotropic incompetence – a possible marker of severe Parkinson's disease phenotype?
Monday, August 28	13:00 - 15:00	241	Sex differences for clinicopathological correlations in people with Lewy body pathology
Monday, August 28	13:00 - 15:00	242	Olfactory discrimination ability is associated with subjective lack of social support in female Parkinson's patients
Monday, August 28	13:00 - 15:00	243	Longitudinal free-water changes in dementia with Lewy bodies
Monday, August 28	13:00 - 15:00	244	A Systematic Review of the Type, Timing, Frequency and Durability of Effect in Parkinson's Disease Physical Therapy
Monday, August 28	13:00 - 15:00	245	The Synuclein-One Study: Detection of Cutaneous Phosphorylated alpha-synuclein for the Diagnosis of the Synucleinopathies
Monday, August 28	13:00 - 15:00	246	Parkinson's disease (PD) progression is associated with past exposure to organic contaminants in water at Marine Corps Base Camp Lejeune
Monday, August 28	13:00 - 15:00	247	Clinical characteristics of patients with dementia with Lewy bodies followed in a movement disorder clinic
Monday, August 28	13:00 - 15:00	248	Are patients presenting earlier in time? Secular changes in REM sleep behavior disorder
Monday, August 28	13:00 - 15:00	249	Parkinson's disease-specific cortical atrophy as an independent contributor to motor symptom in Parkinson's disease
Monday, August 28	13:00 - 15:00	250	Clinical progression in males and females with early treatment-naive Parkinson's disease
Monday, August 28	13:00 - 15:00	251	Current practices for 'timing' of physical therapy in Parkinson's Disease: 'Burst vs. Spaced'
Monday, August 28	13:00 - 15:00	252	Falls in Mild Cognitive Impairment with Lewy bodies (MCI-LB).
Monday, August 28	13:00 - 15:00	253	Widespread Synuclein pathology in hyposmics precedes dopamine transporter deficit in PARS
Monday, August 28	13:00 - 15:00	254	Sex differences in motor and non-motor symptoms in Parkinson's disease in a diverse East London population
Monday, August 28	13:00 - 15:00	255	Utility of quantitative EEG during sleep as a potential biomarker of Lewy body disease progression
Monday, August 28	13:00 - 15:00	256	How does a diagnosis of Dementia with Parkinson's influence future care provision?
Monday, August 28	13:00 - 15:00	257	Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB
Monday, August 28	13:00 - 15:00	259	Clinical-based diagnosis and self-reported Parkinson's disease in a population-based sample in southern Brazil
Monday, August 28	13:00 - 15:00	260	Exploring patient-physician communication in Parkinson's disease management: a qualitative analysis
Monday, August 28	13:00 - 15:00	261	parkinson's disease and coffee: is high consumption a protective factor or aversion to coffee taste a risk factor?
Monday, August 28	13:00 - 15:00	262	Can a single-session of weight-shift training support people with Parkinson's step from a freeze?
Monday, August 28	13:00 - 15:00	263	An Algorithmic Approach to Assessing Cognitive Functioning in Individuals with REM Sleep Behavior Disorder
Monday, August 28	13:00 - 15:00	264	A multicenter, matched case-control study of alpha-synuclein accumulation in the gastrointestinal tract of Parkinson's disease
Monday, August 28	13:00 - 15:00	265	Reaching the hard-to-reach: the representativeness of patients with parkinsonism recruited to the PRIME-UK cross-sectional study
Monday, August 28	13:00 - 15:00	266	RT-QuIC for detection of pathological α -synuclein in the olfactory mucosa and CSF of Parkinson's disease patients
Monday, August 28	13:00 - 15:00	267	Potentially inappropriate medication usage among patients newly diagnosed with dementia with Lewy bodies
Monday, August 28	13:00 - 15:00	268	Nucleus basalis of Meynert and total gray matter atrophy are related to cognitive and gait decline in Parkinson's disease
Monday, August 28	13:00 - 15:00	269	Analysis of the network of genes related to Parkinson's and identification of key proteins
Monday, August 28	13:00 - 15:00	270	Transcriptional dysregulation in iPSC-derived neurons from patients with X-linked dystonia-parkinsonism
Monday, August 28	13:00 - 15:00	271	Prodromal stage early biomarkers in Parkinson's disease and parkinsonism in Uzbek nationality
Monday, August 28	13:00 - 15:00	272	Sex-Specific Association Between Plasma Vitamin D and Parkinson's Disease: A Mendelian Randomization Study

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	273	Early cortical atrophy is related to depression in Parkinson's disease
Monday, August 28	13:00 - 15:00	274	May CSF biomarkers have a role in degenerative parkinsonian syndromes workup?
Monday, August 28	13:00 - 15:00	275	The examination of the relationship between limited thoracic mobility and shoulder joint function in individuals with extrapyramidal syndrome
Monday, August 28	13:00 - 15:00	276	Machine learning classifies Parkinson's Disease and Progressive Supranuclear Palsy on saccade, pupil, and blink measures during a naturalistic free-viewing task
Monday, August 28	13:00 - 15:00	277	Effect of Best Practice Advisory on the administration of contraindicated medications to hospitalized patients with Parkinson's disease and related disorders
Monday, August 28	13:00 - 15:00	278	Disease progression of data-driven subtypes of Parkinson Disease (PD): 5-year longitudinal study from The Early Parkinson's disease Longitudinal Singapore (PALS) cohort
Monday, August 28	13:00 - 15:00	280	Understanding patient perceptions of advanced Parkinson's disease (aPD) treatments
Monday, August 28	13:00 - 15:00	281	Early-onset levodopa-responsive Parkinsonism associated with dysarthria, pyramidalism, and dystonia: a rare condition that can benefit from a combined treatment approach.
Monday, August 28	13:00 - 15:00	282	Utilizing Speech Analysis to Differentiate Progressive Supranuclear Palsy from Parkinson Disease
Monday, August 28	13:00 - 15:00	283	Can optical coherence tomography differentiate Parkinson's disease from drug-induced parkinsonism?
Monday, August 28	13:00 - 15:00	284	The diagnosis value of dopaminergic responsiveness of Parkinson's disease : a systematic review and meta-analysis
Monday, August 28	13:00 - 15:00	286	Comparison of biospecimens for α -synuclein seed amplification assays in Parkinson's disease: A Systematic Review and Network Meta-Analysis
Monday, August 28	13:00 - 15:00	287	DaT-Scans Have Limited Utility in Predicting Treatment Response to Ventriculoperitoneal Shunts in Normal Pressure Hydrocephalus
Monday, August 28	13:00 - 15:00	288	Opicapone's Effects on Progression Scales in Relation to the 9-Symptom Wearing-off Questionnaire: the OPTIPARK Study
Monday, August 28	13:00 - 15:00	289	Glial neurotrophin factor as a differential marker of Parkinson's disease and vascular parkinsonism
Monday, August 28	13:00 - 15:00	290	Understanding Social Isolation before, during and after the Covid-19 pandemic among Patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	291	Transferrin as a possible CSF biomarker in neurodegenerative proteinopathies
Monday, August 28	13:00 - 15:00	292	Clinical and radiological characteristics of elder patients of Parkinson's disease with the onset age of more than 80 years old
Monday, August 28	13:00 - 15:00	293	Prediction of freezing of gait in Parkinson's disease based on wearable sensors
Monday, August 28	13:00 - 15:00	294	The Roche 'End-to-End Matrix' for Patient-Centric Drug Discovery and Development - Focus on Parkinson's disease
Monday, August 28	13:00 - 15:00	295	Post-Covid parkinsonism: a systematic review of clinical presentations
Monday, August 28	13:00 - 15:00	296	Machine Learning Prediction of Motor Score Reduction following DBS Surgery in PD
Monday, August 28	13:00 - 15:00	297	Machine Learning Prediction of Gait Dysfunction from DTI Multi-Spectral Diffusion Weighted Imaging ROIs
Monday, August 28	13:00 - 15:00	298	Oculomotor parameters measured during free viewing of video differentiate Parkinson's disease from progressive supranuclear palsy
Monday, August 28	13:00 - 15:00	299	Vaccination from Covid-19 in people with Parkinson's disease
Monday, August 28	13:00 - 15:00	300	Gait during turning associates with imbalance and falls in PD: 3D Video based analysis from a single camera
Monday, August 28	13:00 - 15:00	301	Validating wearable sensors as an assessment tool for Parkinson's Disease
Monday, August 28	13:00 - 15:00	302	Empowerment of People with Parkinson's disease: development, testing and evaluation of a cross-sectoral, intervention-based self-management program
Monday, August 28	13:00 - 15:00	303	Potential role of Alpha-synuclein levels in Platelets in GBA-related PD
Monday, August 28	13:00 - 15:00	304	Parkinson's Disease Hospital Optimization Project
Monday, August 28	13:00 - 15:00	305	Subjective cognitive decline and Frailty in an Asian cohort of patients with Parkinson's Disease
Monday, August 28	13:00 - 15:00	306	Measuring the heterogeneity of disease progression in Parkinson's disease with multimodal clinical milestones over 10 years in the DeNoPa cohort
Monday, August 28	13:00 - 15:00	307	Alterations of gait as an early marker of incipient alpha-synucleinopathy

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	308	Feasibility, Reliability and Value of Remote Levodopa Challenge Test in Parkinson's Disease
Monday, August 28	13:00 - 15:00	309	DaT Scan Positive Parkinson's Disease in a Patient with Anti-MuSK Positive Myasthenia Gravis
Monday, August 28	13:00 - 15:00	310	Sacral Mass Lesion Mimicking Atypical Foot Dystonia In Parkinsonian Patient
Monday, August 28	13:00 - 15:00	311	Asymptomatic Gaucher disease presented as Parkinsonism in 61 years old patient.
Monday, August 28	13:00 - 15:00	312	To stimulate or not to stimulate? Bilateral subthalamic (STN) Deep Brain Stimulation (DBS) in cases of young-onset parkinsonism with mitochondrial dysfunction induced neurodegeneration.
Monday, August 28	13:00 - 15:00	313	Traveling through the telescope: a neuromuscular and a movement disorders reunion
Monday, August 28	13:00 - 15:00	314	Atypical parkinsonism and psychiatric disorder in hereditary diffuse leukoencephalopathy with spheroids: a novel variant in the CSF1R gene
Monday, August 28	13:00 - 15:00	315	Hemiparkinsonism secondary to a cerebral cavernous malformation (CCM)
Monday, August 28	13:00 - 15:00	316	Hydrocephalus associated with Chiari-I malformation presenting with parkinsonism and dystonia
Monday, August 28	13:00 - 15:00	317	Subacute parkinsonism associated with Zic4 antibodies: a case report
Monday, August 28	13:00 - 15:00	318	Clinical, radiological and genetic spectrum of fifteen cases of PLA2G6-Associated Neurodegeneration - A Single Centre Cohort from India
Monday, August 28	13:00 - 15:00	319	Movement disorders in osmotic demyelination syndrome: A case series from a tertiary care centre
Monday, August 28	13:00 - 15:00	320	Rapidly progressive dementia - catatonia - myoclonus in 80 years old patient: An unusual case
Monday, August 28	13:00 - 15:00	321	Kufor-Rakef syndrome, report of two unrelated cases from Chile studied with DAT-PET
Monday, August 28	13:00 - 15:00	322	Case report- Cavernoma involving substantia nigra and nigrostriatal pathway as a rare cause of secondary parkinsonism with a 3 year follow up
Monday, August 28	13:00 - 15:00	323	Autoimmune encephalitis due to antiglycine antibodies presenting as corticobasal syndrome
Monday, August 28	13:00 - 15:00	324	Parkinsonism and dilated ventricles: not all hydrocephalus is normal-pressure
Monday, August 28	13:00 - 15:00	325	Delayed Diagnosis of Hyperthyroidism in Parkinson's Disease Patient: A Case Report
Monday, August 28	13:00 - 15:00	326	Parkinsonism in sjogren disease
Category: Cognition and Psychiatric Disturbances (327 – 574):			
Monday, August 28	13:00 - 15:00	327	Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a Phase 3b study
Monday, August 28	13:00 - 15:00	329	CSF tau reflects long-term outcome of patients with idiopathic normal pressure hydrocephalus: a longitudinal retrospective study.
Monday, August 28	13:00 - 15:00	330	The effects of mental imagery on balance, anxiety and quality of life of older people with early stage of dementia: Preliminary data
Monday, August 28	13:00 - 15:00	331	Subjective cognitive complaints in participants of the Healthy Brain Ageing (HeBA) study
Monday, August 28	13:00 - 15:00	332	Extent of cognitive impairment in Parkinson's disease with Covid-19
Monday, August 28	13:00 - 15:00	333	Impact of orthostatic hypotension with sleep disturbance on cognition
Monday, August 28	13:00 - 15:00	334	Predictors of cognitive deficits in patients with idiopathic normal pressure hydrocephalus – a pilot MRI volumetric study
Monday, August 28	13:00 - 15:00	336	Influence of square-stepping exercise on brain activation in older adults with cognitive frailty
Monday, August 28	13:00 - 15:00	337	Consanguinity is the key player in complexity of Mendelian form of neurodegeneration with brain iron accumulation in Pakistan
Monday, August 28	13:00 - 15:00	339	Protective effect and mechanism of TREM2 in Parkinson's disease with cognitive impairment
Monday, August 28	13:00 - 15:00	340	Differences by sex in patients with Parkinson's disease (PD) and impulse control disorder (ICD) in the Mexican population.
Monday, August 28	13:00 - 15:00	341	Prediction of postoperative delirium after deep brain stimulation surgery in Parkinson's disease
Monday, August 28	13:00 - 15:00	342	Prevalence of cardiovascular drugs and oral anticoagulants use among persons with and without Parkinson's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	343	Adult hippocampal neurogenesis-associated memory performance in people with Parkinson's disease with and without cognitive impairment
Monday, August 28	13:00 - 15:00	344	Early cognitive decline in Parkinson's disease is anticipated by enhanced frontal theta oscillations and minor hallucinations
Monday, August 28	13:00 - 15:00	345	Subjective cognitive decline as predictor of objective cognitive decline in Parkinson's patients
Monday, August 28	13:00 - 15:00	346	Addition contact with 10 Hz stimulation in the STN may improve stimulation-induced cognitive disturbances
Monday, August 28	13:00 - 15:00	347	local field potential differences in stn subregion during performance of a conflict task in humans with parkinson's disease
Monday, August 28	13:00 - 15:00	348	Evaluation of Cognitive Assessment Tools in Parkinson's Disease
Monday, August 28	13:00 - 15:00	349	The investigation of a novel video game for identifying mild cognitive impairment in individuals with Parkinson's disease
Monday, August 28	13:00 - 15:00	350	Correlation between rem sleep disorders and neurocognitive defects in patients with parkinson's disease
Monday, August 28	13:00 - 15:00	351	Does Cognitive Complaint in Parkinson's Disease Reflect in Neuropsychological Testing?
Monday, August 28	13:00 - 15:00	352	Motor subtype stability and cognitive profiles in early Parkinson's disease
Monday, August 28	13:00 - 15:00	353	Parkinson disease patient's awareness of hyperkinetic movements
Monday, August 28	13:00 - 15:00	354	No laughing white matter: reduced integrity of the lateral nucleus basalis of Meynert pathway in Parkinson's disease-related cognitive impairment
Monday, August 28	13:00 - 15:00	355	Effect of levodopa on the interpretation of social interactions in people living with Parkinson's disease
Monday, August 28	13:00 - 15:00	356	Disease progression in Parkinson's disease patients with Mild Cognitive Impairment: 5-year longitudinal study from The Early Parkinson's disease Longitudinal Singapore (PALS) cohort
Monday, August 28	13:00 - 15:00	357	Excessive daytime sleepiness as a predictor of cognitive decline in Parkinson disease
Monday, August 28	13:00 - 15:00	358	Clinical toolkits to improve conversations about Parkinson's dementia
Monday, August 28	13:00 - 15:00	359	Action- and emotion-related language abilities in Slovenian-speaking individuals with Parkinson's disease – a background normative study
Monday, August 28	13:00 - 15:00	360	Can medicinal mushrooms help to stabilize or improve cognitive function in Parkinson's patients with mild cognitive impairment?
Monday, August 28	13:00 - 15:00	361	Characterization of haemodynamic activity in resting-state networks associated with cognitive decline in PD: a fractal analysis approach
Monday, August 28	13:00 - 15:00	362	Long-term dementia prevalence in Parkinson disease: Glass half-full?
Monday, August 28	13:00 - 15:00	363	Failure of model-based outcome monitoring in Parkinson's Disease Apathy
Monday, August 28	13:00 - 15:00	364	10 year longitudinal change in clinical and biological characteristics of sporadic Parkinson Disease PPMI cohort
Monday, August 28	13:00 - 15:00	365	Automatic cluster analysis using semantic relatedness for verbal fluency tasks in Parkinson's disease
Monday, August 28	13:00 - 15:00	366	Comparison of cognitive, affective and autonomic functions in parkinson's disease patients with and without freezing of gait and its correlation with PET/CT
Monday, August 28	13:00 - 15:00	367	Clinical Assessments and Biomarker Combinations for Prognostic Modeling of Cognitive Progression in PD
Monday, August 28	13:00 - 15:00	368	Influence of Cognitive Function on Obstacle-Crossing Performance in People with Parkinson's Disease: A Cross-Sectional Study
Monday, August 28	13:00 - 15:00	369	Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study
Monday, August 28	13:00 - 15:00	370	Clinical neurological features of diabetic and non-diabetic patients with Parkinson's disease.
Monday, August 28	13:00 - 15:00	371	Verbal Fluency Changes After Unilateral STN Deep Brain Stimulation in Parkinson's Disease: A Connectomics-Based Approach
Monday, August 28	13:00 - 15:00	372	Validation and replication of Parkinson disease behavioral subtypes
Monday, August 28	13:00 - 15:00	373	Does sex affect worsening of cognitive and IADL functions in PD with and without PD-MCI?
Monday, August 28	13:00 - 15:00	375	Piloting the Cats-and-Dogs tool as a culture-fair test for sensory processing impairment in Parkinson's disease
Monday, August 28	13:00 - 15:00	376	Cognitive underside of Parkinson's Disease: A working memory updating failure in freezing of gait

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	377	Cognitive overlap between Parkinson disease (PD) and Alzheimer's disease (AD) is associated with plasma biomarkers and their impact on regional cortical thickness (CT): An ONDRI Study
Monday, August 28	13:00 - 15:00	378	Impact of non-pharmacological strategies on progression in Parkinson's Disease and Cognitive Impairment.
Monday, August 28	13:00 - 15:00	379	Does sleep disorder affect cognitive impairment in Parkinson's disease?
Monday, August 28	13:00 - 15:00	380	An analysis of gender differences in the clinical profile of Parkinson's Disease patients
Monday, August 28	13:00 - 15:00	381	Computerized cognitive training in advanced Parkinson's disease: preliminary feasibility data of an ongoing randomized controlled trial
Monday, August 28	13:00 - 15:00	382	Strategic decision-making in Parkinson's disease with fatigue
Monday, August 28	13:00 - 15:00	383	Comparison in the disability level according to WHODAS 2 between people living with Early and Late Onset Parkinson's Disease
Monday, August 28	13:00 - 15:00	384	using latent class mixed modelling to profile Parkinson's disease patients at risk of cognitive decline
Monday, August 28	13:00 - 15:00	385	PD-PROP reporting in participants own words shows high burden of cognitive symptoms in early Parkinson Disease (PD)
Monday, August 28	13:00 - 15:00	386	Is an integrated Parkinson's Dementia Service the way forward?
Monday, August 28	13:00 - 15:00	387	Effects of cerebellar theta burst stimulation on working memory in Parkinson's disease
Monday, August 28	13:00 - 15:00	388	Understanding the Mechanisms of Brain Dysfunction when Performing the Mental Rotation Task (MRT) in Stage 1 and Stage 2 EOPD using brain imaging
Monday, August 28	13:00 - 15:00	389	Leveraging MRI and machine-learning for early detection of cognitive impairment in Parkinson's disease
Monday, August 28	13:00 - 15:00	390	Changes in word fluency tasks and cognitive function before and after the COVID-19 epidemic in patients with Parkinson's disease:PD.
Monday, August 28	13:00 - 15:00	392	Reduced non-REM sleep in Parkinson disease is associated with memory impairment and non-motor symptom burden
Monday, August 28	13:00 - 15:00	393	Orthostatic hypotension exacerbates gray matter atrophy related to REM sleep behavior disorder in de novo Parkinson's disease
Monday, August 28	13:00 - 15:00	394	Muscle functions on the movement timings and inhibition in Parkinson's disease.
Monday, August 28	13:00 - 15:00	395	Effects of a rhythmic auditory stimulation-enhanced walking program on Veterans with Parkinson's disease with and without subthalamic nucleus deep brain stimulation.
Monday, August 28	13:00 - 15:00	396	Musical Perception in Parkinson's Disease, a Pilot Study
Monday, August 28	13:00 - 15:00	397	The effect of subthalamic deep brain stimulation on response inhibition and voluntary action control depend on connectivity of the volume of activated tissue with the prefrontal cortex
Monday, August 28	13:00 - 15:00	398	The crucial role of the visual system on the PISA syndrome in Parkinson's disease
Monday, August 28	13:00 - 15:00	399	The Parkinson's Disease Composite of Executive-Functioning (PaCEF): A measure for detecting cognitive decline for Parkinson's disease clinical trials
Monday, August 28	13:00 - 15:00	400	London-Dhaka Parkinson's Cognition Study: A collaboration to evaluate cognitive impairment in under-represented Parkinson's disease patients
Monday, August 28	13:00 - 15:00	401	The East London Parkinson Disease Project - preliminary results from a diverse population
Monday, August 28	13:00 - 15:00	402	Changes in artistic style and Parkinson's Disease
Monday, August 28	13:00 - 15:00	403	Effects of Eromomastax speciosa in a Gastric Ulcer in a 6-hydroxydopamine (6-OHDA)-induced Rat Model of Parkinson's Disease.
Monday, August 28	13:00 - 15:00	404	Ramelteon ameliorates abnormal sleep-wake behavior in a zebrafish model of Parkinson's disease by facilitating abnormal lipid metabolism
Monday, August 28	13:00 - 15:00	405	The effect of peptic ulcer disease on Parkinson's disease
Monday, August 28	13:00 - 15:00	406	Correlates of gait impairment in parkinson's disease
Monday, August 28	13:00 - 15:00	408	Cardiovascular complications in Parkinsonism: insights from Luxembourg Parkinson's Study
Monday, August 28	13:00 - 15:00	409	Unveiling the Link between Stress-Related Disorders and Dysautonomic Symptoms in Parkinson's Disease: A Cross-Sectional Study
Monday, August 28	13:00 - 15:00	410	Sleep disorders and their relationship to non-motor symptoms in Mexican Parkinson's disease patients
Monday, August 28	13:00 - 15:00	411	Sex-specific speech correlates of dysphagia in Parkinson's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	412	The significance of myocardial infarction as a developmental factor in parkinsonism and vascular parkinsonism
Monday, August 28	13:00 - 15:00	413	Novel digital marker detects minor hallucinations online at home of patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	414	Association of vestibular disorders with autonomic dysfunction in Parkinson's Disease
Monday, August 28	13:00 - 15:00	415	The role of structural changes in the retina and the vertical vestibulo-ocular reflex abnormality in gait disorders in Parkinson's disease
Monday, August 28	13:00 - 15:00	416	Gender-Specific Classification Models for Parkinson's Disease using Non-Motor Symptoms and DNA Methylation Data
Monday, August 28	13:00 - 15:00	417	Apomorphine effects on Parkinson's disease fluctuation related pain: a pilot study
Monday, August 28	13:00 - 15:00	418	Probiotics for treatment of constipation in Parkinson's patients: a systematic review and meta-analysis
Monday, August 28	13:00 - 15:00	419	Olfactory sniffing is altered in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	420	Prevalence and severity of non-motor symptoms in hispanic at-risk population with REM-sleep behavior disorder.
Monday, August 28	13:00 - 15:00	421	Vagus nerve degeneration in Parkinson's disease: correlation with autonomic symptoms and pupillography
Monday, August 28	13:00 - 15:00	422	Common oscillatory patterns between Parkinson's disease and heroin dependent patients: a resting-state EEG study
Monday, August 28	13:00 - 15:00	423	Recommendations to tackle under-recognition and under-treatment of sialorrhea in Parkinson's Disease: Is it time for a paradigm shift?
Monday, August 28	13:00 - 15:00	425	Incidence of orthostatic hypotension in Parkinson's disease patients starting antiparkinsonian treatment
Monday, August 28	13:00 - 15:00	426	Subtyping Parkinson's disease: Quality of life changes after subthalamic stimulation depend on nonmotor and motor symptoms
Monday, August 28	13:00 - 15:00	427	Assessing non-motor symptoms and associations with quality of life among patients in Korle-Bu Teaching Hospital, Ghana
Monday, August 28	13:00 - 15:00	428	Comparison of original and revised versions of the University of Pennsylvania Smell Identification Test
Monday, August 28	13:00 - 15:00	429	Sleep seasonality in alpha-synucleinopathies: a comparative study with non-neurological sleep disorder patients
Monday, August 28	13:00 - 15:00	430	Dysphagia in Parkinson's disease
Monday, August 28	13:00 - 15:00	431	Impact of dopamine replacement therapy on shame in Parkinson's disease patients
Monday, August 28	13:00 - 15:00	432	Gut microbiota dysbiosis in Parkinson's disease patients: a potential biomarker of disease severity and progression?
Monday, August 28	13:00 - 15:00	433	Obsessive-Compulsive symptoms in Parkinson's Disease: beyond the Impulse Control Disorders
Monday, August 28	13:00 - 15:00	434	Trends in the evaluation and management of constipation in patients with Parkinson disease
Monday, August 28	13:00 - 15:00	435	gender differences of fatigue and sleep characteristics in parkinson's disease patients
Monday, August 28	13:00 - 15:00	436	Efficacy of melatonin in patients with insomnia and Parkinson's disease
Monday, August 28	13:00 - 15:00	437	Gender differences in non-motor fluctuations in Parkinson's disease
Monday, August 28	13:00 - 15:00	438	Nocturnal behavior of people with Parkinson's disease
Monday, August 28	13:00 - 15:00	439	ON/OFF Non-Motor Evaluation: A New Way to Evaluate Non-Motor Fluctuations in Parkinson's Disease
Monday, August 28	13:00 - 15:00	440	Longitudinal follow-up of pure autonomic failure with cardiac sympathetic denervation: Relevance to the body-first theory of Parkinson's disease
Monday, August 28	13:00 - 15:00	441	Alopecia in females with young onset Parkinson's Disease: an exploratory survey
Monday, August 28	13:00 - 15:00	442	Physical exercise as a promising option for treating fatigue in Parkinson's disease? Results of a systematic review and meta-analysis of non-pharmacological interventions
Monday, August 28	13:00 - 15:00	443	Hearing impairment and non-motor symptoms in Parkinson's disease: association and impact on quality of life
Monday, August 28	13:00 - 15:00	444	The prevalence of delirium and subsequent outcomes in inpatients with Parkinson's disease
Monday, August 28	13:00 - 15:00	445	Needs and priorities of people with Parkinson's and care partners regarding neuropsychiatric symptoms

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	447	Sympathetic tone abnormalities in subjects at risk for Parkinson's Disease without evidence of nigrostriatal neurodegeneration: a multimodal biomarker study
Monday, August 28	13:00 - 15:00	448	Pupil response is impaired in clinically isolated REM Sleep Behavior Disorder and Parkinson's Disease
Monday, August 28	13:00 - 15:00	449	White matter hyperintensities associated with impulse control disorders in Parkinson's disease
Monday, August 28	13:00 - 15:00	450	Association between type 2 diabetes mellitus with parkinson's disease and the increase of the severity of depression and anxiety in a mexican population
Monday, August 28	13:00 - 15:00	451	Ventral tegmental deep brain stimulation does not influence risk-taking behaviour in a standard gambling task
Monday, August 28	13:00 - 15:00	452	Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson's Disease
Monday, August 28	13:00 - 15:00	453	Serum Zinc Deficiency could be associated with dementia conversion in Parkinson's disease
Monday, August 28	13:00 - 15:00	454	Signs of Respiratory Dysfunction across Parkinson's Disease Spectrum
Monday, August 28	13:00 - 15:00	455	A comparative analysis of vegetative disorders in Parkinson's disease and vascular parkinsonism.
Monday, August 28	13:00 - 15:00	456	Impact of non-motor fluctuations on QOL in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	458	Management of constipation in Parkinson's patients presenting with acute sigmoid volvulus to Royal Berkshire Hospital, Reading, UK
Monday, August 28	13:00 - 15:00	459	Management of Sigmoid Volvulus in Parkinson's patients presenting to Royal Berkshire Hospital, Reading, UK.
Monday, August 28	13:00 - 15:00	460	Angiotensin-converting enzyme inhibitors prevent pneumonia in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	461	First approach of a sensor-based assessment of the camptocormia angle
Monday, August 28	13:00 - 15:00	462	Regional Pain Syndromes- A potential clinical biomarker of Prodromal Parkinson's Disease
Monday, August 28	13:00 - 15:00	463	Validation of the Japanese version of the King's Parkinson's Disease Pain Scale and the King's Parkinson's Disease Pain Questionnaire
Monday, August 28	13:00 - 15:00	464	Olfactory discrimination differentiate drug-induced parkinsonism and Parkinson's disease
Monday, August 28	13:00 - 15:00	465	Impact of deep brain stimulation of the subthalamic nuclei on non-motor symptoms in Parkinson's disease: a monocentric prospective study with a 12-month follow-up
Monday, August 28	13:00 - 15:00	466	Olfactory and taste function in early Parkinson's disease with mild cognitive impairment
Monday, August 28	13:00 - 15:00	467	Apathy correlated with motor and non-symptoms in de-novo patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	469	Neurogenic orthostatic hypotension is not associated with generalized dysautonomia in early motor PD
Monday, August 28	13:00 - 15:00	470	Association between Parkinson's Disease and Atrial Fibrillation: A Literature Review
Monday, August 28	13:00 - 15:00	471	Differences in patients with Impulse Control Disorder based on antiparkinsonian drug treatment in a Mexican Institute.
Monday, August 28	13:00 - 15:00	472	Machine Learning Model for Prediction of acute orthostatic hypotension after levodopa administration
Monday, August 28	13:00 - 15:00	473	Investigating Digital Biomarkers in Parkinson's Disease
Monday, August 28	13:00 - 15:00	474	Cortical excitability of sensorimotor cortex in Parkinson's disease-related pain
Monday, August 28	13:00 - 15:00	475	Cognitive function in Parkinson's disease: associations with perivascular space in basal ganglia
Monday, August 28	13:00 - 15:00	476	Determinants of quality of life and daily mobility in Parkinson's disease: the role of fear of falling.
Monday, August 28	13:00 - 15:00	477	An objective shortened 5-item smell test: determinants of performance and agreement with subjective assessment
Monday, August 28	13:00 - 15:00	478	Aspects of early detection of parkinson's disease in ambulatory settings
Monday, August 28	13:00 - 15:00	479	motor and non-motor correlates of hyposmia detected by the italian olfactory identification test (ioit) in an italian cohort of parkinson's disease patients
Monday, August 28	13:00 - 15:00	480	The incidence of Parkinson's disease in Nigeria: a systematic review and meta-analysis
Monday, August 28	13:00 - 15:00	481	Supine hypertension is longitudinally associated with cognitive decline in Parkinson disease independent of orthostatic hypotension

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	482	Associations between non-motor symptoms and patient characteristics in Parkinson's disease: A multicenter cross-sectional study
Monday, August 28	13:00 - 15:00	484	Dynamic assessment of levels of depression and anxiety impairment in Parkinson's disease
Monday, August 28	13:00 - 15:00	485	Left hemisphere theta coherence between cortex and STN increases during speech
Monday, August 28	13:00 - 15:00	486	The impact of wearing 'OFF' (WO) episodes on non-motor symptoms (NMS) burden and quality of life (QoL) in Parkinson's disease (PD) patients
Monday, August 28	13:00 - 15:00	487	Chronic pain and the polytrauma clinical triad are risk factors for prodromal PD
Monday, August 28	13:00 - 15:00	488	Effects of Motor Subtype Stability on Non-Motor Symptoms in Early Parkinson's Disease
Monday, August 28	13:00 - 15:00	489	Drizzling is associated with disease severity in Parkinson's disease
Monday, August 28	13:00 - 15:00	490	Sexual health and sleep quality in women living with Parkinson's disease: are we neglecting that?
Monday, August 28	13:00 - 15:00	491	Depression and Activities of Daily Living in Idiopathic Parkinson's Disease without Dementia.
Monday, August 28	13:00 - 15:00	492	Pain and moods disorders as determinants of quality of life in Parkinson
Monday, August 28	13:00 - 15:00	493	Orthostatic hypotension and frailty
Monday, August 28	13:00 - 15:00	494	Drivers of Health-Related Quality of Life in Parkinson's Disease: non-motor symptoms and time spent in daily activities
Monday, August 28	13:00 - 15:00	495	Gut dysbiosis in Indian Parkinson's Disease Patients with Constipation
Monday, August 28	13:00 - 15:00	496	The impact of mild cognitive impairment on functioning in people with Parkinson's disease
Monday, August 28	13:00 - 15:00	497	Pain Phenomenon in Parkinson Disease
Monday, August 28	13:00 - 15:00	498	Distinct striatal connectivity patterns in patients with Parkinson's disease with and without urinary symptoms
Monday, August 28	13:00 - 15:00	499	Exploring brain mechanisms of identity attribution in presence hallucinations of Parkinsonian origin
Monday, August 28	13:00 - 15:00	500	Correlation between dose of dopamine replacement therapy and King's Parkinson's Disease Pain Scale in Mexican Patients with Parkinson's Disease
Monday, August 28	13:00 - 15:00	501	Oculomotor changes in the premotor stage of LRRK2- G2019S associated Parkinson's disease.
Monday, August 28	13:00 - 15:00	502	Psychometric properties of the Neuropsychiatric Fluctuations Scale: preliminary results in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	503	The Impact of Diabetes Mellitus on Motor and Non-Motor Symptoms of Parkinson's Disease: A Cross-Sectional Study.
Monday, August 28	13:00 - 15:00	504	Compliance with national and international guidelines in the treatment of non-motor symptoms in late stage Parkinson's disease
Monday, August 28	13:00 - 15:00	505	Effect of deep brain stimulation on dysphagia in Parkinson's disease: A Systematic Review
Monday, August 28	13:00 - 15:00	506	Sleep disorders in Parkinson's disease patients. A case-control study.
Monday, August 28	13:00 - 15:00	507	Characteristics of Pain in Parkinson's Disease with Arabic translation and validation of King's Parkinson's Disease Pain Scale
Monday, August 28	13:00 - 15:00	508	Genetic and psychiatric risk factors for impulse control disorders in de novo Parkinson's disease
Monday, August 28	13:00 - 15:00	509	Impact of vitamin supplements intake on non-motor fluctuations measured by (NoMoFA) in people living with Parkinson's disease.
Monday, August 28	13:00 - 15:00	510	Microbiota and Gastrointestinal Manifestations of Parkinson's Disease with Arabic Translation of Gastrointestinal Dysfunction Scale
Monday, August 28	13:00 - 15:00	511	Association between dysphagia and body mass index and his impact on the severity of anxiety in patients with Parkinson Disease
Monday, August 28	13:00 - 15:00	512	Non-motor Symptoms Progression in Parkinson's Disease. A 4-year Follow-up Study.
Monday, August 28	13:00 - 15:00	513	Risk factors of sleep disordered breathing in Veterans with Parkinson's disease.
Monday, August 28	13:00 - 15:00	514	Improvement of short-term satisfaction with life and treatment in Parkinson's disease after subthalamic stimulation
Monday, August 28	13:00 - 15:00	515	Identifying prodromal NMS in a population-based recruitment strategy: Kassel data of Healthy Brain Ageing

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	516	Polyneuropathy in Parkinson's disease: cross-sectional analysis of the Bochum Parkinson Nerve Study cohort
Monday, August 28	13:00 - 15:00	517	Quantitative Evaluation of Seborrheic Dermatitis in Patients with Autonomic Dysfunction.
Monday, August 28	13:00 - 15:00	519	Fluorescence-lifetime ophthalmoscopy findings in Parkinson's disease patients with visual disturbances
Monday, August 28	13:00 - 15:00	520	Development and preliminary results of a new picture-based self-rating tool for neuropsychiatric syndromes in Parkinson's disease
Monday, August 28	13:00 - 15:00	522	Hospital based motor cognitive rehabilitation training. what after? An intervention aimed at patients support between admissions
Monday, August 28	13:00 - 15:00	523	A comparison of national data on Parkinson's disease mortality between the USA and UK
Monday, August 28	13:00 - 15:00	524	Non-motor symptoms of Parkinson's disease: an analysis of gender and age-related differences in a large online cohort
Monday, August 28	13:00 - 15:00	525	The characterization of Parkinson's disease related nociceptive pain based on the classification system
Monday, August 28	13:00 - 15:00	526	Bowel symptoms and management practices in Parkinson's disease and related conditions: results from the PRIME-UK study.
Monday, August 28	13:00 - 15:00	527	Characterization of at-home sleep macrostructure in Parkinson disease using a wearable sleep monitoring device
Monday, August 28	13:00 - 15:00	528	PDQ-39 predicts quality of life improvement following neurostimulation for Parkinson's disease: Prospective observational study
Monday, August 28	13:00 - 15:00	529	Defining neuropsychiatric symptoms fluctuations in Parkinson's disease
Monday, August 28	13:00 - 15:00	530	Analysis of excessive daytime sleepiness and clinical findings in Parkinson's disease
Monday, August 28	13:00 - 15:00	531	Association between supine hypertension and plasma free triiodothyronine in drug-naïve Parkinson's disease
Monday, August 28	13:00 - 15:00	532	Correlation between fatigue, sleep dysfunction and health-related quality of life in Parkinson's disease patients
Monday, August 28	13:00 - 15:00	533	Diplopia (Double vision) in Parkinson's disease patients: prevalence and nonmotor effect
Monday, August 28	13:00 - 15:00	534	Levodopa-induced orthostatic hypotension in a large cohort of patients with Parkinson's disease undergoing an acute levodopa challenge test
Monday, August 28	13:00 - 15:00	535	Is a Parkinson's Sialorrhoea service effective?
Monday, August 28	13:00 - 15:00	536	Sleep quality in GBA, LRRK2 and idiopathic Parkinson disease
Monday, August 28	13:00 - 15:00	537	Neurologic dysfunction assessment in Parkinson's disease based on fundus photographs using deep learning
Monday, August 28	13:00 - 15:00	538	Sleep hygiene practice in patients with Parkinson's disease
Monday, August 28	13:00 - 15:00	539	Pain and sleep in Parkinson's disease
Monday, August 28	13:00 - 15:00	540	Risk factors for Freezing of Gait in Parkinson's Disease: A Systematic Review and Meta-analysis
Monday, August 28	13:00 - 15:00	541	Constipation in Parkinson's disease, a common problem with rare but serious complications
Monday, August 28	13:00 - 15:00	543	Dopamine dysregulation syndrome in Parkinson's disease controlled by safinamide
Monday, August 28	13:00 - 15:00	544	Risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia patients with Parkinson's disease: a meta-analysis of randomized controlled trials
Monday, August 28	13:00 - 15:00	545	Effort-based decision-making and neuropsychiatric symptoms before and after subthalamic nucleus deep brain stimulation in Parkinson's disease
Monday, August 28	13:00 - 15:00	546	Depression in Parkinson's disease is associated with subcortical neurodegeneration and increased risk of all-cause mortality and dementia
Monday, August 28	13:00 - 15:00	547	Safety assessment of pimavanserin in Parkinson's disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials
Monday, August 28	13:00 - 15:00	548	Anxiety in Parkinson's disease is associated with changes in brain structural connectivity
Monday, August 28	13:00 - 15:00	549	The impact of anxiety symptoms and treatment on Parkinson's disease-related disability: findings from the Parkinson's Progression Markers Initiative
Monday, August 28	13:00 - 15:00	550	Parkinson's disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.
Monday, August 28	13:00 - 15:00	551	'That dark place' - A thematic exploration of why people with Parkinson's living in the UK, may, at times, experience suicidal ideation, as conveyed through an internet Forum

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	552	A 16-week open-label study of the effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson's disease psychosis (PDP)
Monday, August 28	13:00 - 15:00	553	Risk of Depression after Parkinson's disease, stroke, multiple sclerosis, and migraine in an Iranian population
Monday, August 28	13:00 - 15:00	554	Olfactory dysfunction and neuropsychiatric manifestations in early drug-naïve Parkinson's disease
Monday, August 28	13:00 - 15:00	556	A cross regional investigation into the effects of fractures on the quality of life for elderly people with Parkinson's disease in rural India
Monday, August 28	13:00 - 15:00	557	Suicidal ideation and suicide risk in Parkinson's disease
Monday, August 28	13:00 - 15:00	558	Identifying delirium in Parkinson's: evaluation of existing tools and measures
Monday, August 28	13:00 - 15:00	559	Apathy and Parkinson's disease motor phenotypes: A preliminary study
Monday, August 28	13:00 - 15:00	560	Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson's disease
Monday, August 28	13:00 - 15:00	561	Expanding the reach of a telehealth psychotherapy hub to advance coordinated depression care for rural veterans with Parkinson's Disease
Monday, August 28	13:00 - 15:00	562	Pain as a Risk Factor for Developing Depression among Patients with Parkinson's Disease: A Systematic Review of 1426 patients
Monday, August 28	13:00 - 15:00	563	Jumping to Conclusions bias, psychosis and impulsivity in early stages of Parkinson's disease
Monday, August 28	13:00 - 15:00	564	Novelty Seeking: A Narrative Review
Monday, August 28	13:00 - 15:00	565	Neurophysiological architecture of visual categorization in early Parkinson's disease with minor hallucinations
Monday, August 28	13:00 - 15:00	566	Neuropsychiatric Symptoms in Early-Onset Parkinson's Disease
Monday, August 28	13:00 - 15:00	567	Longitudinal association of mild behavioral impairment with cognitive decline in Parkinson's disease
Monday, August 28	13:00 - 15:00	568	Incremental Hospitalizations and Associated Costs of Co-existing Dementia in Patients with Parkinson's Disease Psychosis: An analysis of US Medicare Beneficiaries
Monday, August 28	13:00 - 15:00	569	Apathy in Parkinson's disease: Relation to autonomic symptoms
Monday, August 28	13:00 - 15:00	570	Depression profile in Mexican patients with Parkinson Disease: a cross-sectional study
Monday, August 28	13:00 - 15:00	571	Specific Parkinson's disease phenotype in patients with long term PTSP
Monday, August 28	13:00 - 15:00	572	The role of depression in the development of Impulse Control Disorders in Parkinson's Disease.
Monday, August 28	13:00 - 15:00	573	Apathy, white-matter microstructure, and effort-based decision making in Parkinson's Disease
Monday, August 28	13:00 - 15:00	574	Clozapine Therapy for Parkinson's Disease Psychosis: A 21-Year Service Analysis
Category: Functional Movement Disorders and Drug-Induced Movement Disorders (576 – 605)			
Monday, August 28	13:00 - 15:00	576	Stop signal reaction time: A promising Diagnostic marker for Functional Cervical Dystonia
Monday, August 28	13:00 - 15:00	577	Non-intrusive Video-Based Solution for Continuous Quantitative Monitoring of Parkinson's Patients' Motor Functions
Monday, August 28	13:00 - 15:00	578	Hypnosis as an adjunctive treatment for FND, a case series
Monday, August 28	13:00 - 15:00	579	Increased incidence of Functional movement disorders during COVID-19 pandemic
Monday, August 28	13:00 - 15:00	580	Comorbid Functional Neurologic disorders in patients with Parkinson's disease in a rural hospital in Western part of India
Monday, August 28	13:00 - 15:00	581	Spectrogram helps to differentiate functional tremor from organic
Monday, August 28	13:00 - 15:00	582	Clinical characterization of patients with functional movement disorders
Monday, August 28	13:00 - 15:00	583	Incidence of childhood trauma in patients with functional movement disorder and its impact on motor symptoms severity
Monday, August 28	13:00 - 15:00	584	Vertigo: Sway pattern indicating a functional movement disorder
Monday, August 28	13:00 - 15:00	585	Motor imagery ability in patients with functional dystonia

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	586	Technological Approach to Phenotypical Characterization of Functional Movement Disorders
Monday, August 28	13:00 - 15:00	587	PRRT2 paroxysmal dyskinesia mimicking functional motor disorders: a pediatric case.
Monday, August 28	13:00 - 15:00	589	Functional movement disorders in dopa-responsive dystonia – A case series with implications for diagnosis and treatment
Monday, August 28	13:00 - 15:00	590	Severe movement disorder initially suspected of being conversion - key insights from the psychiatrist
Monday, August 28	13:00 - 15:00	591	Treatment induced psychogenic movement disorders: a case series
Monday, August 28	13:00 - 15:00	593	Tramadol Induces Neuroinflammation, Mitochondrial Oxidative Stress, Neurotransmitters Dysbalanced and Produced Parkinson's Disease Like Symptoms in Experimental Wistar Rats
Monday, August 28	13:00 - 15:00	594	Quercetin hinders Glial Activation to Alleviate the Cadmium Induced Dopaminergic Alteration via TNF α mediated CAMKII α /ERK activation
Monday, August 28	13:00 - 15:00	595	Pharmacological In vivo and in vitro potential of resveratrol in experimental rat models of Parkinson's disease
Monday, August 28	13:00 - 15:00	596	The comparison of curcumin and naringenin effects on motor function in rotenone model of Parkinson's disease
Monday, August 28	13:00 - 15:00	597	Hesperidin ameliorates rotenone-induced Parkinson's disease in mice via improving neuroinflammation and oxidative stress
Monday, August 28	13:00 - 15:00	598	Functional Neuroimaging and Follow up trends in Drug induced movement disorders.
Monday, August 28	13:00 - 15:00	599	Tardive dystonia manifesting in lid-opening apraxia, oromandibular dystonia, and laterocollis after long-term sulpiride use
Monday, August 28	13:00 - 15:00	600	Drug-induced Parkinsonism and nonmotor symptoms: a case of gustatory rhinorrhea
Monday, August 28	13:00 - 15:00	601	Serotonin Coma: An Antipodal emergency
Monday, August 28	13:00 - 15:00	602	Ipilimumab/Nivolumab-related orthostatic myoclonus in a patient with metastatic melanoma
Monday, August 28	13:00 - 15:00	603	Clebopride-induced Rabbit Syndrome: A Case Report.
Monday, August 28	13:00 - 15:00	604	Severe tacrolimus-induced parkinsonism after kidney transplantation
Monday, August 28	13:00 - 15:00	605	Clinical Profile Of Drug-Induced Movement Disorders In Cipto Mangunkusumo Hospital, Indonesia
Category: Epidemiology and Rating Scales (606 – 666)			
Monday, August 28	13:00 - 15:00	606	Risk of Parkinson's disease in spinal cord injury: a nationwide cohort study in south Korea
Monday, August 28	13:00 - 15:00	608	Prevalence of depression and cognitive impairment in a Hungarian Parkinson's disease Center
Monday, August 28	13:00 - 15:00	610	Trajectories of Physical Performance in Prodromal and Early Parkinson's Disease
Monday, August 28	13:00 - 15:00	611	Frequency of Parkinson's Disease in All Case Hospitalization Among Native Hawaiian/Pacific Islanders, Asian American Subgroups and Whites
Monday, August 28	13:00 - 15:00	612	Publication rates and characteristics of clinical trials in deep brain and responsive neurostimulation
Monday, August 28	13:00 - 15:00	613	Risk and protective factors in Parkinson's disease: a simultaneous and prospective study with linear and machine learning models
Monday, August 28	13:00 - 15:00	614	Estimation of global age-specific prevalence of essential tremor by literature review of population-based studies
Monday, August 28	13:00 - 15:00	615	The comparison of vaccination rate, health impact, and confidence of COVID-19 vaccines between patients with Parkinson's disease and healthy population: evidence from a large multicenter survey
Monday, August 28	13:00 - 15:00	616	Estimating the Incidence of Parkinson's Disease in Patients with Epilepsy: A Nationwide Cohort Study in South Korea
Monday, August 28	13:00 - 15:00	618	The cause of death in Parkinson's disease
Monday, August 28	13:00 - 15:00	620	Specific ethnicity could have different risk factors for Parkinson's disease: a descriptive study
Monday, August 28	13:00 - 15:00	621	National Luxembourg Sleep Study: An enriched, at risk, prodromal Parkinson's Disease cohort
Monday, August 28	13:00 - 15:00	622	A 20-year review of a Movement Disorders Database in Singapore
Monday, August 28	13:00 - 15:00	623	Drivers of longitudinal healthcare cost in Parkinson Disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	624	Prevalence and clinical characteristics of young onset Parkinson's Disease among Nepalese Population
Monday, August 28	13:00 - 15:00	625	Obesity is a protective factor for the development of Parkinson's disease in participants of the Framingham Heart Study Cohort
Monday, August 28	13:00 - 15:00	627	Dry Cleaning Chemicals and Parkinson's Disease
Monday, August 28	13:00 - 15:00	628	Epidemiology of late-onset Parkinson's disease in least-developed to Upper Middle-Income Countries: A Systematic Review and Meta-analysis
Monday, August 28	13:00 - 15:00	629	Movement disorders at the National Institute of Neurology and Neurosurgery (INNN, Mexico City): most common diagnoses during 2022.
Monday, August 28	13:00 - 15:00	630	Impact of the COVID-19 pandemic on DBS accessibility: a single center experience
Monday, August 28	13:00 - 15:00	631	The prevalence of Parkinson's disease in a predominantly rural area of North West England
Monday, August 28	13:00 - 15:00	632	Applying the COM-B model to identify potential barriers for in-person on-site visits within the Healthy Brain Ageing (HeBA) study in Luxembourg
Monday, August 28	13:00 - 15:00	633	Frequency of Parkinson disease following COVID-19 infection: a two-year retrospective cohort study
Monday, August 28	13:00 - 15:00	634	Nutritional traits in the prodromal phase on Parkinson's disease in community-dwelling older adults in Japan
Monday, August 28	13:00 - 15:00	635	Association Between Antiepileptic Drugs and Subsequent Parkinson's Disease in East London
Monday, August 28	13:00 - 15:00	636	Prevalence, clinical characteristics, and quality of life of orthostatic tremor and orthostatic myoclonus in Thai patients with Parkinson's disease: Prospective cross-sectional study
Monday, August 28	13:00 - 15:00	637	Filipino's and Parkinson's Disease: A Scoping Review of the Literature
Monday, August 28	13:00 - 15:00	638	Characterizing Hospital Admissions in Parkinson's Disease: 10-Year Retrospective Study of Administrative Data in Alberta, Canada
Monday, August 28	13:00 - 15:00	639	The long and short of contemporary parkinsonism survival: A 47-year clinicopathological study
Monday, August 28	13:00 - 15:00	640	Putting the patient's voice at the venter: Tracking the impact of botulinum neurotoxin therapy for movement disorders using patient-reported outcomes
Monday, August 28	13:00 - 15:00	641	Living with Parkinson's disease scale: First validation study among English-speaking population
Monday, August 28	13:00 - 15:00	642	Correlation between Motor Sections of UMSARS and MDS-UPDRS
Monday, August 28	13:00 - 15:00	643	Preliminary results of the validation study of the Shame in Parkinson's disease (SPARK) Scale
Monday, August 28	13:00 - 15:00	644	Inferring Rigidity Scores in MDS-UPDRS Motor Assessment from Other Items
Monday, August 28	13:00 - 15:00	645	Use and Misuse of the Unified Multiple System Atrophy Rating Scale
Monday, August 28	13:00 - 15:00	646	Electronic Development of the MDS-UPDRS and MDS-NMS: Process and User Feedback
Monday, August 28	13:00 - 15:00	647	A validation study of the Mini-BESTest in a Spanish population with Parkinson's disease.
Monday, August 28	13:00 - 15:00	648	MDS-UPDRS Part 3 cannot be summed with other parts of the MDS-UPDRS: a clinimetric evaluation
Monday, August 28	13:00 - 15:00	649	ELectronic Archimedes spiral Neural Network (ELANN)
Monday, August 28	13:00 - 15:00	650	Reliability of the severity subscale of the Toronto Western Spasmodic Torticollis Rating Scale in a multidisciplinary team
Monday, August 28	13:00 - 15:00	651	Subjective assessment of parkinson's disease in relation to changes in brain microstructure
Monday, August 28	13:00 - 15:00	652	Resolving missing data from the MDS-UPDRS: implications for telemedicine
Monday, August 28	13:00 - 15:00	654	Development of an Item Bank for Assessing Psychosis in Parkinson's Disease: A Systematic Review
Monday, August 28	13:00 - 15:00	655	Validation of a Remote Patient Monitoring System for Parkinson Symptom Severity
Monday, August 28	13:00 - 15:00	656	Bridging the Gap between Statistical significance and Clinical Relevance: A Systematic Review of Minimum clinically important difference (MCID) thresholds of scales reported in trials of Movement
Monday, August 28	13:00 - 15:00	657	Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment
Monday, August 28	13:00 - 15:00	658	Reliability of Indonesian Version Wearing Off Questionnaire

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Monday, August 28	13:00 - 15:00	659	Peroperative use of the MDS-UPDRS Motor Section: Agreement between Sitting and Supine position
Monday, August 28	13:00 - 15:00	660	Parkinson's Disease Stigma Questionnaire (PDStigmaQuest): Development and Pilot Study of a Questionnaire for Stigma in Patients with Idiopathic Parkinson's Disease
Monday, August 28	13:00 - 15:00	661	Loneliness, Self-Efficacy, and Resilience: Neglected Modifiable Contributors to Parkinson's Disease Symptom Severity and Quality of Life
Monday, August 28	13:00 - 15:00	662	Multiple methods to improve recruitment, enrollment, and retention of study participants for validation of the Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)
Monday, August 28	13:00 - 15:00	663	Development and Clinimetric Testing Plan for the MDS Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS)
Monday, August 28	13:00 - 15:00	664	Association between subjective and objective language measures in DBS candidates
Monday, August 28	13:00 - 15:00	665	Validation of the Patient Reported Outcomes in Parkinson's Disease scale in outpatients
Monday, August 28	13:00 - 15:00	666	An IMU- based Objective Quantification Method for Bradykinesia Evaluation in Parkinson's disease
Category: Hyperkinetic Movement Disorders I (676 – 863)			
Tuesday, August 29	13:00 - 15:00	676	The neuroprotective miRNA family hsa-miR-451 has a distinctive pattern of downregulation in neurodegenerative diseases.
Tuesday, August 29	13:00 - 15:00	677	Studies on mitochondrial dysfunction in the peripheral blood mononuclear cells in an ethnic Indian population of SCA 12 patients
Tuesday, August 29	13:00 - 15:00	678	Dopamine dysfunction in nigro-striatal pathway—multi-axial pathology in SCA 12
Tuesday, August 29	13:00 - 15:00	680	Course of HIV-associated cerebellar ataxia on the background of antiretroviral therapy: clinical cases of 5 patients
Tuesday, August 29	13:00 - 15:00	681	Clinical spectrum, imaging characteristics and care giver burden assessment of early onset non-dominant progressive cerebellar ataxias
Tuesday, August 29	13:00 - 15:00	682	Unique consecutive order of brain atrophy in spinocerebellar ataxia type 3 (SCA3)
Tuesday, August 29	13:00 - 15:00	683	Argentine Translation and Adaptation of the Scale for the Assessment and Classification of Ataxia (SARA)
Tuesday, August 29	13:00 - 15:00	684	Cerebellar volumetry in SCA1, SCA3, SCA6, MSA-C, and SAOA
Tuesday, August 29	13:00 - 15:00	686	Clinical and genetic analyses of a Swedish patient series diagnosed with ataxia
Tuesday, August 29	13:00 - 15:00	687	Fragile X Related Tremor in FMR1 Premutation Women without FXTAS
Tuesday, August 29	13:00 - 15:00	688	Effectiveness of non-invasive therapy of tPCS & peripheral nerve stimulation on Ataxia patients
Tuesday, August 29	13:00 - 15:00	689	Systemic and intracellular iron starvation response in Friedreich's Ataxia
Tuesday, August 29	13:00 - 15:00	690	Disease progression of spinocerebellar ataxia types 1, 2, 3, and 6 before and after ataxia onset: a joint analysis of two longitudinal cohort studies
Tuesday, August 29	13:00 - 15:00	691	Preparing for a clinical trial: a run-in natural history study in POLR3A-associated spastic ataxia with intronic mutations amenable to splice-modulating therapeutic approaches
Tuesday, August 29	13:00 - 15:00	692	Neurotological evaluation on cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (canvas)
Tuesday, August 29	13:00 - 15:00	694	atrophy of cranial nerves v and viii is a hallmark of rfc1-related disorder
Tuesday, August 29	13:00 - 15:00	695	cerebellar cognitive affective syndrome is frequent in rfc1-related disorder
Tuesday, August 29	13:00 - 15:00	696	Presence of neuropathy in most frequent hereditary cerebellar ataxia SCA1, SCA2 and FRDA in Serbian population
Tuesday, August 29	13:00 - 15:00	697	FGF14 repeat expansions: Case series of adult-onset cerebellar ataxia patients from Serbia
Tuesday, August 29	13:00 - 15:00	698	Frequency of SCA 2, 3 and 7 in Slovak patients with spinocerebellar ataxia - first report of SCA2 patient from Slovakia
Tuesday, August 29	13:00 - 15:00	699	Brain functional state mapping in resting state and network alteration in Spinocerebellar Ataxia Type 2 in comparison with healthy controls
Tuesday, August 29	13:00 - 15:00	700	Intronic FGF14 GAA repeat expansions are a common cause of ataxia syndromes with neuropathy and bilateral vestibulopathy
Tuesday, August 29	13:00 - 15:00	701	Network localization of limb ataxia
Tuesday, August 29	13:00 - 15:00	702	Cognitive flexibility associates with atrophy and disrupted connectivity of the cognitive cerebellum in degenerative cerebellar ataxia

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	703	Association of Early and late age of onset with Mitochondrial DNA haplogroup in Indian Spinocerebellar Ataxia type- 2 patients.
Tuesday, August 29	13:00 - 15:00	704	Repetitive trans-spinal magnetic stimulation and kinesiotherapy could reduce motor and gait symptoms in patients with neurodegenerative ataxia?
Tuesday, August 29	13:00 - 15:00	705	Diffusion Tensor Imaging of Spinocerebellar ataxia type 12 patients in comparison of Healthy control
Tuesday, August 29	13:00 - 15:00	706	Targeted sequencing of regulatory regions shows potential SNVs affecting FXN gene expression in Friedreich's ataxia patients
Tuesday, August 29	13:00 - 15:00	707	Impact of dual tasking and sensory manipulation on balance in Fragile X-associated tremor/ataxia syndrome (FXTAS) and potential prodromal postural sway deficits in asymptomatic FMR1
Tuesday, August 29	13:00 - 15:00	708	Learnings from inaugural year of foundation sponsored genetic counseling and testing program for Spinocerebellar Ataxia (SCA) types 1, 2, and 3
Tuesday, August 29	13:00 - 15:00	709	Novel CACNA1A splice site variant associated with cerebellar ataxia and mild cognitive impairment; case report of Czech family.
Tuesday, August 29	13:00 - 15:00	710	Low serum vitamin E in a genetically confirmed Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)
Tuesday, August 29	13:00 - 15:00	711	Spontaneous intracranial hypotension presenting with progressive cerebellar ataxia and myelopathy
Tuesday, August 29	13:00 - 15:00	713	Episodic ataxia type 2: a previously undescribed variant in the CACNA1A gene
Tuesday, August 29	13:00 - 15:00	714	Diffuse cerebellar edema in acute anti-Yo positive paraneoplastic cerebellar degeneration: A case report
Tuesday, August 29	13:00 - 15:00	715	A case of progressive ataxia with palatal tremor (PAPT) syndrome due to idiopathic bilateral hypertrophic olivary degeneration
Tuesday, August 29	13:00 - 15:00	716	"Speaking aids in neurodegenerative ataxia: how to deal with own disability"
Tuesday, August 29	13:00 - 15:00	717	Spinocerebellar Ataxia Autosomal Recessive Type 10 Misdiagnosed as a Multiple System Atrophy Type C: a Case Report.
Tuesday, August 29	13:00 - 15:00	718	Genetic and phenotypic characterization of ATX-FAT2 (SCA45) in three Indian families
Tuesday, August 29	13:00 - 15:00	719	Isolated ZIC-4 antibody associated cerebellar dysfunction triggered by Tuberculosis
Tuesday, August 29	13:00 - 15:00	720	A novel missense variant in the TTBK2 gene in a north American family with late-onset cerebellar ataxia.
Tuesday, August 29	13:00 - 15:00	721	Late onset cerebellar ataxia in patients treated with VIM DBS
Tuesday, August 29	13:00 - 15:00	722	Rare genetic and clinical presentation of SPG7-related Hereditary Spastic Paraplegia.
Tuesday, August 29	13:00 - 15:00	723	A 78-year-old man with progressive ataxia, palatal tremor, parkinsonism and motor neuron disease.
Tuesday, August 29	13:00 - 15:00	724	Description of a series of GAA-FGF14 ataxia / SCA27b patients
Tuesday, August 29	13:00 - 15:00	725	Cerebellar ataxia as primary manifestation of HIV: a rare etiological association
Tuesday, August 29	13:00 - 15:00	726	Early-onset spastic ataxia in a patient with prion (PRNP) p.Val180Ile mutation
Tuesday, August 29	13:00 - 15:00	727	Extended phenotypes of autosomal recessive cerebellar ataxia type 1: learn from a novel mutation of SYNE1 gene
Tuesday, August 29	13:00 - 15:00	728	The phenotypic spectrum and assessment of severity in patients of Spinocerebellar Ataxia-12.
Tuesday, August 29	13:00 - 15:00	729	Oculomotor findings in paraneoplastic neurological syndromes with cerebellar ataxia
Tuesday, August 29	13:00 - 15:00	730	Case report on heterozygous OPA3 gene mutation causing ataxia
Tuesday, August 29	13:00 - 15:00	731	An elderly female with subacute cerebellar ataxia: A case report
Tuesday, August 29	13:00 - 15:00	733	Paraneoplastic cerebellar degeneration due to an anti-SOX 1 antibody manifesting as head tremors, without evidence of underlying malignancy
Tuesday, August 29	13:00 - 15:00	734	Expanding the clinical phenotype of ataxia associated with PMPCA mutations
Tuesday, August 29	13:00 - 15:00	735	Late Onset Cerebellar Ataxia in a Patient with a Heterozygous Pathogenic KIF1A Mutation: A Case Report
Tuesday, August 29	13:00 - 15:00	736	Generalized chorea, cerebellar ataxia and spastic tetraparesis with a genetic mutation in FAT2 gene – coincidence or a new SCA45 phenotype?
Tuesday, August 29	13:00 - 15:00	737	Cerebellar ataxia due to vitamin E deficiency

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	738	POU4F1-related ataxia: phenotyping of a rare genetic ataxia.
Tuesday, August 29	13:00 - 15:00	740	The role of Anti-Ribosomal P antibody in Autoimmune cerebellar ataxia
Tuesday, August 29	13:00 - 15:00	741	Cervical Dystonic Tremor: A Characteristic Feature Of Ataxia With Vitamin E Deficiency
Tuesday, August 29	13:00 - 15:00	742	Calcium phenotype in cellular models of VPS13A disease
Tuesday, August 29	13:00 - 15:00	743	Disorder of bulk lipid transfer? Lipid composition and distribution in cellular models of VPS13A disease
Tuesday, August 29	13:00 - 15:00	744	Neurofilament light chain in Huntington's Disease Like 2: a cross-sectional comparison with Huntington's Disease.
Tuesday, August 29	13:00 - 15:00	745	Chorea following SARS-CoV-2 infection and vaccination: a systematic review
Tuesday, August 29	13:00 - 15:00	746	Huntington's disease-like 2 phenotypes: a case series from a Brazilian referral center
Tuesday, August 29	13:00 - 15:00	747	Pallidal activity as a driving force of choreic movements
Tuesday, August 29	13:00 - 15:00	748	Deep brain stimulation in chorea: four cases and literature review
Tuesday, August 29	13:00 - 15:00	749	Autoimmune Chorea. Therapy with Monoclonal Antibodies: Experimental and Clinical Approach
Tuesday, August 29	13:00 - 15:00	750	feeding dystonia: a hallmark of chorea-acanthocytosis
Tuesday, August 29	13:00 - 15:00	751	A new era in etiologies of chorea
Tuesday, August 29	13:00 - 15:00	752	Hypoxic brain injury: a rare cause of chorea and dystonia
Tuesday, August 29	13:00 - 15:00	753	Huntington disease-like: an atypical presentation of Niemann-Pick type C.
Tuesday, August 29	13:00 - 15:00	754	Chorea as a clinical manifestation in adult-onset of metachromatic leukodystrophy
Tuesday, August 29	13:00 - 15:00	756	Nonketotic hyperglycemia-induced hemichorea/hemiballism in El Salvador: A case Series
Tuesday, August 29	13:00 - 15:00	757	Treatment of chorea in pediatric subjects with pallidal and thalamic deep brain stimulation
Tuesday, August 29	13:00 - 15:00	758	Case series of Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT); different presentations and different treatment outcomes.
Tuesday, August 29	13:00 - 15:00	759	Uremic encephalopathy (UE) mimicking acute bulbar stroke with progression from bradykinesia to choreic movements in a diabetic patient undergoing hemodialysis: A case report
Tuesday, August 29	13:00 - 15:00	760	Hemichorea syndrome secondary to diabetic striatopathy with contralateral drug-induced parkinsonism: a different threshold for drug induced movement disorders?
Tuesday, August 29	13:00 - 15:00	761	Primary CNS Lymphoma presenting with Hemichorea Hemiballismus.
Tuesday, August 29	13:00 - 15:00	762	Prospective, Multicenter, International Registry of Deep Brain Stimulation for Dystonia: A Sub-Analysis of Cervical Dystonia Patients
Tuesday, August 29	13:00 - 15:00	763	Benefit of multiple incobotulinumtoxinA injections for pain reduction in adults with cervical dystonia: an analysis of pooled data
Tuesday, August 29	13:00 - 15:00	764	Pain reduction in adults with cervical dystonia and moderate or severe baseline pain following repeated injections of incobotulinumtoxinA: an analysis of pooled data from phase 3 and 4 studies
Tuesday, August 29	13:00 - 15:00	765	Development of a Vibro-Tactile Stimulation wristband for targeted therapy of Focal Task Specific Dystonias
Tuesday, August 29	13:00 - 15:00	766	Impact of the COVID-19 pandemic in the long-term efficacy of botulinum toxin treatment
Tuesday, August 29	13:00 - 15:00	767	A 10-year service evaluation of a Cervical Dystonia Botulinum Toxin A Clinic: Factors associated with a patient satisfaction.
Tuesday, August 29	13:00 - 15:00	768	A novel mobile application for monitoring the response to botulinum toxin in patients with Cervical Dystonia.
Tuesday, August 29	13:00 - 15:00	769	Persistence, Health Care Resource Utilization, and Costs Among OnabotulinumtoxinA-Treated Patients with Cervical Dystonia in the US
Tuesday, August 29	13:00 - 15:00	770	Botulinum toxin injections for lingual protrusion dystonia: a review of the muscle target and dosage
Tuesday, August 29	13:00 - 15:00	771	Dystonia Treatment With Injections Supplemented by TMS: the D-TWIST Study
Tuesday, August 29	13:00 - 15:00	772	Double lesion magnetic resonance-guided focused ultrasound treatment for cervical dystonia: a pilot study of two targets combination based on clinical symptoms

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	773	Role of bilateral pallidotomy in status dystonicus
Tuesday, August 29	13:00 - 15:00	774	Telehealth Follow-up for Cervical Dystonia Treated with Neurotoxin Injection
Tuesday, August 29	13:00 - 15:00	775	Effects of thalamic deep brain stimulation on focal hand dystonia
Tuesday, August 29	13:00 - 15:00	776	Patient characteristics and real-world use of botulinum toxins for treatment of cervical dystonia and blepharospasm
Tuesday, August 29	13:00 - 15:00	777	Botulinum toxin treatment for focal dystonia in a Tunisian cohort
Tuesday, August 29	13:00 - 15:00	778	A Phase 2, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults with Isolated Cervical Dystonia
Tuesday, August 29	13:00 - 15:00	779	Bilateral Globus Pallidus Internus Deep Brain Stimulation for Cervical Dystonia: Effects on Motor and Non-Motor Symptoms within 5 Years Follow Up
Tuesday, August 29	13:00 - 15:00	780	Risk Factors for Stimulation-Induced Bradykinesia in Dystonia Patients Treated with Deep Brain Stimulation: A Retrospective Analysis.
Tuesday, August 29	13:00 - 15:00	781	Perception of the subjective visual vertical in subjects with cervical dystonia
Tuesday, August 29	13:00 - 15:00	782	Real-world retrospective safety analysis of onabotulinumtoxinA for the treatment of patients with concurrent cervical dystonia and chronic migraine
Tuesday, August 29	13:00 - 15:00	783	Incidence of dysphagia and comorbidities in patients with cervical dystonia, analyzed by botulinum neurotoxin treatment exposure
Tuesday, August 29	13:00 - 15:00	784	New DBS targets for dystonia in thalamus and brainstem
Tuesday, August 29	13:00 - 15:00	785	Validating A New Writer's Cramp Impairment Scale
Tuesday, August 29	13:00 - 15:00	786	The effect of botulinum toxin on anxiety in cervical dystonia.
Tuesday, August 29	13:00 - 15:00	787	Sex Is Not a Major Determinant of Pallidus Internus Deep Brain Stimulation Outcome in Dystonia
Tuesday, August 29	13:00 - 15:00	788	blepharoplasty yes or not? a single-centre study on the influence of blepharoplasty on the treatment with botulinum toxin injections.
Tuesday, August 29	13:00 - 15:00	789	Updates on the Outcomes of Botulinum Toxin Injections in Patients with Lower Limb Dystonia
Tuesday, August 29	13:00 - 15:00	790	Ultra long-term outcome of deep brain stimulation (DBS) compared to botulinum toxin (BoNT) treatment in cervical dystonia (CD)
Tuesday, August 29	13:00 - 15:00	791	Long term treatment with botulinum neurotoxin for focal dystonia – effect of dose and dilution
Tuesday, August 29	13:00 - 15:00	792	A case of idiopathic lower limb dystonia treated with combined use of botulinum toxin type A and phenol nerve block
Tuesday, August 29	13:00 - 15:00	793	The use of pallidal deep brain stimulation (GPI-DBS) to treat GNAO1 gene associated hyperkinetic syndromes
Tuesday, August 29	13:00 - 15:00	794	Case report of 21 y/o. patient with 9 years of DBS in dystonia history and socioeconomic outcome.
Tuesday, August 29	13:00 - 15:00	795	Transcriptomic profiling in DYT1 dystonia: unravelling pathogenic pathways.
Tuesday, August 29	13:00 - 15:00	796	Establishing a Natural History of X-linked Dystonia Parkinsonism
Tuesday, August 29	13:00 - 15:00	797	The Pain in Dystonia Scale (PIDS): Development and Validation
Tuesday, August 29	13:00 - 15:00	798	Dystonia and women: impact on reproductive life, life satisfaction and psychosocial factors
Tuesday, August 29	13:00 - 15:00	799	Oh man: Why are males more prone to Musician's Dystonia?
Tuesday, August 29	13:00 - 15:00	800	The role of genetic testing in Dystonia diagnosis
Tuesday, August 29	13:00 - 15:00	801	Pain and quality of life in cervical dystonia
Tuesday, August 29	13:00 - 15:00	802	A Comparison of Cervical Dystonia in Parkinson's Disease and Idiopathic Isolated Cervical Dystonia
Tuesday, August 29	13:00 - 15:00	803	Bradykinesia in Patients with Cervical Dystonia: Objective Assessment with Optical Sensor
Tuesday, August 29	13:00 - 15:00	804	Hand to mouth: differences between musicians' hand and embouchure dystonia
Tuesday, August 29	13:00 - 15:00	805	Mutation screening of PCDHGB1 variants in a large dystonia cohort

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	806	Presenting the Dystonia Pain Classification System (Dystonia-PCS)
Tuesday, August 29	13:00 - 15:00	807	Dystonia in the Middle East - The Cleveland Clinic Abu Dhabi Experience
Tuesday, August 29	13:00 - 15:00	808	Monogenic Dystonia and Deep Brain Stimulation: Single Center Experience
Tuesday, August 29	13:00 - 15:00	809	Chromosomal Microarray Analysis for genetic evaluation of dystonia
Tuesday, August 29	13:00 - 15:00	810	Exome-wide and Mitogenome Sequencing of Indian Dystonia Patients
Tuesday, August 29	13:00 - 15:00	811	Clinical presentation and evolution of isolated focal and segmental dystonia in adults – 20 years experience from a botulinum toxin clinic
Tuesday, August 29	13:00 - 15:00	812	Custom-made Application Interface using Wacom® Tablet for Assessment of Writer's Cramp
Tuesday, August 29	13:00 - 15:00	813	Cervical Dystonia Patients with Psychiatric Disorders Show More Motor and Less Non-Motor Improvement after DBS surgery.
Tuesday, August 29	13:00 - 15:00	814	Hemi-dystonia secondary to encephalitis and its response to staged pallidotomy
Tuesday, August 29	13:00 - 15:00	815	Diagnostic and treatment burden of dystonia in Turkey: a patient journey map
Tuesday, August 29	13:00 - 15:00	816	The Link between Handedness and Prevalence of Writer's Cramp – A Systematic Literature Review
Tuesday, August 29	13:00 - 15:00	817	DYT1 gene mutation: an atypical presentation with myoclonic dystonia
Tuesday, August 29	13:00 - 15:00	818	PFBC and dystonia: description of a cohort and peculiar cases
Tuesday, August 29	13:00 - 15:00	819	Hereditary spastic paraparesis due to SPG11 gene mutation presenting as dopa responsive dystonia
Tuesday, August 29	13:00 - 15:00	820	Hereditary generalised dystonia associated with a new large duplication on the X chromosome
Tuesday, August 29	13:00 - 15:00	821	A novel THAP1 variant presenting with early-onset generalized dystonia in a family
Tuesday, August 29	13:00 - 15:00	822	dystonia caused by a rare variant of TUBB4A gene: a case report in a non-asian population
Tuesday, August 29	13:00 - 15:00	823	Voice- tremor in a patient with positive VPS 16 nonsense mutation: Expanding the phenotype
Tuesday, August 29	13:00 - 15:00	824	Association of NOTCH2NLC repeat expansions with dystonia
Tuesday, August 29	13:00 - 15:00	825	Case of neuroferritinopathy with isolated dystonic leg cramps and normal neuroimaging
Tuesday, August 29	13:00 - 15:00	826	The Link between Handedness and Prevalence of Musician's Dystonia – A Systematic Literature Review
Tuesday, August 29	13:00 - 15:00	827	Case report of atypical PKAN expressed in late sixth-decade
Tuesday, August 29	13:00 - 15:00	828	Genetic spectrum of monogenic dystonia in Asian Indian patients
Tuesday, August 29	13:00 - 15:00	829	Understanding neuropsychological features of dopa responsive dystonia in children
Tuesday, August 29	13:00 - 15:00	830	Genetic variant in the VPS16 gene in a 43-year-old patient with generalized dystonia.
Tuesday, August 29	13:00 - 15:00	831	Double trouble: dystonic tremor due to FXTAS in a SCA1 family
Tuesday, August 29	13:00 - 15:00	832	Metoclopramide-induced acute dystonic reaction caused by CYP2D6 *4/*4 and CYP2D6 *10/*10 genotypes
Tuesday, August 29	13:00 - 15:00	833	Childhood-onset writer's cramp evolving to generalised dystonia –a new mutation in KMT2B gene
Tuesday, August 29	13:00 - 15:00	834	Pronounced Cervical Dystonia in Ataxia with Vitamin E Deficiency
Tuesday, August 29	13:00 - 15:00	835	The Pistol Sign
Tuesday, August 29	13:00 - 15:00	836	Dystonic tremor as main manifestation of a large SCA21 family
Tuesday, August 29	13:00 - 15:00	837	Exploring the effects of torsinA dysfunction in an iPSC-derived neuronal model of TOR1A dystonia
Tuesday, August 29	13:00 - 15:00	838	Analysis of functional connectivity using machine learning and deep learning in EEG data from patients with focal dystonia

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	840	Multimodal neuroimaging to probe brain networks in Cervical Dystonia.
Tuesday, August 29	13:00 - 15:00	841	A portable and distributable measure of temporal discrimination: an objective means for diagnosis of cervical dystonia.
Tuesday, August 29	13:00 - 15:00	842	The use of contrast-enhanced ultrasonography of muscle spasticity and myofascial trigger points
Tuesday, August 29	13:00 - 15:00	843	Structural MRI Analysis of Basal Ganglia volume and White Matter Tracts in Upper Limb Dystonia
Tuesday, August 29	13:00 - 15:00	844	Transcranial magnetic stimulation study in primary dystonia of presumed genetic etiology
Tuesday, August 29	13:00 - 15:00	845	Visual dysfunction of the Superior Colliculus in idiopathic Blepharospasm: a pilot study
Tuesday, August 29	13:00 - 15:00	846	Individual-specific brain functional connectivity mapping of therapeutic response in task-specific focal dystonia
Tuesday, August 29	13:00 - 15:00	847	A role of transcranial sonography in evaluating patients with dystonia and tremor
Tuesday, August 29	13:00 - 15:00	848	Brain metabolic response of primary sensory cortex transcranial magnetic stimulation in cervical dystonia
Tuesday, August 29	13:00 - 15:00	849	The Dystonic Drive – A Systematic Review on Coherence Analysis in Dystonia
Tuesday, August 29	13:00 - 15:00	850	Quantifying the impact of sensory tricks on the overall severity of cervical dystonia
Tuesday, August 29	13:00 - 15:00	852	In vivo assessment of striatal compartments in patients with idiopathic upper limb dystonia
Tuesday, August 29	13:00 - 15:00	853	Social cognition in cervical dystonia: an fMRI study
Tuesday, August 29	13:00 - 15:00	854	DBS and neck muscle vibration shift impaired pallidal multifractal complexity towards the normal state in dystonia patients
Tuesday, August 29	13:00 - 15:00	855	Abnormal sense of agency is involved in myoclonus dystonia phenotype through a cerebellar impairment
Tuesday, August 29	13:00 - 15:00	856	Epidemiological, clinical and paraclinical characteristics of paroxysmal dystonia in multiple sclerosis : A study of Tunisian cohort
Tuesday, August 29	13:00 - 15:00	857	Hemidystonia of cerebellar origin
Tuesday, August 29	13:00 - 15:00	858	Post encephalitic dystonia-ataxia syndrome
Tuesday, August 29	13:00 - 15:00	859	A white matter disease with blooming grey matter
Tuesday, August 29	13:00 - 15:00	860	Cervical Dystonia as a post Wernicke's Encephalopathy sequelae.
Tuesday, August 29	13:00 - 15:00	861	Space-occupying lesion presenting with hand dystonia
Tuesday, August 29	13:00 - 15:00	862	Hemibody dystonia secondary to Neurobehçet disease : a case report
Tuesday, August 29	13:00 - 15:00	863	A rare case of PDE10A associated dystonia with bilateral striatal lesions
Category: Hyperkinetic Movement Disorders II (865 – 1030)			
Tuesday, August 29	13:00 - 15:00	865	AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington's disease minipigs up to 5 years
Tuesday, August 29	13:00 - 15:00	866	Effects of a small molecule angiotensin IV analog on Huntington's disease animal model
Tuesday, August 29	13:00 - 15:00	868	Understanding caffeine consumption in Huntington's Disease
Tuesday, August 29	13:00 - 15:00	869	The Blood-Brain Barrier Integrity and Prevalence of Intrathecal T Helper 17.1 Cells in Huntington's Disease
Tuesday, August 29	13:00 - 15:00	870	The role of the default mode network and striatal circuits in the expression of depressive symptoms in premanifest Huntington's disease
Tuesday, August 29	13:00 - 15:00	871	Characterization of social cognition impairment in Huntington's disease
Tuesday, August 29	13:00 - 15:00	872	Levodopa-induced dyskinesia and Huntington's chorea: link to current motor control theories
Tuesday, August 29	13:00 - 15:00	873	A case of trichotillomania as the preceding symptom of Huntington's disease and the effect of risperidone
Tuesday, August 29	13:00 - 15:00	874	Longitudinal imaging of regional volumes, presynaptic terminals and glucose metabolism in brains of people with early Huntington's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	876	Case Study: Pitfalls of Commercial Genetic Testing for Huntington's Disease
Tuesday, August 29	13:00 - 15:00	877	Neurologic music therapy for fine motor rehabilitation in Huntington's disease: a pilot study
Tuesday, August 29	13:00 - 15:00	878	Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington's disease
Tuesday, August 29	13:00 - 15:00	879	Chorea improvements over time with once-daily valbenazine treatment in adults with Huntington disease
Tuesday, August 29	13:00 - 15:00	880	A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease
Tuesday, August 29	13:00 - 15:00	881	Regional brain volume and cognitive alterations in Huntington's Disease Patients
Tuesday, August 29	13:00 - 15:00	882	Telemedicine and in-person encounters in a Huntington's disease cohort: virtually the same
Tuesday, August 29	13:00 - 15:00	883	24(S)-Hydroxycholesterol and cognition in Huntington's disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)
Tuesday, August 29	13:00 - 15:00	884	Discriminative properties and sensitivity to change of three cognitive assessment instruments in Huntington's disease
Tuesday, August 29	13:00 - 15:00	885	Self-report vs. informant-report of problematic behaviors using the Huntington's Disease-Behavioral Questionnaire
Tuesday, August 29	13:00 - 15:00	886	Emerging treatments targeting DNA and RNA in Huntington's disease: a review of future perspectives and current challenges
Tuesday, August 29	13:00 - 15:00	887	Pilot study of outpatient rehabilitation of patients with Huntington's disease in Russia
Tuesday, August 29	13:00 - 15:00	888	Effects of cerebellar cTBS on motor symptoms in Huntington's disease: a feasibility and pilot study
Tuesday, August 29	13:00 - 15:00	889	Epidemiological analysis of autosomal dominant chorea in Eastern Algeria
Tuesday, August 29	13:00 - 15:00	890	Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease
Tuesday, August 29	13:00 - 15:00	891	Racial and Ethnic Differences in Suicidal Ideation in North American patients with Huntington's Disease: Analysis using the ENROLL-HD Dataset
Tuesday, August 29	13:00 - 15:00	892	Transition among HD-ISS stages as an endpoint in clinical trials for HD
Tuesday, August 29	13:00 - 15:00	893	Apathy and impulsivity co-occur in Huntington's disease
Tuesday, August 29	13:00 - 15:00	894	Huntington's disease patients with intermediate allele in Tunisia
Tuesday, August 29	13:00 - 15:00	895	Cortical Control of Gait and Balance During Single and Dual Tasks in Huntington's Disease: an fNIRS study
Tuesday, August 29	13:00 - 15:00	896	Melatonin for huntington disease (HD) gene carriers with HD-related sleep disturbance - a pilot study
Tuesday, August 29	13:00 - 15:00	897	Hazard ratios of suicidality in a large Huntington disease population compared with controls: marginal structural modeling of Enroll-HD registry data
Tuesday, August 29	13:00 - 15:00	898	Clinical correlates of olfactory dysfunction in Huntington's disease
Tuesday, August 29	13:00 - 15:00	900	Gemini digital twins identified neuro-common and disease-specific drivers of rate of change in NFL in Huntington's disease, Parkinson disease and Alzheimer disease
Tuesday, August 29	13:00 - 15:00	901	Real-world effectiveness and safety of deutetrabenazine in patients with chorea associated with Huntington disease
Tuesday, August 29	13:00 - 15:00	902	Modifying clinical and electrophysiological parameters through Transcranial pulsed current stimulation (tPCS) in Huntington disease
Tuesday, August 29	13:00 - 15:00	903	Study protocol for the iMarkHD study in individuals with Huntington's disease
Tuesday, August 29	13:00 - 15:00	904	Localisation of distinct brain networks in premanifest and manifest Huntington's disease
Tuesday, August 29	13:00 - 15:00	905	Education level and the onset and severity of symptoms in Huntington's disease
Tuesday, August 29	13:00 - 15:00	906	Feeding dystonia revealing Huntington's disease, about a case
Tuesday, August 29	13:00 - 15:00	907	Huntington's disease in Senegal Epidemiological and clinical aspects
Tuesday, August 29	13:00 - 15:00	909	Clinical and molecular features of Tunisian patients with Biallelic mutations in Huntington's Disease
Tuesday, August 29	13:00 - 15:00	910	A family of Huntington's disease with genetic anticipation in its paternal inheritance

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	911	Characteristics of Huntington disease in a north Indian cohort
Tuesday, August 29	13:00 - 15:00	912	Effectiveness of deep brain stimulation in the treatment of Huntington's disease
Tuesday, August 29	13:00 - 15:00	913	Cervical dystonia with early onset as initial manifestation of adult-onset Huntington's disease
Tuesday, August 29	13:00 - 15:00	914	Opsoclonus Myoclonus Syndrome due to subdural hematoma: an uncommon etiology
Tuesday, August 29	13:00 - 15:00	915	Unilateral GPi DBS in Secondary Myoclonus-Dystonia Syndrome after Acute Disseminated Encephalomyelitis: A Case Report
Tuesday, August 29	13:00 - 15:00	916	Diaphragmatic flutter - when the diaphragm does not obey
Tuesday, August 29	13:00 - 15:00	917	Initial triggering in tibial group and subsequent slow spread of myoclonus from brain stem to eye-balls in Subacute Sclerosing Pan Encephalitis
Tuesday, August 29	13:00 - 15:00	918	Jaw opening myoclonus in Subacute Sclerosing Panencephalitis: A new phenotypic observation which may be a diagnostic clue
Tuesday, August 29	13:00 - 15:00	919	Generalized acute myoclonus caused by chikungunya virus encephalitis: case report.
Tuesday, August 29	13:00 - 15:00	920	Atypical Manifestations of Subacute Sclerosing Panencephalitis (SSPE): A Case Series from India
Tuesday, August 29	13:00 - 15:00	922	refractory myoclonus after COVID-19 with resolution after corticosteroids; a case report with brain biopsy and serial neuroimaging.
Tuesday, August 29	13:00 - 15:00	923	Autoantibody-negative but probable autoimmune hyperreflexia myoclonus syndrome: a case report
Tuesday, August 29	13:00 - 15:00	924	Myoclonus Phenomenology and its Response to Antiepileptic drugs in Patients with Sub acute Sclerosing Pan encephalitis
Tuesday, August 29	13:00 - 15:00	925	COVID-19 associated opsoclonus myoclonus ataxia syndrome
Tuesday, August 29	13:00 - 15:00	926	Hemifacial Spasm: Recent experience in a movement disorders reference center in Chile
Tuesday, August 29	13:00 - 15:00	927	The Great Mimicker Strikes Again
Tuesday, August 29	13:00 - 15:00	928	Post-hypoxic myoclonus after bilateral pallidal stimulation: A case report
Tuesday, August 29	13:00 - 15:00	929	Clinical features and phenoconversion risk in women with isolated REM sleep behavior disorder
Wednesday, August 30	13:00 - 15:00	1987	REM sleep behavior disorder in Parkinson's Disease: a risk factor for Impulse Control Disorders.
Wednesday, August 30	13:00 - 15:00	930	REM sleep behavior disorder in Parkinson's Disease: a risk factor for Impulse Control Disorders.
Tuesday, August 29	13:00 - 15:00	931	Post stroke Restless Limb Syndrome and its impact on sleep and life quality in patients in Rural Gujarat, India
Tuesday, August 29	13:00 - 15:00	932	restless leg syndrome in parkinson's disease patients: prevalence and correlates with sleep parameters
Tuesday, August 29	13:00 - 15:00	933	REM sleep behaviour disorder in Parkinson's disease: prevalence and correlation with other sleep parameters
Tuesday, August 29	13:00 - 15:00	934	Prevalence of sleep disorders in patients with Parkinson's disease undergoing screening: a retrospective study.
Tuesday, August 29	13:00 - 15:00	935	Restless legs syndrome may be associated with freezing of gait, start hesitation and falls in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	936	Neural activity in pedunculo pontine nucleus during sleep
Tuesday, August 29	13:00 - 15:00	937	Impact of globus pallidus interna deep brain stimulation on REM sleep behavior disorder in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	938	Epigenetic clock acceleration is linked to earlier onset and phenoconversion of Rapid-eye-movement sleep behavior disorder
Tuesday, August 29	13:00 - 15:00	939	Gender differences in REM Sleep Behavior Disorder in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	940	Globus pallidus interna deep brain stimulation for Parkinson's Disease: Impact on Restless Legs Syndrome
Tuesday, August 29	13:00 - 15:00	941	Stiff-Person Syndrome: Diagnosis and Experimental Models
Tuesday, August 29	13:00 - 15:00	943	Neuroimaging and correlation with functional status in children with cerebral palsy
Tuesday, August 29	13:00 - 15:00	944	Ultrasound-guided selective diagnostic nerve block in patients with elbow spasticity: a retrospective pilot study.

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	946	Improvement in spasticity-associated dressing- and hygiene-related disability in adults following treatment with incobotulinumtoxinA: a pooled analysis
Tuesday, August 29	13:00 - 15:00	947	Quantitative gait analysis to evaluate changes in gait pattern after Botulinum toxin A injection by hemiparesis
Tuesday, August 29	13:00 - 15:00	948	Spectrum of Hereditary Spastic Paraparesis (HSP): A study from India
Tuesday, August 29	13:00 - 15:00	949	Expanding the spectrum of Hereditary Spastic Paraplegia: An interesting Case .
Tuesday, August 29	13:00 - 15:00	950	Association of sex with health-related quality of life in adults with chronic tic disorders
Tuesday, August 29	13:00 - 15:00	951	New machine learning approaches in tic detection: Seeking to learn more about the characteristic of tics
Tuesday, August 29	13:00 - 15:00	952	Long-term safety and durability of effect of ecopipam in pediatric patients with Tourette Syndrome: Results of a 12-month open-label extension (OLE) study
Tuesday, August 29	13:00 - 15:00	953	Automatic assessment of tic expression using selfie-video
Tuesday, August 29	13:00 - 15:00	954	Premonitory urge in patients with tics and functional tic-like behaviors
Tuesday, August 29	13:00 - 15:00	955	Tourettism occurring during gender transition with testosterone therapy
Tuesday, August 29	13:00 - 15:00	957	Anti-tremor efficacy of Nabiximols (JZP378) in a rat Model of essential tremor
Tuesday, August 29	13:00 - 15:00	958	Frequency coding mechanism of tremor in the cerebellar circuitry
Tuesday, August 29	13:00 - 15:00	959	Spiral drawing features are similar between essential tremor and essential tremor plus
Tuesday, August 29	13:00 - 15:00	960	Asymmetry and side concordance of rest tremor and bradykinesia in patients with essential tremor
Tuesday, August 29	13:00 - 15:00	961	Reconstruction of the dentato-rubro-thalamic tract based on the anatomy of the rubral wing
Tuesday, August 29	13:00 - 15:00	962	Weighing tremor reduction and side effects: Impact of efficacy and safety outcomes on patient satisfaction at 6 months in MR-guided focused ultrasound thalamotomy for tremor treatment
Tuesday, August 29	13:00 - 15:00	963	Relationship between postural and kinetic tremor control with VIM-DBS in Essential Tremor
Tuesday, August 29	13:00 - 15:00	964	Subject-specific investigation of pathways underlying therapeutic outcomes of deep brain stimulation for Essential Tremor
Tuesday, August 29	13:00 - 15:00	965	An evaluation of NBI-827104 for essential tremor: results from a randomized, double-blind, placebo-controlled, dose-escalation, crossover study
Tuesday, August 29	13:00 - 15:00	966	Development and validation of a new wearable device for the differential diagnosis of resting tremor
Tuesday, August 29	13:00 - 15:00	967	Testing for alcohol responsivity in familial essential tremor
Tuesday, August 29	13:00 - 15:00	968	Peripheral Synucleinopathy in Essential Tremor Plus Patients with Parkinsonian Features and Normal Dopamine Transporter Imaging
Tuesday, August 29	13:00 - 15:00	969	Instability after MRig-FUS thalamotomy: why does it appear?
Tuesday, August 29	13:00 - 15:00	970	Internal tremor in Parkinson disease and essential tremor: a new glance at a common symptom
Tuesday, August 29	13:00 - 15:00	971	Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research
Tuesday, August 29	13:00 - 15:00	972	Deep Brain Stimulation for Multiple Sclerosis Tremors: A Case Series
Tuesday, August 29	13:00 - 15:00	973	Asymmetry and the development of phase-specific deep brain stimulation for essential tremor
Tuesday, August 29	13:00 - 15:00	974	Accelerometric Classification of Resting and Postural Tremor in Essential Tremor and Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	975	Association of fecal short-chain fatty acids with clinical severity and gut microbiota in Essential tremor and its differences from Parkinson's disease
Tuesday, August 29	13:00 - 15:00	976	Age at Onset and Therapeutic Efficacy of Primidone in Essential Tremor Patients
Tuesday, August 29	13:00 - 15:00	977	Usability of Parkinson's KinetiGraph in deep brain stimulation for essential tremor
Tuesday, August 29	13:00 - 15:00	978	Cortical mean diffusivity and cortical thickness in essential tremor
Tuesday, August 29	13:00 - 15:00	979	Evaluation of blood heavy metal concentrations in patients with essential tremor

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	980	Asymmetry of striatal dopaminergic function in essential tremor is associated with kinetic tremor asymmetry
Tuesday, August 29	13:00 - 15:00	981	The feasibility of MRI guided focused ultrasound for posttraumatic tremor with prior hemicraniotomy and skull defect
Tuesday, August 29	13:00 - 15:00	982	Bilateral staged MR-guided focused ultrasound thalamotomy for Essential Tremor: one-year follow-up results
Tuesday, August 29	13:00 - 15:00	983	Essential tremor suppression using a novel anti-tremor orthosis
Tuesday, August 29	13:00 - 15:00	984	transformation of essential tremor into Parkinson's disease
Tuesday, August 29	13:00 - 15:00	985	A randomised, double blind, placebo controlled, crossover trial of incobotulinum toxin A treatment for upper limb tremor
Tuesday, August 29	13:00 - 15:00	986	Preliminary report of cerebellar transcranial focused ultrasound for primary orthostatic tremor
Tuesday, August 29	13:00 - 15:00	987	Rest Tremor in Parkinson's Disease Is Associated with Increased Ipsilateral DAT Binding
Tuesday, August 29	13:00 - 15:00	988	Tremor characteristics in patients with chronic inflammatory demyelinating polyneuropathy
Tuesday, August 29	13:00 - 15:00	989	Relationship between bradykinesia and cognitive functions in patients with essential tremor
Tuesday, August 29	13:00 - 15:00	990	A digital differential diagnostic aid for Parkinson's disease and other tremor disorders
Tuesday, August 29	13:00 - 15:00	991	Microstructural abnormalities of the dentato-rubro thalamo-cortical tract in tremor dominant PD and ET plus syndrome: A DTI, NODDI and free water-based analysis
Tuesday, August 29	13:00 - 15:00	992	Phenotypic presentation of essential tremor patients with Rapid eye movement disorder
Tuesday, August 29	13:00 - 15:00	993	Axial tremor response to tractography-defined focused ultrasound thalamotomy for essential tremor: a prospective study
Tuesday, August 29	13:00 - 15:00	994	Proposed model for the delivery of tertiary-care, interdisciplinary tremor evaluations.
Tuesday, August 29	13:00 - 15:00	995	Outcomes of patients treated with staged bilateral MRgHIFU thalamotomy using four-tract tractography targeting for medically refractory Essential Tremor
Tuesday, August 29	13:00 - 15:00	996	Serum neurofilament light-chain concentrations in essential tremor: A case-control study
Tuesday, August 29	13:00 - 15:00	998	Botulinum toxin-A in head and upper extremities tremor. A hand-made option
Tuesday, August 29	13:00 - 15:00	999	A single centre retrospective study of dual target deep brain stimulation for clinically complex essential and dystonic tremor – a 5-year follow up
Tuesday, August 29	13:00 - 15:00	1000	Cognition evaluation in patients following focused ultrasound thalamotomy for tremor
Tuesday, August 29	13:00 - 15:00	1001	3D-accelerometry characteristics of essential tremor and dystonic tremor
Tuesday, August 29	13:00 - 15:00	1002	Essential tremor and essential tremor plus are essentially similar on electrophysiological tremor analysis
Tuesday, August 29	13:00 - 15:00	1003	Human cerebellum contributes to the motor frequency coding for essential tremor and volitional rhythmic movements
Tuesday, August 29	13:00 - 15:00	1004	Diagnostic accuracy of susceptibility map-weighted MRI for discriminating tremor-dominant Parkinson's disease and essential tremor
Tuesday, August 29	13:00 - 15:00	1005	Comparing the Connectivity of Thalamic Deep Brain Stimulation Sites in ET and ET Plus Syndrome
Tuesday, August 29	13:00 - 15:00	1006	Circadian rhythm and adaptive deep brain stimulation in essential tremor
Tuesday, August 29	13:00 - 15:00	1007	Isolated vocal tremor: a case series
Tuesday, August 29	13:00 - 15:00	1008	Botulinum neurotoxin in FXTAS-related tremor: a “successful” case report
Tuesday, August 29	13:00 - 15:00	1009	Worsening of Essential Tremor after SARS-CoV-2 infection: 1 year follow up.
Tuesday, August 29	13:00 - 15:00	1010	Tremors and More: A Case Report of TBK1 Mutation and Electrophysiological Assessment
Tuesday, August 29	13:00 - 15:00	1011	Jerky dystonic hand revisited: post-stroke thalamic tremor
Tuesday, August 29	13:00 - 15:00	1012	Parkinsonian tremor secondary to Sinking flap syndrome - An atypical presentation
Tuesday, August 29	13:00 - 15:00	1013	A Case of Post-malaria neurological syndrome presenting with tremor

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1014	Myotonic Dystrophy type 1 presenting as postural tremor
Tuesday, August 29	13:00 - 15:00	1015	Cognitive profile of essential tremor patients: Beyond the cerebellar cognitive affective syndrome
Tuesday, August 29	13:00 - 15:00	1016	Tremor in patients with chronic inflammatory demyelinating polyneuropathy: prevalence and severity
Tuesday, August 29	13:00 - 15:00	1017	Billiards-related tremor: a form of task-specific tremor
Tuesday, August 29	13:00 - 15:00	1018	A clinical case of subdural hematoma caused by a tic-like head banging in a patient with neurodevelopmental disorder
Tuesday, August 29	13:00 - 15:00	1019	Pilot study incorporating outcome measures after paediatric deep brain stimulation with patient and carer expectations and satisfaction
Tuesday, August 29	13:00 - 15:00	1020	Movement disorders in children with progressive myoclonic epilepsies
Tuesday, August 29	13:00 - 15:00	1021	Efficacy and safety of deutetrabenazine in children and adolescents with dyskinesia in cerebral palsy
Tuesday, August 29	13:00 - 15:00	1022	The phenotypic landscape and genetic profile of movement disorders in a cohort of tunisian children
Tuesday, August 29	13:00 - 15:00	1023	Deep Brain Stimulation Duration and Changes in Basal Ganglia Excitatory/Inhibitory Balance in Children and Young Adults with Dystonia
Tuesday, August 29	13:00 - 15:00	1024	Movement disorders in children with neurometabolic and neurodegenerative disorders: A single-center prospective study
Tuesday, August 29	13:00 - 15:00	1025	Hyperkinetic dystonia in dyskinetic cerebral palsy responds to combined DBS stimulation in thalamus and pallidum.
Tuesday, August 29	13:00 - 15:00	1026	Pediatric Myoclonus-Dystonia misdiagnosed as CASPR2 encephalitis – a diagnostic challenge
Tuesday, August 29	13:00 - 15:00	1027	Deep brain stimulation for the management of movement disorders in Rett syndrome
Tuesday, August 29	13:00 - 15:00	1028	Movement disorders (MD) after stroke in childhood
Tuesday, August 29	13:00 - 15:00	1029	TELO2 defect presenting with childhood-onset complex hyperkinetic MD
Tuesday, August 29	13:00 - 15:00	1030	VPS11 associated movement disorder in a pediatric case
Category: Genetics and Metabolic Diseases (1031 – 1180):			
Tuesday, August 29	13:00 - 15:00	1031	Mosaic divergent repeat interruptions in X-linked dystonia-parkinsonism: stability over generations and time
Tuesday, August 29	13:00 - 15:00	1032	Overlapping Pathogenetic Findings in Developmental Coordination Disorder (DCD), Ataxia, Dystonia and Myoclonus: is DCD part of a Movement Disorder Spectrum?
Tuesday, August 29	13:00 - 15:00	1033	Striatal neurodegeneration in female carriers of the TAF1 Mutation Causing X-linked Dystonia-Parkinsonism
Tuesday, August 29	13:00 - 15:00	1034	Exome sequencing of 584 Chinese proband with brain calcification
Tuesday, August 29	13:00 - 15:00	1035	Gene rearrangement as the cause of hereditary Hypomyelinating Leukodystrophy disease type 5 (HLD5)
Tuesday, August 29	13:00 - 15:00	1036	Outcomes From Genetic Testing in a UK Movement Disorder Clinic
Tuesday, August 29	13:00 - 15:00	1037	Identification of atlastin genetic modifiers in a Hereditary Spastic Paraplegia model in Drosophila
Tuesday, August 29	13:00 - 15:00	1038	Combined GWAS of Dementia with Lewy Bodies, REM-Sleep Behavior Disorder, Parkinson's Disease and Alzheimer's Disease
Tuesday, August 29	13:00 - 15:00	1039	Genetic diagnosis of parkinsonian phenotype of Machado Joseph Disease (SCA-3) presenting with dopa induced dyskinesia
Tuesday, August 29	13:00 - 15:00	1040	Speech, gait and vestibular instrumental assessment in CANVAS: a case series.
Tuesday, August 29	13:00 - 15:00	1041	Clinical and genetic characteristics of a cohort of 20 patients with confirmed biallelic pathogenic SPG7 mutations from the North West of England
Tuesday, August 29	13:00 - 15:00	1042	Spinocerebellar ataxia type 28 presenting as spastic paraparesis
Tuesday, August 29	13:00 - 15:00	1043	Paroxysmal Kinesigenic Dyskinesia caused by a novel missense variant in NBEA
Tuesday, August 29	13:00 - 15:00	1044	Heterozygous aprataxin gene mutation associated with atypical multiple system atrophy phenotype: a case report
Tuesday, August 29	13:00 - 15:00	1045	FRMD5 de novo variants in two cases with childhood onset ataxia and seizures

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1046	Hereditary spastic paraplegia type 4 (SPG4): an international multicenter clinical and genetic study
Tuesday, August 29	13:00 - 15:00	1047	Yet another cause of Corticobasal Syndrome: A case of TREM2 related Alzheimer's Disease presenting as Corticobasal Syndrome
Tuesday, August 29	13:00 - 15:00	1048	Progressive myoclonic epilepsy ataxia syndrome associated with NUS1 gene mutation
Tuesday, August 29	13:00 - 15:00	1049	Impacts of mutations in Parkinson's disease-related genes on telomere maintenance
Tuesday, August 29	13:00 - 15:00	1050	Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson's disease patients.
Tuesday, August 29	13:00 - 15:00	1051	The role of RNA-carrying exosomes in synaptic physiology and in synucleinopathies
Tuesday, August 29	13:00 - 15:00	1053	Genome Wide Association Studies using TRACTOR reveals new associated loci with Parkinson Disease in a Latino Cohort
Tuesday, August 29	13:00 - 15:00	1054	Uncovering the mechanisms of genotype by environment interaction in an idiopathic Parkinson's disease model in Drosophila
Tuesday, August 29	13:00 - 15:00	1055	The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening
Tuesday, August 29	13:00 - 15:00	1056	Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson's disease: comparison with plasma miRNA
Tuesday, August 29	13:00 - 15:00	1057	Genome-wide association identifies novel etiological insights associated with Parkinson's Disease in African and African admixed populations
Tuesday, August 29	13:00 - 15:00	1058	Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1059	The study of genetic factors in levodopa-induced motor complications development in Russian patients with Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1060	Clinical characterization of Parkinson's disease patients with LRRK2 mutation: Insights from a Portuguese reference center
Tuesday, August 29	13:00 - 15:00	1061	Are GBA-Parkinson Disease patients' good candidates for Deep Brain Stimulation? A Longitudinal Multicentric study on a Large Italian Cohort
Tuesday, August 29	13:00 - 15:00	1062	Population-Scale Long-Read Sequencing to Catalog Structural Variants in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1063	Evaluation of possible pre-motor symptoms of Parkinson's disease in a GBA-mutation positive cohort, as well as Gaucher disease patients.
Tuesday, August 29	13:00 - 15:00	1064	Exome-wide contribution of ultra-rare variants to the genetic architecture of Parkinson's disease and Cutaneous Malignant Melanoma
Tuesday, August 29	13:00 - 15:00	1065	Effect of Sex on the association between GBA mutations and Cognitive Decline in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1066	Iron deposition and volume change of deep grey matter nuclei in PARK14 by Quantitative Susceptibility Mapping
Tuesday, August 29	13:00 - 15:00	1067	Genetic and functional analysis of CCDC88C mutations in patients with Parkinson's disease.
Tuesday, August 29	13:00 - 15:00	1068	The epigenetic association of Parkinson's disease risk gene- GPNMB rs199347 with drinking
Tuesday, August 29	13:00 - 15:00	1069	Genetics of Neurogenic Orthostatic Hypotension in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1070	Informing people with Parkinson's disease of their gene variant status: PD GENERation, a North American observational and registry study
Tuesday, August 29	13:00 - 15:00	1071	Genetic profile of early-onset Parkinson's Disease patients at a movement disorders center in Brazil
Tuesday, August 29	13:00 - 15:00	1072	Using Long read sequencing to identify complex structural variants in PRKN-PD
Tuesday, August 29	13:00 - 15:00	1073	Diffusion Tensor Imaging in GBA-related Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1074	Cardiovascular autonomic function in GBA-associated Parkinson's disease: a cross-sectional study
Tuesday, August 29	13:00 - 15:00	1075	Role of ATP10B variants in Parkinson Disease in a southern Spanish cohort
Tuesday, August 29	13:00 - 15:00	1076	Associations of IL-1 β and IL-6 gene polymorphisms with Parkinson's disease(PD)
Tuesday, August 29	13:00 - 15:00	1077	Analysis of α -Synuclein Seed Amplification Assay in Carriers of GBA and LRRK2 Pathogenic Variants
Tuesday, August 29	13:00 - 15:00	1078	Apolipoprotein E e4 genotype affects early motor progression in Parkinson's disease through an effect on cognition
Tuesday, August 29	13:00 - 15:00	1079	Testing gene-environment interaction in Parkinson's disease (PD) using whole-genome sequencing of pesticide-exposed cohorts.

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1080	Longitudinal clinical and biomarker characteristics of non-manifest GBA1 N409S carriers: the PPMI cohort
Tuesday, August 29	13:00 - 15:00	1081	DNA Methylation is associated with gene expression changes in sporadic Parkinson Disease in the PPMI cohort.
Tuesday, August 29	13:00 - 15:00	1082	Clinical Prediction of GBA Carrier Status in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1083	Plasma glucosylsphingosine in GBA1 E326K, N370S and L444P mutation carriers with and without Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1084	The spectrum of GBA mutations in the Korean population with Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1085	Mitochondrial DNA copy number is associated with the severity of motor symptoms and dementia in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1086	Whole exome sequencing of 67 Swedish Parkinson patients identifies a family with VPS35 D620N
Tuesday, August 29	13:00 - 15:00	1087	Clinico-genetic analysis of patients with Parkinson's disease and GBA mutations from a tertiary care teaching centre in India
Tuesday, August 29	13:00 - 15:00	1088	SLC1A7 mutation is a cause of the autosomal dominant form of Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1089	Cognitive assessment of Parkinson's disease carriers of the novel p.A30G mutation in the SNCA gene
Tuesday, August 29	13:00 - 15:00	1090	The prevalence and clinical features of GBA-related Parkinson's disease in a Slovak patient cohort
Tuesday, August 29	13:00 - 15:00	1091	Genetic subtypes of Parkinson's disease in a Colorado clinic
Tuesday, August 29	13:00 - 15:00	1092	Combined effect of polygenic background and GBA Pathogenic variants in Parkinson's disease risk
Tuesday, August 29	13:00 - 15:00	1093	Longitudinal change in clinical characteristics of LRRK2 carriers in a remote cohort
Tuesday, August 29	13:00 - 15:00	1094	GBA haplotypes and age at onset of Parkinson's disease in the Asian population
Tuesday, August 29	13:00 - 15:00	1096	Investigate the association of MAPT haplotype and neuroanatomical structure and its influence on the risk of Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1097	Genetics of Parkinson's Disease in Polish patients with positive family history-preliminary study.
Tuesday, August 29	13:00 - 15:00	1098	A newly implemented NGS-based method to detect GBA1 variants in patients with Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1099	Clinal comprehensive Next-gen gene panel for Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1101	Parkinson's disease in patients with Gaucher's disease - causation or association?
Tuesday, August 29	13:00 - 15:00	1102	Genetic outcomes of South Asian Parkinsonism cohort: from a tertiary care hospital
Tuesday, August 29	13:00 - 15:00	1103	Harmonizing genetic testing for early-onset Parkinson's disease: results of the PARKNET multicentric study
Tuesday, August 29	13:00 - 15:00	1104	A strategic training framework for building research capacity in the Global Parkinson's Genetics Program (GP2)
Tuesday, August 29	13:00 - 15:00	1105	Integrative analysis of fecal metabolomics and metagenomics for Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1106	The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1107	Detection and classification of GBA variants PD-related: is there sex unbalance?
Tuesday, August 29	13:00 - 15:00	1108	MR-morphological changes in PD patients with heterozygous GBA mutation
Tuesday, August 29	13:00 - 15:00	1109	monogenic parkinson's disease in a chilean cohort
Tuesday, August 29	13:00 - 15:00	1110	Dopamine Receptor Gene Polymorphism in L-Dopa Induced Dyskinesia- A Study from Eastern India
Tuesday, August 29	13:00 - 15:00	1111	Potential genetic link between type I diabetes and Parkinson's disease.
Tuesday, August 29	13:00 - 15:00	1112	Multimodal imaging analysis of autosomal recessive Parkinson's disease.
Tuesday, August 29	13:00 - 15:00	1113	Caffeine Intake Interacts with Gene Variants in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1114	Genetic study of early-onset Parkinson's disease in the Malaysian population

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1115	Very high frequency of early-onset Parkinson's disease with homozygous PRKN exon 3 deletion amongst indigenous populations in Sabah, Malaysia
Tuesday, August 29	13:00 - 15:00	1116	Gene-environment interactions for Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1117	Classification and genotype-phenotype relationships of GBA1 variants and Parkinson's disease: MDSGene Systematic Review
Tuesday, August 29	13:00 - 15:00	1118	A benign course of Parkinson's disease associated with different mutations in the glucocerebrosidase gene – a case series
Tuesday, August 29	13:00 - 15:00	1119	Machine learning reveals candidate genes from Parkinson's disease associated loci
Tuesday, August 29	13:00 - 15:00	1120	Pain in Monogenic Parkinson's disease: A systematic review
Tuesday, August 29	13:00 - 15:00	1121	Caveats regarding a family with PD and LRRK2 mutations
Tuesday, August 29	13:00 - 15:00	1122	Parkinson's Disease and Chronic Inflammatory Demyelinating Polyneuropathy: Broadening the Clinical Spectrum of VCP Mutations?
Tuesday, August 29	13:00 - 15:00	1123	Clinical and genetic profile of fifteen patients with PARK-PRKN: A largest single-center cohort from India.
Tuesday, August 29	13:00 - 15:00	1124	Novel RAB39B stop mutation in patient with typical Early-Onset Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1125	An SNCA triplication in a Kazakhstani patient with young-onset Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1126	The natural history of Parkinson's disease in LRRK2 G2019S carriers
Tuesday, August 29	13:00 - 15:00	1128	Dopamine-responsive x-linked parkinsonism-epilepsy due to phosphoglycerate kinase-1 deficiency
Tuesday, August 29	13:00 - 15:00	1129	Parkinson's disease and Charcot-Marie-Tooth type 2: coincidental or causal?
Tuesday, August 29	13:00 - 15:00	1130	GBA p.K198E mutation causing Parkinson Disease in Colombian population: the first clinical description
Tuesday, August 29	13:00 - 15:00	1131	monogenic parkinsonism in latin america: systematic review and meta-analysis
Tuesday, August 29	13:00 - 15:00	1132	Autosomal dominant Parkinson's disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report
Tuesday, August 29	13:00 - 15:00	1133	First case of sporadic ATP6AP2 Mutation reported in Asia in a Parkinson's Disease patient
Tuesday, August 29	13:00 - 15:00	1134	Conventional anti-epileptic drugs used in North Sea Progressive Myoclonus Epilepsy revisited in a Drosophila model
Tuesday, August 29	13:00 - 15:00	1135	Quasi tandem repeat in TCEG1 may influence age at onset of X-linked dystonia-parkinsonism
Tuesday, August 29	13:00 - 15:00	1136	Understanding the natural history of adrenomyeloneuropathy: disease burden and functional impairment over the first year of the CYGNET study
Tuesday, August 29	13:00 - 15:00	1137	Impaired Nt-acetylation and the Golgi, a new disease mechanism leading to autosomal recessive primary familial brain calcifications
Tuesday, August 29	13:00 - 15:00	1139	Neurological symptom severity in Wilson disease is associated with increased white matter mean diffusivity
Tuesday, August 29	13:00 - 15:00	1140	Prevalence of seizures in patients with Neurodegeneration with Brain Iron Accumulation
Tuesday, August 29	13:00 - 15:00	1141	Therapeutic Plasma Exchange in the Management and Outcome of Stiff-Person Syndrome: A Systematic Review
Tuesday, August 29	13:00 - 15:00	1142	Minimum clinically important difference (MCID) on the Unified Wilson Disease Rating Scale (UWDRS) Part III: results from the Phase 3 FoCUS Trial
Tuesday, August 29	13:00 - 15:00	1143	DNAJC12 defect a new neurodevelopmental disorder associated with parkinsonism-dystonia
Tuesday, August 29	13:00 - 15:00	1144	Correlation between neurological phenotype, neuroimaging and clinical outcome in a single centre Wilson disease cohort.
Tuesday, August 29	13:00 - 15:00	1145	How COVID-19 Impacted Patients with Wilson's disease? A Questionnaire-based Study From An Indian Movement Disorder Clinic
Tuesday, August 29	13:00 - 15:00	1147	Potential treatment for CMT2S caused by IGHMBP2 cryptic splice variant, with ASO based therapeutic
Tuesday, August 29	13:00 - 15:00	1149	Free water neuro-imaging changes as the biomarker in new diagnosis of Wilson's disease
Tuesday, August 29	13:00 - 15:00	1150	Neurodegeneration with Brain Iron Accumulation: A case series from a single center in India
Tuesday, August 29	13:00 - 15:00	1151	D-penicillamine induced myasthenia gravis – the possible complication of Wilson's disease treatment.

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1153	Autosomal recessive Primary Familial Brain Calcification caused by MYORG mutations. Two unrelated cases from the south of Chile
Tuesday, August 29	13:00 - 15:00	1154	Cerebellar ataxia in Hypomyelinating Leukodystrophies: A case series
Tuesday, August 29	13:00 - 15:00	1155	Movement disorders spectrum in CTNNB1-related neurodevelopmental disorders
Tuesday, August 29	13:00 - 15:00	1156	Diagnostic challenges in a case of SLC6A3-related Dopamine Transporter Deficiency Syndrome
Tuesday, August 29	13:00 - 15:00	1157	Unusual Neuronal Intranuclear Inclusion Disease (NIID) with initial presentation mimicking recurrent Transient Global Amnesia (TGA)
Tuesday, August 29	13:00 - 15:00	1158	A novel truncating variant in UBAP1 gene causing hereditary spastic paraplegia type 80
Tuesday, August 29	13:00 - 15:00	1159	Late-onset cerebellar ataxia revealing a Pantothenate-kinase-associated neurodegeneration
Tuesday, August 29	13:00 - 15:00	1160	Severe parkinsonism late-onset in Wilson's disease without typical basal ganglia involvement
Tuesday, August 29	13:00 - 15:00	1161	Slow progressive neurocognitive impairment with Parkinsonism: A rare, adult-onset Neuronal Intranuclear Inclusion disease (NIID) case report
Tuesday, August 29	13:00 - 15:00	1162	The neurological manifestations of PHARC syndrome: a systematic review
Tuesday, August 29	13:00 - 15:00	1163	Idiopathic Intracranial Hypertension as the presenting symptom in Wilson's Disease: how is it possible?
Tuesday, August 29	13:00 - 15:00	1164	Dystonia as presenting feature of Witteveen-kolk Syndrome
Tuesday, August 29	13:00 - 15:00	1165	Adult onset neuronal Intranuclear Inclusion Disease (NIID) which initially presented with gait imbalance and fall
Tuesday, August 29	13:00 - 15:00	1166	Detailed illustration of a Turkish patient with homozygous C19ORF12 mutation
Tuesday, August 29	13:00 - 15:00	1167	Progressive myoclonus ataxia and resting tremor in hypoceruloplasminemia
Tuesday, August 29	13:00 - 15:00	1168	First Report of ERCC1-Associated Adult-Onset Hepatocellular Carcinoma, Ataxia, and Cognitive Decline
Tuesday, August 29	13:00 - 15:00	1169	From foot to head: look after your socks !
Tuesday, August 29	13:00 - 15:00	1170	Generalized dystonia and spasticity: The fault in the mitochondria
Tuesday, August 29	13:00 - 15:00	1171	A Peruvian family with neurodegeneration with ataxia, dystonia and gaze palsy, childhood-onset (NADGP): A case report
Tuesday, August 29	13:00 - 15:00	1172	Acute-onset parkinsonism secondary to bilateral extrapontine myelinolysis of the basal ganglia: case report
Tuesday, August 29	13:00 - 15:00	1173	RNF216-associated neurodegeneration: Is it a new NBIA disorder?
Tuesday, August 29	13:00 - 15:00	1174	Adult onset cerebrotendinous xanthomatosis (CTX) with parkinsonism responding to bilateral subthalamic nucleus deep brain stimulation
Tuesday, August 29	13:00 - 15:00	1175	Non classified SCA-like presentation of GEMIN5 + GYG-1 mutation. Case report
Tuesday, August 29	13:00 - 15:00	1176	Can very early levodopa prevent self-injury in Lesch-Nyhan Disease?
Tuesday, August 29	13:00 - 15:00	1177	POLR3A-Related Disorders and Response to Deep Brain Stimulation
Tuesday, August 29	13:00 - 15:00	1178	A juvenile onset Sandhoff disease case caused by hemizygous mutations of HEXB
Tuesday, August 29	13:00 - 15:00	1179	Huntingtonism and bilateral basal ganglia hypointensity in a male with an XK variant but no McLeod red cell phenotype
Tuesday, August 29	13:00 - 15:00	1180	Wilson disease: a single-center study from Tunisia
Category: Physiology (1181 – 1324)			
Tuesday, August 29	13:00 - 15:00	1181	Cued movement preparation and movement coding in human thalamic neurons
Tuesday, August 29	13:00 - 15:00	1182	Reaching kinematics in patients with Spinocerebellar Ataxia Type 12 using a markerless motion tracking system
Tuesday, August 29	13:00 - 15:00	1184	Encoding of action plans and confidence in the human basal ganglia-thalamic circuit
Tuesday, August 29	13:00 - 15:00	1185	Motor control of finger individuation and strength in patients with Parkinson's disease and Spinocerebellar Ataxia type 12

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1186	Electrophysiological evaluation of brainstem function in patients with idiopathic normal pressure hydrocephalus
Tuesday, August 29	13:00 - 15:00	1187	Neurophysiological analysis of the posterior subthalamic area in a patient with Holmes' tremor
Tuesday, August 29	13:00 - 15:00	1188	Neuromyotonia in surgical scars: two case reports and review of literature.
Tuesday, August 29	13:00 - 15:00	1189	Reticulospinal tract integrity in patients with SCA12 having impairment of Corticospinal tract- a clinical and electrophysiological study
Tuesday, August 29	13:00 - 15:00	1190	Narcolepsy type 1, supranuclear vertical gaze palsy, and agrypnia excitata in a patient with anti-Ma associated encephalitis.
Tuesday, August 29	13:00 - 15:00	1191	A clinical and neurophysiological study of movement disorders in Wilson's disease
Tuesday, August 29	13:00 - 15:00	1192	Tourette Syndrome with Functional Overlay: A Diagnosis Challenge and The Role of Electrophysiological Study
Tuesday, August 29	13:00 - 15:00	1193	In vitro α -synuclein aggregation and propagation model
Tuesday, August 29	13:00 - 15:00	1194	Alterations in Cortico-basal ganglia Directed Connectivity in Parkinsonism and during Therapeutic STN DBS
Tuesday, August 29	13:00 - 15:00	1195	Representation of movement repertoire in subthalamic neural circuits using a markerless 3D behavioral tracking system.
Tuesday, August 29	13:00 - 15:00	1196	The changes in alpha-synuclein level and oscillatory activity of substantia nigra by nigral electrical stimulation
Tuesday, August 29	13:00 - 15:00	1197	The effect of dopaminergic medication on force fluctuation in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1198	Differences in EEG spectral features in Alzheimer's and Parkinson's disease with mild cognitive impairment
Tuesday, August 29	13:00 - 15:00	1199	Movement-related modulation of beta/high frequency oscillations and low-beta pallido-cortical coherence in Parkinson's disease.
Tuesday, August 29	13:00 - 15:00	1200	The effect of cathodal transcranial direct current stimulation in the treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease: a preliminary report.
Tuesday, August 29	13:00 - 15:00	1201	Clinical practice feasibility of a wearable appcessory for quantitative evaluation of motor symptoms in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1202	Deep brain stimulation modulates subthalamic beta bursts related to movement velocity adjustments in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1203	Emergent alpha-beta oscillations are accompanied with worsening motor symptoms in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1204	Keyboard tapping performance in people with subjective REM sleep behaviour disorder
Tuesday, August 29	13:00 - 15:00	1205	Modulatory effect of posture on prepulse inhibition in Parkinson's disease and atypical Parkinsonism
Tuesday, August 29	13:00 - 15:00	1206	Early functional disruption in body-first compared to brain-first Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1207	Modulation of pallidal activity by circadian rhythms: a new variable to be accounted for closed-loop DBS?
Tuesday, August 29	13:00 - 15:00	1208	Beta LFP Power Change After Levodopa Intake in Parkinson's Disease Patients with Chronic Sensing-Enabled DBS Systems
Tuesday, August 29	13:00 - 15:00	1209	The effects of dopaminergic treatment on interhemispheric disinhibition and bradykinesia asymmetry in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1210	Differences in brain activity and oscillatory responses in resting and re-emergent tremor in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1211	Artificial Intelligence to detect and classify tremors in patients with Parkinson's disease and related conditions
Tuesday, August 29	13:00 - 15:00	1212	Detecting clinical fluctuations in chronic biomarker recordings: experiences with chronic subthalamic peak beta band recordings in a large Parkinson's disease patient cohort
Tuesday, August 29	13:00 - 15:00	1213	Gait cycle-related neural activity during cued and uncued gait in Parkinson's disease patients
Tuesday, August 29	13:00 - 15:00	1214	Deep brain stimulation enhances movement velocity during spiral drawing in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1215	Effects of theta burst transcranial ultrasound stimulation on motor cortex excitability in Parkinson's disease.
Tuesday, August 29	13:00 - 15:00	1216	Tai Chi training of people with Parkinson's disease (PD) – neuropsychological and electrophysiological analyses
Tuesday, August 29	13:00 - 15:00	1217	Detection of Levodopa induced Dyskinesia based on spectral features from subthalamic-LFP and sensorimotor-ECOG
Tuesday, August 29	13:00 - 15:00	1218	Stability of basal ganglia beta band power distribution during continuous deep brain stimulation in Parkinson's disease: analysis of sub-cohort from the ADAPT-PD trial

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1219	Enrollment phase sensing data from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial
Tuesday, August 29	13:00 - 15:00	1220	Linking volume of tissue activated to neural oscillations in deep brain stimulation
Tuesday, August 29	13:00 - 15:00	1221	Relationship between balance performance and corticomotor Inhibition in individuals with Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1222	Supra-ON state freezing of gait: The unpredictable response to levodopa in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1223	Transcranial Pulse Stimulation in Parkinson's rest tremor: a pilot study.
Tuesday, August 29	13:00 - 15:00	1224	Delta(0.5-2Hz) Spectral Power reduction in the frontal region in NREM Sleep are Associated with dyskinesia in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1225	Differential effect of dopaminergic medication on smooth pursuit vs. saccadic eye movements Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1226	Neurophysiological markers of motor reserve in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1227	Optimizing DBS in PD: Investigating LFP beta power fluctuations in response to chronic stimulation
Tuesday, August 29	13:00 - 15:00	1228	Identifying neural biomarkers of motivated behavior in Parkinson's disease using sensing-capable DBS devices
Tuesday, August 29	13:00 - 15:00	1229	Inhibitory and facilitatory alterations in prodromal and de novo Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1230	Aberrant brain plasticity in patients with Parkinson's disease and levodopa-induced dyskinesias
Tuesday, August 29	13:00 - 15:00	1231	The effect of subthalamic therapeutic deep brain stimulation on pallidal and cortical activity in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1232	Cortical gamma oscillations in Parkinson's disease: ipsi- and contralateral deep brain stimulation-induced entrainment
Tuesday, August 29	13:00 - 15:00	1233	Wavelet-based bracketing, time-frequency beta-burst detection: new insights in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1234	Longitudinal recordings of subthalamic local field potentials show intra-subject consistency of beta-based physiomarkers in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1235	Low Beta-Band Suppression as a Tool for DBS Contact Selection for Akinetic-rigid Symptoms in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1237	Pilot study to investigate the use of monopolar sensing to improve the efficiency of DBS programming in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1238	Sleep-Wake Dependent Modulation in Pallidal Beta and High-Frequency Oscillations in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1239	Subthalamic nucleus deep brain stimulation in the beta range modulates cortical beta oscillations in Parkinson's disease patients
Tuesday, August 29	13:00 - 15:00	1240	Beta is jumping the queue: Temporal overlap of beta desynchronization and synchronization during rapid movement changes
Tuesday, August 29	13:00 - 15:00	1241	Differences in gray matter atrophy and functional connectivity between motor subtypes of Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1242	Electrophysiological correlates of the increase in rigidity with the Froment maneuver in Parkinson's patients
Tuesday, August 29	13:00 - 15:00	1243	Patterns of subthalamic synchronized oscillatory activity associated with parkinsonian subtypes
Tuesday, August 29	13:00 - 15:00	1244	PSP-like phenotype triggered by STN DBS in PD: a case report
Tuesday, August 29	13:00 - 15:00	1245	Chronic sensorimotor cortex sensing using permanently implanted subgaleal leads in a patient receiving deep brain stimulation for Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1246	Pathological neuronal Oscillations in an animal model of Rapid-Onset Dystonia-Parkinsonism
Tuesday, August 29	13:00 - 15:00	1247	Neuropathic mechanism of paroxysmal kinesigenic dyskinesia based on EEG
Tuesday, August 29	13:00 - 15:00	1248	Does the dopaminergic pathway interfere with the sustained CSF tap test effect in normal-pressure hydrocephalus?
Tuesday, August 29	13:00 - 15:00	1249	Evoking Parkinsonism in Mice by a Pharmacological Approach Combined with Targeted Viral-based Manipulations of Neuronal Ensembles
Tuesday, August 29	13:00 - 15:00	1250	Dopaminergic Neuronal attributes in aging Substantia Nigra and Ventral Tegmental Area of mice strains distinctly sensitive to MPTP
Tuesday, August 29	13:00 - 15:00	1251	A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development
Tuesday, August 29	13:00 - 15:00	1252	Decreased α -synuclein membrane-binding in the enteric nervous system as a marker of early pathology in Parkinson's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1253	The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1255	Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming
Tuesday, August 29	13:00 - 15:00	1256	IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with synucleinopathy
Tuesday, August 29	13:00 - 15:00	1257	Incidence and Predictors of Axial Postural Abnormalities in Parkinson disease: data from the PPMI cohort
Tuesday, August 29	13:00 - 15:00	1258	Risk of Parkinson's Disease due to Helicobacter Pylori and High Salt Consumption
Tuesday, August 29	13:00 - 15:00	1259	Morphometric assessment of age-associated neuronal changes in the human locus coeruleus
Tuesday, August 29	13:00 - 15:00	1260	Reproductive life factors and sex hormones in post-menopausal female patients with Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1261	Axial impairment and bradykinesia are related to increased CSF sTREM2, a neuroinflammation biomarker, in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1262	Use of insect model to study Parkinson's disease pathophysiology by inducing GSH-depletion and behavioral deficits among larvae: Evidences of ameliorative properties of phytoconstituents
Tuesday, August 29	13:00 - 15:00	1263	Association between severity of freezing of gait and turning characteristics in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1264	Incidence of Parkinson's disease and modifiable risk factors in Korean population: A longitudinal follow-up study of a nationwide cohort
Tuesday, August 29	13:00 - 15:00	1265	Alzheimer's Disease Co-pathology and its Influence on Biofluid Biomarkers in Autopsied Subjects from the PPMI Study
Tuesday, August 29	13:00 - 15:00	1266	Olfactory dysfunction as a predictor of the future development of parkinsonism in COVID patients
Tuesday, August 29	13:00 - 15:00	1267	Assessing akinesia domains during multitasking in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1268	Amplifying or suppressing subthalamic beta oscillations in real-time in Parkinson's disease using evoked interference deep brain stimulation (eiDBS): feasibility in the human
Tuesday, August 29	13:00 - 15:00	1269	Elevated plasma CREG1 levels are linked to a lower risk of Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1270	Parkinson's disease and human gut microbiota in an Egyptian population: a pilot study
Tuesday, August 29	13:00 - 15:00	1271	Heart-rate variability as a new marker for freezing predisposition in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1273	Fecal tyrosine decarboxylase and motor response complications in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1274	Effect of multi-strain probiotics on gut microbiome and metabolites in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1275	Plasma biomarkers in iRBD patients serve as potential markers of early PD and motor severity
Tuesday, August 29	13:00 - 15:00	1276	Concordant RNA patterns in Parkinson's disease brain and peripheral blood.
Tuesday, August 29	13:00 - 15:00	1277	Distinct characteristics of gut microbiome in patients with Parkinson's disease according to the presence of premotor REM sleep behavior disorders
Tuesday, August 29	13:00 - 15:00	1278	Prognostic significance of peripheral neutrophils and lymphocytes in early Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1279	Salivary α -synuclein in Parkinson's disease – a pilot study
Tuesday, August 29	13:00 - 15:00	1280	Pareidolias and color discrimination deficits differently correlate with cognitive dysfunction in prodromal Lewy body disease
Tuesday, August 29	13:00 - 15:00	1281	Effect of ventricular morphometrics on the treatment of Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1282	Orthostatic vital sign changes do not influence 5-year motor outcomes in PD
Tuesday, August 29	13:00 - 15:00	1283	Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis
Tuesday, August 29	13:00 - 15:00	1285	The contribution of Brain Bank for Aging Research to pathomechanism of Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1286	Dysphagia and dopaminergic neurodegeneration in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1287	Speech difficulties and dopaminergic neurodegeneration in Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1288	Aging brain in Parkinson's: A study through biomarkers

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Tuesday, August 29	13:00 - 15:00	1289	Analysis of subthalamic-nuclei deep brain stimulation using radiomic feature-manifestations: a quantitative approach
Tuesday, August 29	13:00 - 15:00	1290	Modeling Parkinson's disease progression accounting for the effect of symptomatic treatments in the Parkinson's Progression Markers Initiative study
Tuesday, August 29	13:00 - 15:00	1291	Identification of potential oxidative biomarkers in saliva of Parkinson's disease patients
Tuesday, August 29	13:00 - 15:00	1292	Flavonoid intake and risk of Parkinson's Disease
Tuesday, August 29	13:00 - 15:00	1293	Assessment of variation in α -synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia
Tuesday, August 29	13:00 - 15:00	1294	Self-perception of symptoms lateralization and association with symptoms severity in Parkinson's disease.
Tuesday, August 29	13:00 - 15:00	1295	Diagnostic Utility of Blood α -Synuclein in Parkinson's Disease: A Systematic Review and Meta-analysis
Tuesday, August 29	13:00 - 15:00	1296	Serum Metabolomics in Parkinson's Disease: Correlations with Fecal Microbiome, Fecal Metabolomics and Clinical Status
Tuesday, August 29	13:00 - 15:00	1297	Asymmetric and profound nigrostriatal dopaminergic dysfunction in Parkinson's disease with preceding REM sleep behavior disorders
Tuesday, August 29	13:00 - 15:00	1299	Correlation between levels of plasma neurofilament light chain and freezing of gait in Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1300	Pathological findings in a case of DJ-1 early onset Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1301	Comparative Assessment of Gait and Balance in Patients with Parkinson's Disease and Normal Pressure Hydrocephalus
Tuesday, August 29	13:00 - 15:00	1302	Development of a patient journey map for people living with Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1303	A novel model of care for an integrated movement assessment program (I-MAP) targeted for patients with movement disorders
Tuesday, August 29	13:00 - 15:00	1305	Motor evaluation of Parkinson disease and Vascular parkinsonism using the TUG encephalog application
Tuesday, August 29	13:00 - 15:00	1306	Free-viewing eye tracking in Parkinson's disease and correlation with clinical features
Tuesday, August 29	13:00 - 15:00	1308	A comparative study of non-motor symptoms in Huntington's disease and Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1309	Identification of pre-frailty in the elderly through serum metabolomics and its impact on Parkinson's disease phenotype
Tuesday, August 29	13:00 - 15:00	1310	Women and PD: experienced changes in parkinson symptoms after menopause
Tuesday, August 29	13:00 - 15:00	1311	Spectrum of hyperkinetic movement disorders in a Tunisian Cohort: an observational study
Tuesday, August 29	13:00 - 15:00	1312	Manifestations of aging and Parkinson's Disease in low-frequency fluctuations of postural sway velocity
Tuesday, August 29	13:00 - 15:00	1313	Clinical usefulness of tandem gait test for estimating gait and balance in de novo Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1314	Real-world utility of MANAGE PD tool by physicians and patients in Germany
Tuesday, August 29	13:00 - 15:00	1315	Sensitivity, consistency and test-retest reliability of home-based freezing of gait-provoking tests in people with Parkinson's disease
Tuesday, August 29	13:00 - 15:00	1316	A forgotten cause of ocular motor apraxia
Tuesday, August 29	13:00 - 15:00	1317	Prevalence of cogwheel phenomenon in Parkinson disease
Tuesday, August 29	13:00 - 15:00	1318	Anti-glutamic acid decarboxylase associated encephalitis presenting with new onset movement disorder after COVID-19 infection
Tuesday, August 29	13:00 - 15:00	1319	Acute movement disorder with atypical topography. Acute hemichorea secondary to cortical stroke.
Tuesday, August 29	13:00 - 15:00	1320	Stiff person syndrome vs functional neurological disorder: two patients with hyperkinetic movement disorder
Tuesday, August 29	13:00 - 15:00	1321	Motor phenotype and disease burden among Parkinson's disease patients of Addis Ababa, Ethiopia.
Tuesday, August 29	13:00 - 15:00	1322	Holmes Tremor and Dystonia as Manifestation of Benedikt Syndrome in HIV-Related Cerebral Toxoplasmosis : A Case Report
Tuesday, August 29	13:00 - 15:00	1323	An uncommon task specific dystonia masquerading as Myasthenia Gravis
Tuesday, August 29	13:00 - 15:00	1324	Monocular Ocular Bobbling with Holmes Tremor Due to Ruptured Cavernoma

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Category: Pharmacology and Therapy (1329 – 1511):			
Wednesday, August 30	13:00 - 15:00	1329	Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset
Wednesday, August 30	13:00 - 15:00	1330	Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Wednesday, August 30	13:00 - 15:00	1333	Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset
Wednesday, August 30	13:00 - 15:00	1334	Quantitative investigation of the pathway between dopamine receptors and Ca ²⁺ channels in layer II stellate cells towards Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1336	Polyaromatic hydrocarbons in Ambient Particulate Matter (PM 2.5) mediate neurodegeneration through the olfactory-brain axis in C57BL/6 mice
Wednesday, August 30	13:00 - 15:00	1337	The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF
Wednesday, August 30	13:00 - 15:00	1339	Motor function in Parkinson's disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa
Wednesday, August 30	13:00 - 15:00	1340	Quetiapine for the treatment of psychosis in dementia with Lewy bodies: a systematic review.
Wednesday, August 30	13:00 - 15:00	1341	Neuroprotective properties of arylpiperazine-sulphonamides in an in vitro model of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1342	Increased alpha power in basal ganglia and thalamus following levodopa administration in a dystonic young adult
Wednesday, August 30	13:00 - 15:00	1343	Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease
Wednesday, August 30	13:00 - 15:00	1344	The induction of mitochondrial damage by alpha synuclein In Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1346	Identification of ZYL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson's disorder
Wednesday, August 30	13:00 - 15:00	1347	Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains
Wednesday, August 30	13:00 - 15:00	1348	Evaluation of neuroprotective role of carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model
Wednesday, August 30	13:00 - 15:00	1350	Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1351	Therapeutic effects of citral nanoliposome on Parkinson's treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways
Wednesday, August 30	13:00 - 15:00	1352	Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline
Wednesday, August 30	13:00 - 15:00	1353	Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson's disease in a marmoset monkey model
Wednesday, August 30	13:00 - 15:00	1354	The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Wednesday, August 30	13:00 - 15:00	1357	modulation of sodium potassium ATPase activity by norepinephrine and serotonin to find an effective cure of parkinson's disease by introducing the novel concept of insilico drug repurposing
Wednesday, August 30	13:00 - 15:00	1358	Honey prevented MPTP-induced oxidative stress, neuroinflammation and gliosis in adult male Swiss mice.
Wednesday, August 30	13:00 - 15:00	1359	Glunomab: a novel therapeutics for the treatment of Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1360	LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte-derived
Wednesday, August 30	13:00 - 15:00	1361	Investigation of superficial brain stimulation (SBS) in Parkinsonian rats as a non-invasive alternative treatment for patients with movement disorders
Wednesday, August 30	13:00 - 15:00	1362	Development of therapeutic substances for the disassembly of α -synuclein aggregates as disease-modifying treatment of synucleinopathies
Wednesday, August 30	13:00 - 15:00	1363	Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson's Disease Based on Network Pharmacology and Molecular Docking
Wednesday, August 30	13:00 - 15:00	1364	Levodopa-carbidopa intestinal gel for managing severe refractory tremors of idiopathic Parkinson's disease: Case Series
Wednesday, August 30	13:00 - 15:00	1365	Comparative efficacy of pharmacological cognitive treatments in Parkinson's disease and Dementia of Lewy Bodies: systemic review & network meta-analysis
Wednesday, August 30	13:00 - 15:00	1366	Analysis of levodopa use in patients with Parkinson's Disease during pregnancy: a systematic review of the last twenty years
Wednesday, August 30	13:00 - 15:00	1367	Effect of differences in stomach and small intestine pH on response to levodopa in patients with Parkinson's Disease.
Wednesday, August 30	13:00 - 15:00	1368	Initial clinical experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson's disease in Croatia

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1369	Effects of Subthalamic Nucleus Deep Brain Stimulation on Phase Amplitude Coupling in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1370	Home-based titration with Duodenal infusion of Levodopa in People with Parkinson's disease: an observational feasibility study
Wednesday, August 30	13:00 - 15:00	1371	Adverse Events of Opicapone Adjunctive Therapy in 60 Consecutive Patients
Wednesday, August 30	13:00 - 15:00	1372	Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1373	The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease
Wednesday, August 30	13:00 - 15:00	1374	Gluten-free diet in Parkinson's disease patients – feasibility, safety and preliminary results
Wednesday, August 30	13:00 - 15:00	1376	GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1377	Levodopa-induced orthostatic hypotension in parkinsonism: a red flag of autonomic failure
Wednesday, August 30	13:00 - 15:00	1378	Safinamide in Parkinson's Disease. A retrospective study
Wednesday, August 30	13:00 - 15:00	1379	Pisa syndrome and botulinum toxin injection in paraspinal muscles ipsilateral to the bending side: a pilot study
Wednesday, August 30	13:00 - 15:00	1380	The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis
Wednesday, August 30	13:00 - 15:00	1381	Assessment of non-motor symptoms of Parkinson's disease after the repeated courses of the autologous stem cell therapy
Wednesday, August 30	13:00 - 15:00	1382	Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson's disease: a single center experience
Wednesday, August 30	13:00 - 15:00	1383	LRRK2 Inhibition by BIIB122/DNL151 Demonstrates Robust Target and Lysosomal Engagement: Pharmacokinetics, Pharmacodynamics and Safety in Phase 1 and Phase 1b Studies in Healthy and
Wednesday, August 30	13:00 - 15:00	1384	Computerized assessment of Handwriting in Parkinson's Disease Before and After Dopaminergic Medication
Wednesday, August 30	13:00 - 15:00	1385	Observations on 5 Parkinson's patients taking Mucuna pruriens as natural source of levodopa
Wednesday, August 30	13:00 - 15:00	1386	Utilization pattern and factors associated with amantadine use in Parkinson's disease (PD) of the French NS-Park cohort
Wednesday, August 30	13:00 - 15:00	1387	Efficacy and safety of safinamide in PD patients over 70 years vs. under 70 years old;
Wednesday, August 30	13:00 - 15:00	1388	Exercise and levodopa metabolism in Parkinson disease
Wednesday, August 30	13:00 - 15:00	1389	Motor complications in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1390	Correlation between hemoglobin level and disease severity in patients with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1391	Predicting motor outcome and quality of life after subthalamic DBS for Parkinson's Disease: the role of standard screening measures and wearable-data
Wednesday, August 30	13:00 - 15:00	1392	Sex differences in motor response to levodopa in early Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1393	Evaluation of cases of psychosis from opicapone safety data
Wednesday, August 30	13:00 - 15:00	1394	SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation
Wednesday, August 30	13:00 - 15:00	1395	Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I naïve People with Parkinson's
Wednesday, August 30	13:00 - 15:00	1396	Design of a Phase 2 Study of Suvealtamide in Moderate to Severe Parkinson's Disease Tremor
Wednesday, August 30	13:00 - 15:00	1399	Anodal transcranial direct current stimulation could change the metabolomic profiles of cerebrospinal fluid in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1400	Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson's disease: safety and short-term effects
Wednesday, August 30	13:00 - 15:00	1402	Combination COMT inhibitor with Levodopa reduces consumption of vitamin B6
Wednesday, August 30	13:00 - 15:00	1403	Retrospective exploration of the 5-2-1 criteria in clinical practice
Wednesday, August 30	13:00 - 15:00	1404	Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1405	Bone Health in Parkinson's Disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1406	Closed-loop gait improvement in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1407	Pharmacological combinations in early stages of Parkinson's disease and association with motor complications
Wednesday, August 30	13:00 - 15:00	1408	Safety in Levodopa/carbidopa Intestinal Gel (LCGI) titration in the Intensive Care Unit (ICU) setting for Parkinson's Disease (PD) patient with severe dysphagia
Wednesday, August 30	13:00 - 15:00	1409	Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson's disease: observational retrospective study
Wednesday, August 30	13:00 - 15:00	1410	Screening and Treatment of Depression in Parkinson's Disease Within Movement Disorders Centers
Wednesday, August 30	13:00 - 15:00	1411	Effectiveness of use of Pictographs on Levodopa packaging to ensure awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1412	LRKK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing
Wednesday, August 30	13:00 - 15:00	1413	VALidation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson's disease (VALIDATE)
Wednesday, August 30	13:00 - 15:00	1414	Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson's disease, in a movement disorder
Wednesday, August 30	13:00 - 15:00	1415	Pre-operative predominance of Tremor versus PIGD scores in drug OFF state predicts motor and non-motor outcomes of STN-DBS for Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1416	Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson's disease treated with opicapone
Wednesday, August 30	13:00 - 15:00	1417	Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson's disease: An analysis of data collected from the Swedish national register of Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1418	Freezing of gait in Parkinson's disease with glucocerebrosidase mutations: prevalence, clinical correlates and effect on quality of life
Wednesday, August 30	13:00 - 15:00	1419	On-demand therapy (ODT) in Parkinson's disease: a survey of advanced practice providers
Wednesday, August 30	13:00 - 15:00	1420	Response of extraocular movements in parkinson's disease to levodopa: an electrooculographic perspective
Wednesday, August 30	13:00 - 15:00	1421	Sport based approach in patients with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1422	The effect of continuous subcutaneous apomorphine infusion on vitamin B metabolites and plasma homocysteine in Parkinson's disease patients
Wednesday, August 30	13:00 - 15:00	1423	A Parkinson Shoe with Combined Plantar Pressure and Vibratory Stimulation in Parkinson's Disease Patients with Freezing of Gait: A Randomized Controlled Trial with Plantar Pressure Analysis
Wednesday, August 30	13:00 - 15:00	1424	Sex differences for off episodes in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1425	Real-World Utilization of Istradefylline Among Patients with Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1426	Clinical analysis of Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease. A single-center retrospective cohort study.
Wednesday, August 30	13:00 - 15:00	1427	First Case Series on the use of a High Frequency Vibrotactile Stimulation and Cueing Device in Panama
Wednesday, August 30	13:00 - 15:00	1428	Use of stimview technology in deep brain stimulation of Parkinson's disease patients
Wednesday, August 30	13:00 - 15:00	1429	Response to Levodopa in Parkinson's Disease Over Time. A 4-year Follow-up Study.
Wednesday, August 30	13:00 - 15:00	1430	Effect of intensive Game-based neurorehabilitation (GBNR) on gait, balance and quality of life (QOL) in Parkinson's patients: A prospective randomized control study
Wednesday, August 30	13:00 - 15:00	1431	Local field potentials can guide programming of Deep Brain Stimulation in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1432	Anodal Transcranial Direct Current Stimulation (tDCS) on sensorimotor cortex in patients with early-onset Parkinson's Disease: a Pilot Study.
Wednesday, August 30	13:00 - 15:00	1433	Efficacy and safety of adjunctive oral therapy in Parkinson's disease with motor complications: a systematic review and network meta-analysis
Wednesday, August 30	13:00 - 15:00	1434	Use of a wearable vibration-based device for the treatment of Parkinson's disease tremor
Wednesday, August 30	13:00 - 15:00	1435	NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson's disease (PD)
Wednesday, August 30	13:00 - 15:00	1436	Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1437	Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson's Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment
Wednesday, August 30	13:00 - 15:00	1438	Factors affecting adaptive deep brain stimulation (aDBS) indications in Parkinson's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1439	Testing the applicability of the dysarthria analyzer to detect levodopa effects on speech in a German cohort of people with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1440	The effect of taVNS on gait in advanced Parkinson's disease—a double blind, sham controlled motion sensors study in 30 patients
Wednesday, August 30	13:00 - 15:00	1441	Levodopa Carbidopa Intestinal Gel for Parkinson's Disease over 11 years: A Single Center "Real-World" Experience
Wednesday, August 30	13:00 - 15:00	1442	Levodopa-entacapone-carbidopa-infusion treatment in Parkinson's disease: A six-month follow-up study
Wednesday, August 30	13:00 - 15:00	1443	The specific application of a motor rehabilitation package in correcting the psycho-emotional sphere in patients with Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1444	Analysis of the therapeutic potential of IKT-148009 in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1445	Tremor characteristics differentially respond to levodopa and subthalamic nucleus deep brain stimulation in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1446	Controlled-release zolpidem improves freezing of gait and levodopa-induced dyskinesias in a patient with Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1447	Istradefylline therapy for PD plus oromandibular dystonia
Wednesday, August 30	13:00 - 15:00	1448	Patterned alternating-coloured strips for freezing of gait - Novel solution for a disabling symptom.
Wednesday, August 30	13:00 - 15:00	1449	Long duration response to levodopa in advanced Parkinson disease
Wednesday, August 30	13:00 - 15:00	1452	Metabolic modulation of mitochondrial DNA release in cellular models of Parkin-associated Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1453	miRNAs from blood serum as an early diagnostic biomarker for Parkinson's disease: A study in an animal model
Wednesday, August 30	13:00 - 15:00	1454	Sub-cellular alterations in MPTP-induced in-vivo and in-vitro systems and Non-MPTP human Parkinsonian skin biopsies: Verifying the sequelae of differential toxicity
Wednesday, August 30	13:00 - 15:00	1455	LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia
Wednesday, August 30	13:00 - 15:00	1456	Inhibition of LRRK2 kinase activity promotes glucocerebrosidase transport to the lysosomes in primary monocyte-derived macrophages from patients with GBA-associated Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1457	SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models
Wednesday, August 30	13:00 - 15:00	1458	Impaired CaMKII/ERK activation in mouse mutant LRRK2 R1441G fibroblasts was associated with reduced mitochondrial calcium store and efflux in response to depolarization stress
Wednesday, August 30	13:00 - 15:00	1459	Glycated alpha-synuclein and its emerging role in early onset of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1460	SARS-CoV-2 infection exacerbates the cellular pathology in Parkinson's disease progression
Wednesday, August 30	13:00 - 15:00	1461	Small Molecule Inhibitors for Precise Inhibition of α -Synuclein Oligomer Generation in Parkinson's Disease (PD)
Wednesday, August 30	13:00 - 15:00	1462	Impairment of SHH signaling in PD LRRK2 I1371V iPSC derived floor plate cells contribute to ontogenic origin of lower dopaminergic-neuron yield
Wednesday, August 30	13:00 - 15:00	1463	Exploring mitochondrial mechanisms defining Parkinson's disease penetrance in LRRK2 G2019S neuronal cultures
Wednesday, August 30	13:00 - 15:00	1464	Characterization of the pathogenic α -Synuclein variant p.V15A in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1466	Parkin Coregulates Glutathione Metabolism in Adult Brain to Contribute to Redox Homeostasis
Wednesday, August 30	13:00 - 15:00	1467	Proteomic profiles analysis of plasma exosomes and WBC reveals new insights of PD patients classified into H&Y clinical stage
Wednesday, August 30	13:00 - 15:00	1468	A novel, population-specific PINK1 p.F385S loss of function mutation in an Indian family with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1471	Novel modifiers of heterozygous pathogenic Parkin variant penetrance in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1474	Membrane-associated properties and ER stress alterations in LRRK2 I1371V patient iPSC derived neurons increase susceptibility to oxidative stress.
Wednesday, August 30	13:00 - 15:00	1475	Targeting autophagy to identify novel modulators of Parkinson's disease using midbrain organoids
Wednesday, August 30	13:00 - 15:00	1476	The Role of Adaptive Immunity caused by α -synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson's Disease Pathogenesis
Wednesday, August 30	13:00 - 15:00	1477	Selenium mitigates ferroptosis-mediated dopaminergic cell death by regulating the Nrf2/GPX4 pathway: Implication for Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1478	Impaired lysophagy function exacerbates propagation of α -synuclein aggregation

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1479	Modulation of autophagy and neuroinflammation by Niclosamide in MPTP Induced- Parkinson's disease model
Wednesday, August 30	13:00 - 15:00	1480	Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia
Wednesday, August 30	13:00 - 15:00	1481	Hypoxia-induced astrocyte activation and its protective effect on Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1482	LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α -synuclein through NF- κ B pathway
Wednesday, August 30	13:00 - 15:00	1483	Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1484	Identification of reproducible metabolites for Parkinson's Disease diagnosis using clinical data and computational modelling
Wednesday, August 30	13:00 - 15:00	1485	Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's
Wednesday, August 30	13:00 - 15:00	1486	Selegiline drives autophagic secretion of α -synuclein
Wednesday, August 30	13:00 - 15:00	1487	Distinct temporal and spatial alteration of immunoproteasome in Parkinson's Disease pathogenesis
Wednesday, August 30	13:00 - 15:00	1488	Impaired Mitophagy and Mitochondrial-energetics in Parkinson's disease: A Novel Therapeutic Strategy of Re-tasking Felodipine
Wednesday, August 30	13:00 - 15:00	1489	Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?
Wednesday, August 30	13:00 - 15:00	1490	Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity.
Wednesday, August 30	13:00 - 15:00	1491	Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1493	RNA editing contributes to the inflammatory astrocytic response in Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1494	TREM2 maintain microglial proliferation and α -syn accumulation in PD models via the PI3K-Akt pathway
Wednesday, August 30	13:00 - 15:00	1495	The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1496	Non-invasive Vagus Nerve Stimulation Alters Molecular Markers in Parkinson's Disease Patients with Freezing of Gait
Wednesday, August 30	13:00 - 15:00	1497	Comparative whole transcriptome analysis of human and mice models of Parkinson's disease bearing defective glucocerebrosidase activity revealed alteration of expression profile of genes
Wednesday, August 30	13:00 - 15:00	1498	Synaptic density and α -synuclein oligomers in skin biopsies: differences between idiopathic and GBA-linked Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1500	Blood derived α -synuclein seeding in the course of Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1501	Impaired mitochondrial respiration as a peripheral tissue biomarker for stratifying idiopathic Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1502	Correlation of clinical profile of Parkinsonism with molecular imaging
Wednesday, August 30	13:00 - 15:00	1503	Isolation of L1CAM-extracellular vesicles reveals signs of insulin resistance in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1504	Cholinergic deficits in Parkinson Disease
Wednesday, August 30	13:00 - 15:00	1505	Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease
Wednesday, August 30	13:00 - 15:00	1506	The effect of levodopa on the blood activity of calpains in patients with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1507	Protein X: a key player in Parkinson's Disease pathophysiology? - insights from compound screening in gba1 knock-out medaka
Wednesday, August 30	13:00 - 15:00	1508	Country and Sex Differences in Diagnosis Latency of Parkinson's Disease in Latin American Populations
Wednesday, August 30	13:00 - 15:00	1509	Olfactory neurons' Substance P is highly expressed in Parkinson's disease reflecting gastrointestinal dysfunction
Wednesday, August 30	13:00 - 15:00	1510	Estrogen derivatives and hydrogen peroxide as promising biomarkers in parkinson's disease- preliminary results
Wednesday, August 30	13:00 - 15:00	1511	Premenstrual worsening of UPDRS motor scale in women affected by Parkinson's Disease
Category: Surgery, Imaging and Technology (1512 – 1810):			
Wednesday, August 30	13:00 - 15:00	1512	White matter integrity in patients with PSP-RS and VaP: A TBSS Study

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1514	Phenotype and brain [18F] FDG patterns in patients with freezing of gait as the main clinical feature
Wednesday, August 30	13:00 - 15:00	1515	Altered cognitive control processes in the prodromal phase of X-linked dystonia-parkinsonism (XDP)
Wednesday, August 30	13:00 - 15:00	1516	Consideration of age and initial putaminal rim segment in distinguishing multiple system atrophy parkinsonian type
Wednesday, August 30	13:00 - 15:00	1517	A network imaging biomarker of X-linked dystonia-parkinsonism
Wednesday, August 30	13:00 - 15:00	1518	Hypothalamic involvement in Multiple System Atrophy: a clinical and neuroimaging study
Wednesday, August 30	13:00 - 15:00	1519	Quantification of Striatal and Extrastriatal Dopamine Transporters with [18F]PR04.MZ and [18F] PI-2620 PET in Patients with Progressive Supranuclear Palsy.
Wednesday, August 30	13:00 - 15:00	1520	Identification of a Metabolic Brain Pattern Specific to Corticobasal Degeneration and Its Utility in Differential Diagnosis
Wednesday, August 30	13:00 - 15:00	1521	Functional brain network alterations in the prodromal phase of X-linked dystonia-parkinsonism
Wednesday, August 30	13:00 - 15:00	1522	Tau PET imaging in a patient with progressive supranuclear palsy-parkinsonism-a case report
Wednesday, August 30	13:00 - 15:00	1523	Examining the association between adverse effects of magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy for essential tremor and structural connectivity using
Wednesday, August 30	13:00 - 15:00	1524	The hypometabolism in anterior cingulate gyrus and thalamus: potential biomarkers of disease progression in progressive supranuclear palsy
Wednesday, August 30	13:00 - 15:00	1525	Structural analysis of the basal ganglia using ex vivo 7T MRI can differentiate frontotemporal lobar degeneration with TDP-43 vs tau accumulation.
Wednesday, August 30	13:00 - 15:00	1526	Association between fine motor function and brain structure: Findings from the population-based Rhineland Study
Wednesday, August 30	13:00 - 15:00	1527	Diabetic striatopathy presenting without hyperkinetic movements
Wednesday, August 30	13:00 - 15:00	1528	Atypical Parkinsonian Syndrome with evocative brain MRI imaging. About seven cases.
Wednesday, August 30	13:00 - 15:00	1529	Two Distinctive Anatomic Location in Brain Tumor Patients with Secondary Parkinsonism Manifestation: A Serial Case Report
Wednesday, August 30	13:00 - 15:00	1530	Mesencephalic neuroglial cyst can produce clinical manifestations and a metabolic [18F] FDG PET pattern mimicking a Progressive Supranuclear Palsy Syndrome
Wednesday, August 30	13:00 - 15:00	1532	Non-tremor motor dysfunction in Parkinson's disease is associated with decreased [18F]FMPEP-d2 binding
Wednesday, August 30	13:00 - 15:00	1533	Impact of Image-Guided Programming (IGP) in Bilateral STN Deep Brain Stimulation on Programming Time and Setting Outcomes
Wednesday, August 30	13:00 - 15:00	1534	Diffusion imaging study of mild behavioral impairment in Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1535	Asymmetric synaptic density and glucose consumption in subjects with non-demented Parkinson's Disease, as measured with [11C]UCB-J and [18F]FDG PET.
Wednesday, August 30	13:00 - 15:00	1536	Structural MRI and tremor analysis in the differential diagnosis of rest tremor
Wednesday, August 30	13:00 - 15:00	1537	Network attack tolerance: A resilience proxy for Parkinson's disease?
Wednesday, August 30	13:00 - 15:00	1538	Dopamine depletion of striatal subregions and motor dysfunction in prodromal and clinical Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1539	Association between changes in hippocampal volumes, cognition, and CSF markers in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1540	Brain first-body first: is the dat-scan useful?
Wednesday, August 30	13:00 - 15:00	1541	Altered brain energetics in Parkinson's Disease: a multimodal neuroimaging study
Wednesday, August 30	13:00 - 15:00	1542	Cerebral Topography of [11C]-Flumazenil GABAA Receptor Expression in Parkinson's Disease Fallers and Freezers
Wednesday, August 30	13:00 - 15:00	1543	Cholinergic subtyping in Parkinson disease: differential 2-year interval changes
Wednesday, August 30	13:00 - 15:00	1544	6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET striatal binding patterns in patients with Parkinson's Disease and Parkinson Plus Syndromes.
Wednesday, August 30	13:00 - 15:00	1545	Neuroimaging analysis of postural instability in Progressive Supranuclear Palsy: a Voxel-based morphometry approach
Wednesday, August 30	13:00 - 15:00	1546	Genetic polymorphisms associated with nigrostriatal dopaminergic depletion as measured with [1123]-FP-CIT SPECT in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1547	Dysconnectivity of the Parafascicular Nucleus in Parkinson's Disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1548	Machine learning selects common fMRI features of cognitive impairment in Parkinson's disease from cross-institution datasets
Wednesday, August 30	13:00 - 15:00	1549	Subthalamic stimulation reshapes the reliable inherent brain state in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1550	Early-phase 18F-FP-CIT PET images: a promising imaging biomarker for predicting early dementia conversion in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1551	T1 MRI reveals differential hippocampal atrophy in Lewy body disorders with and without Alzheimer's copathology
Wednesday, August 30	13:00 - 15:00	1552	Explainable deep learning based detection of Parkinson's changes in MRI brain scans
Wednesday, August 30	13:00 - 15:00	1553	Integrative brain states facilitate the expression of Parkinson's tremor
Wednesday, August 30	13:00 - 15:00	1554	Radiological markers of CSF α -synuclein aggregation in Parkinson's disease patients
Wednesday, August 30	13:00 - 15:00	1555	Artificial intelligence for the improvement of imaging biomarkers in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1556	Comparison of the MIBG uptake in the major salivary glands between progressive supranuclear palsy/corticobasal syndrome and Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1557	PET visualization of α -synuclein pathologies in humans using [18F]C05-05
Wednesday, August 30	13:00 - 15:00	1558	Automated parcellation of the cerebellum in patients with newly diagnosed Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1559	Accelerated longitudinal brain atrophy in the 'diffuse malignant' Parkinson's disease subtype
Wednesday, August 30	13:00 - 15:00	1560	Insular dopamine deficits in prodromal α -synucleinopathies
Wednesday, August 30	13:00 - 15:00	1561	Diabetes impact on nigrostriatal vulnerability in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1562	Is working memory training success in Parkinson's disease determined by cortical thickness and white matter lesions?
Wednesday, August 30	13:00 - 15:00	1564	Connectivity Profile for Deep Brain Stimulation in Early-Stage Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1565	The impact of STN-DBS on brain metabolic activity during dynamic obstacle avoidance in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1566	Multimodal neuroimaging of Parkinson's disease with diffusion tensor imaging (DTI) and dopamine transporter (DAT) positron emission tomography
Wednesday, August 30	13:00 - 15:00	1567	Network analysis of brain perfusion in [11C]UCB-J PET: Parkinson's related motor pattern (PDRP)
Wednesday, August 30	13:00 - 15:00	1568	People with Parkinson's Disease present compensatory cortical activity patterns during split-belt treadmill walking, regardless of leg or disease side dominance.
Wednesday, August 30	13:00 - 15:00	1569	Deep brain stimulation impacts functional brain connectivity in Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1570	Progressive cortical cerebrovascular reactivity reduction occurs in Parkinson's disease: a longitudinal study
Wednesday, August 30	13:00 - 15:00	1571	Clinical severity in Parkinson's disease is determined by decline in cortical compensation
Wednesday, August 30	13:00 - 15:00	1572	Neurite Orientation Dispersion and Density Imaging and Diffusion Kurtosis Imaging in Brainstem Nuclei for Subtypes of Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1573	White matter lesions and motor symptoms in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1574	Dysconnectivity Profiles of Raphe Nuclei in Parkinson's Disease: From Prodromal to Advanced Stage
Wednesday, August 30	13:00 - 15:00	1575	Challenges in the measurement of brain iron deposition in Parkinson's disease in non-academic research settings.
Wednesday, August 30	13:00 - 15:00	1576	Longitudinal brain volume decline in PD with RBD and olfactory dysfunction
Wednesday, August 30	13:00 - 15:00	1577	Effects of intermittent theta burst stimulation over primary motor cortex on functional connectivity in Parkinson's disease patients
Wednesday, August 30	13:00 - 15:00	1578	Imaging the noradrenergic system in Parkinson's disease: A [11C]Yohimbine PET and neuromelanin MRI study
Wednesday, August 30	13:00 - 15:00	1579	The effect of APOE ϵ 4 on striatal vesicular monoamine transporter-2 density in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1580	Gray matter volume changes in occipital and temporal visual brain region are associated with freezing of gait in Parkinson's
Wednesday, August 30	13:00 - 15:00	1582	Patterns of Parkinson disease mitochondrial brain function indexed by 31P magnetic resonance spectroscopy

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1583	Comparing neuromelanin intensity estimation techniques for Parkinson's disease image analysis
Wednesday, August 30	13:00 - 15:00	1584	Automated VMAT2 [18F]AV-133 PET analysis in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1585	Clinical and radiological gender differences in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1586	Clinical and radiological factors associated with mortality in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1587	Distinct deep grey matter iron accumulation in tremoric syndromes; an apparent quantitative susceptibility mapping magnetic resonance study
Wednesday, August 30	13:00 - 15:00	1588	Does hyposmia induce apathy in early Parkinson's disease? Lessons from structural brain connectivity
Wednesday, August 30	13:00 - 15:00	1589	Altered nucleus accumbens functional connectivity precedes apathy in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1590	The Critical Path for Parkinson's Consortium approach to developing consensus recommendations for neuroimaging biomarkers appropriate for use in Parkinson's disease drug development
Wednesday, August 30	13:00 - 15:00	1592	Cortical thickness and global atrophy progression in Parkinson's disease with probable RBD
Wednesday, August 30	13:00 - 15:00	1593	Impaired structural connectivity in Parkinson's disease with probable RBD
Wednesday, August 30	13:00 - 15:00	1594	Visuo-spatial processing is linked to cortical glutamate dynamics in Parkinson's disease – a 7 Tesla functional MRS study
Wednesday, August 30	13:00 - 15:00	1595	Association Between Anticholinergic Burden, MCI, and Cholinergic Denervation
Wednesday, August 30	13:00 - 15:00	1596	An in-vivo study of the integrity of the nigrostriatal pathways in drug-naïve Parkinson's disease patients using [11C]PE2I PET and neuromelanin-Magnetic Resonance Imaging
Wednesday, August 30	13:00 - 15:00	1597	Neurogenic Orthostatic Hypotension in Parkinson's Disease: Is there a role for Locus Coeruleus Magnetic Resonance Imaging?
Wednesday, August 30	13:00 - 15:00	1598	Cortical mean diffusivity changes in Parkinson's disease with probable RBD
Wednesday, August 30	13:00 - 15:00	1599	Machine learning diagnosis of parkinsonian syndromes: network approach with two different sites
Wednesday, August 30	13:00 - 15:00	1600	Alterations of the Right Olfactory Orbitofrontal Cortex and olfactory impairment in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1601	Relevance of amyloid deposition for REM sleep behavior disorder in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1602	Combined approach in the diagnosis of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1603	Clinical and functional determinants of motor reserve in patients with de novo Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1604	Marked reduction of energy supply due to levodopa treatment in patients with Parkinson's disease and healthy controls
Wednesday, August 30	13:00 - 15:00	1605	Neuroimaging correlates of postural instability in motor subtypes of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1606	Role of the direct subthalamo-cerebellar tract in memory and learning: Implications for the pathophysiology of late-stage Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1607	Free water imaging of the cholinergic forebrain in body vs. brain-first Parkinson's disease subtypes
Wednesday, August 30	13:00 - 15:00	1608	Assessing the swallow tail sign in clinical practice
Wednesday, August 30	13:00 - 15:00	1609	Metabolic connectivity assessed by dynamic FDG-fPET acquisition in Parkinson's disease: a multimodal fPET and fMRI study
Wednesday, August 30	13:00 - 15:00	1610	An investigation of early changes in the brain due to mild cognitive impairment in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1611	Habenula Volume in Mood Disorders in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1612	Functional network correlates of APOE ε4 allele in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1613	The High Prevalence of Developmental Vascular Anomalies in Parkinson's Disease using USPIO-based MICRO MRI
Wednesday, August 30	13:00 - 15:00	1614	Examining the Correlation Between Multi-Spectral Diffusion Weighted Imaging Quantitative Maps and Unified Parkinson's Disease Rating Scale Scores
Wednesday, August 30	13:00 - 15:00	1615	Assessing Gait Disturbances in Parkinson's Disease Using Multi-Spectral Diffusion Weighted Imaging
Wednesday, August 30	13:00 - 15:00	1616	White Matter Lesion Characteristics of Patients with Multiple Sclerosis and Parkinsonism

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1618	Correlation between Striatal degeneration and Cerebellar fiber alterations of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1619	Application of multi-parametric diffusion MRI in detecting visual disturbances in advanced Parkinson's disease population
Wednesday, August 30	13:00 - 15:00	1620	Visual networks connectivity in subjects with Parkinson's disease and visual disturbances using resting state fMRI
Wednesday, August 30	13:00 - 15:00	1621	Basal ganglia shape in de novo Parkinson's disease patients can predict the onset of Levodopa Induced Dyskinesias
Wednesday, August 30	13:00 - 15:00	1622	Cholinergic topography and clinical profile of early Parkinson's patients with GBA mutations
Wednesday, August 30	13:00 - 15:00	1623	Functional connectivity fingerprints in Parkinson's disease patients with hallucinations
Wednesday, August 30	13:00 - 15:00	1624	Progression of striatocortical dysfunction in Parkinson's disease: a longitudinal combined PET and fMRI study
Wednesday, August 30	13:00 - 15:00	1625	Diagnosis of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy with 7T-MRI substantia nigra imaging
Wednesday, August 30	13:00 - 15:00	1626	Disruption of Locus Coeruleus-Related Functional Networks in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1627	3D Multi-Delay pCASL to Understand Perfusion Changes in Patients with Parkinson's disease with Mild Cognitive Impairment
Wednesday, August 30	13:00 - 15:00	1628	Functional circuit abnormalities in Levodopa-induced dyskinesia in Parkinson's disease: A systematic review
Wednesday, August 30	13:00 - 15:00	1629	White matter lesion burden is associated with poorer clinical and driving outcomes in mild Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1630	Modulation of a subthalamic nucleus related network associated with motor response following Deep Brain Stimulation
Wednesday, August 30	13:00 - 15:00	1631	Early neurotransmitters changes in Parkinson's disease with REM sleep behaviour disorder
Wednesday, August 30	13:00 - 15:00	1632	Brain MRI volumetry analysis for patients with Parkinson's disease suffering from REM sleep behavior disorder: a pilot study
Wednesday, August 30	13:00 - 15:00	1633	A 20-Year Follow-Up Case Report with Three DaT-SPECT Scans in Parkinson's Disease Diagnosis
Wednesday, August 30	13:00 - 15:00	1634	Association of Increased Frontal White Matter A2A Receptor Availability with Decreased Frontal Gray Matter Volume in Patients with Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1635	Longitudinal changes in brain networks associated with clinical symptoms in idiopathic rapid eye movement sleep behavior disorder
Wednesday, August 30	13:00 - 15:00	1636	Neuromelanin related 7T MRI of the locus coeruleus differs between Parkinson's disease and controls
Wednesday, August 30	13:00 - 15:00	1637	Evidence of Central Autonomic Network dysfunction in orthostatic hypotension of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1638	Monoamine loss and depression in Parkinson's disease: a PET study
Wednesday, August 30	13:00 - 15:00	1639	Detection of Camptocormia Using Ultrasound in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1640	Increased free water in the putamen in idiopathic REM sleep behaviour disorder
Wednesday, August 30	13:00 - 15:00	1641	How helpful is the Swallow tail sign in Parkinson's disease?
Wednesday, August 30	13:00 - 15:00	1642	An Interesting Case of COVID-19 related Parkinsonism
Wednesday, August 30	13:00 - 15:00	1643	In vivo positive amyloid PET in a patient with PDD, always reliable?
Wednesday, August 30	13:00 - 15:00	1644	Agreement between swallow tail sign asymmetry and clinical laterality in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1645	Deep Brain Stimulation for Orthostatic Tremor: An observational study'
Wednesday, August 30	13:00 - 15:00	1646	Predicting clinical response after Gamma Knife thalamotomy in essential tremor
Wednesday, August 30	13:00 - 15:00	1647	Connectomics of Chronic VIM vs Rescue VIM/VO Deep Brain Stimulation in Essential Tremor
Wednesday, August 30	13:00 - 15:00	1648	Deep Brain Stimulation Outcomes in Underreported Dystonias: A Case Series
Wednesday, August 30	13:00 - 15:00	1649	Novel utilization of deep brain stimulation in the pedunculopontine nucleus for treatment of childhood-onset dystonia
Wednesday, August 30	13:00 - 15:00	1650	Tremor Reduction Using DBS: Outcomes of a Real-world, Prospective, Multicenter Essential Tremor Registry

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1652	Success of MRI-guided focused ultrasound thalamotomy after failure of Gamma Knife radiosurgery for essential tremor
Wednesday, August 30	13:00 - 15:00	1653	Staged and simultaneous bilateral MRI-guided focused ultrasound treatment of essential tremor
Wednesday, August 30	13:00 - 15:00	1654	MRgFUS thalamotomy in dystonic and essential tremor: a prospective study with one year follow up
Wednesday, August 30	13:00 - 15:00	1655	Clinical accuracy of Medtronic's Percept built in longevity estimate algorithm following device exchange.
Wednesday, August 30	13:00 - 15:00	1656	Improved Tremor Response to Focused Ultrasound Thalamotomy
Wednesday, August 30	13:00 - 15:00	1657	Active contact proximity to the CTT predicts initial therapeutic current requirement in DBS for ET: an application of 7T MRI
Wednesday, August 30	13:00 - 15:00	1658	Neuropsychological Outcomes After Bilateral Focused Ultrasound Thalamotomy within Essential Tremor
Wednesday, August 30	13:00 - 15:00	1659	The efficacy of thalamic and pallidal deep brain stimulation rescue leads in dystonic tremor depends on the affected body region - a case series
Wednesday, August 30	13:00 - 15:00	1660	Outcomes of Focused Ultrasound Thalamotomy in Tremor Syndromes
Wednesday, August 30	13:00 - 15:00	1661	Is there a common structural network for stimulation-induced dysarthria in subthalamic and thalamic deep brain stimulation?
Wednesday, August 30	13:00 - 15:00	1662	Long-term outcomes of deep brain stimulation for VPS16-related dystonia: A multi-center international study
Wednesday, August 30	13:00 - 15:00	1663	Double-blind, randomized, crossover clinical trial to compare VIM vs PSA deep brain stimulation in patients with disabling essential tremor. Preliminary results.
Wednesday, August 30	13:00 - 15:00	1665	Focused ultrasound as rescue treatment of essential tremor after deep brain stimulation.
Wednesday, August 30	13:00 - 15:00	1666	Safety and efficacy of focused ultrasound thalamotomy in essential tremor: a real scenario within the public health system.
Wednesday, August 30	13:00 - 15:00	1667	Bilateral Globus Pallidus Internus Deep Brain Stimulation in Progressive Dystonia in Mohr-Tranebjaerg Syndrome: Case Report and Review
Wednesday, August 30	13:00 - 15:00	1668	Apparition of a thalamic hand after focused ultrasound thalamotomy
Wednesday, August 30	13:00 - 15:00	1669	Long-term follow up of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration Syndrome: two case reports
Wednesday, August 30	13:00 - 15:00	1670	Efficacy of emergency deep brain stimulation in the Globus pallidus pars interna (GPI-DBS) for dystonic storm in an adult patient with de novo GNAO1-Mutation
Wednesday, August 30	13:00 - 15:00	1671	Pallidal DBS improves myoclonus in 2 patients with post-hypoxic myoclonus
Wednesday, August 30	13:00 - 15:00	1672	A case of dystonia-predominant spinocerebellar ataxia type 3 treated with bilateral deep brain stimulation to the globus pallidus internal segment
Wednesday, August 30	13:00 - 15:00	1673	Dual globus pallidus internus and subthalamic nucleus deep brain stimulation for medically refractory craniocervical dystonia: a case report
Wednesday, August 30	13:00 - 15:00	1675	Effect of Deep Brain Stimulation on the Motor Profile of Parkinson's Disease in Egypt; A Developing Country Experience
Wednesday, August 30	13:00 - 15:00	1676	Effects of GBA1 mutations and STN-DBS on response inhibition in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1677	Reliability of brainsense technology as compared to SoC in STN DBS programming
Wednesday, August 30	13:00 - 15:00	1678	Unveiling the role of subthalamic nucleus stimulation on freezing of gait in Parkinson disease using wearable sensors
Wednesday, August 30	13:00 - 15:00	1679	Can radiofrequency lesion be better than DBS?
Wednesday, August 30	13:00 - 15:00	1680	Evoked resonant neural activity in Globus Pallidus vs. Subthalamic Nucleus of patients with Parkinson's Disease, preliminary results
Wednesday, August 30	13:00 - 15:00	1681	Moving beyond trial and error: a strategy for anatomically informed contact selection in subthalamic deep brain stimulation for Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1682	Is STN a good target for decrease off period by DBS, Gpi – for reduction of dyskinesia in PD patients?
Wednesday, August 30	13:00 - 15:00	1683	Long-term outcomes after subthalamic nucleus deep brain stimulation (STN-DBS) in patients with Parkinson's Disease (PD) in Singapore
Wednesday, August 30	13:00 - 15:00	1684	DBS Stim Analyzer: An Innovative Tool for Analysis of Chronic Local Field Potential Sensing Data in Deep Brain Stimulation
Wednesday, August 30	13:00 - 15:00	1685	Spinal cord stimulation for gait in Parkinsons disease in subthreshold settings
Wednesday, August 30	13:00 - 15:00	1686	Subthalamic Nucleus Deep Brain Stimulation in GBA-associated Parkinson Disease: Cognitive and motor follow-up of two clinical cases

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1687	MDS-UPDRS III Off Severity Level changes as a marker of DBS response
Wednesday, August 30	13:00 - 15:00	1688	Theoretical Definition of DBS Electrode Misplacement
Wednesday, August 30	13:00 - 15:00	1689	APOE-ε4 status and cognitive decline after subthalamic nucleus-deep brain stimulation in Parkinson's disease: preliminary results of the GENEPARK-DBS study
Wednesday, August 30	13:00 - 15:00	1690	Single-center experience of deep brain stimulation (DBS) surgery in Malaysia
Wednesday, August 30	13:00 - 15:00	1691	Preoperative Dyskinesia Impacts Postoperative Quality of Life in PD Patients with Subthalamic Deep Brain Stimulation
Wednesday, August 30	13:00 - 15:00	1692	Short and long-term effects of deep brain stimulation on cognition in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1693	The impact on religiosity following Deep Brain Stimulation (DBS) in patients with Essential Tremor (ET) and Parkinson's Disease (PD)
Wednesday, August 30	13:00 - 15:00	1694	MR-guided focused ultrasound pallidothalamic tractotomy in non-tremor dominant (akinetic-rigid) Parkinson's disease treatment
Wednesday, August 30	13:00 - 15:00	1695	Pallidal or subthalamic DBS for advanced Parkinson's disease in the era of high-resolution MRI
Wednesday, August 30	13:00 - 15:00	1696	Factors influencing voice function after deep brain stimulation in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1697	Pre-surgical correlates of QoL (PDQ-39) in a DBS eligible PD population
Wednesday, August 30	13:00 - 15:00	1698	Local field potential changes by the patient's conditions; 1-year follow-up of adaptive deep brain stimulation in the real world.
Wednesday, August 30	13:00 - 15:00	1699	Characteristics of cases in which stimulation was programmed for multiple targets in deep brain stimulation therapy for Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1700	Effects of combined subthalamic and dorsolateral nigral deep brain stimulation on gait performance in Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1701	Comparing the outcome under General Anaesthesia (GA) and Monitored Anesthesia Care (MAC) of Subthalamic Nucleus (STN) - Deep Brain Stimulation (DBS) Surgery for Parkinson's Disease (PD) in
Wednesday, August 30	13:00 - 15:00	1702	Clinical implication of small vessel disease burden on deep brain stimulation outcome in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1703	Deep Brain Stimulation in Parkinson's Disease: real-world outcomes at a single centre
Wednesday, August 30	13:00 - 15:00	1704	Utility of neurophysiological markers in clinical management of subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD)-a case report.
Wednesday, August 30	13:00 - 15:00	1705	Image-guided programing in useful in DBS for Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1706	Differences of social and clinical factors related with distribution of DBS in Mexican PD population
Wednesday, August 30	13:00 - 15:00	1707	Can the Ohm's law predict the amplitude of neurostimulation when adapting systems in deep brain stimulation?
Wednesday, August 30	13:00 - 15:00	1708	Adaptive Deep Brain Stimulation for Parkinson's Disease: from tolerability to patient preference and clinical outcomes
Wednesday, August 30	13:00 - 15:00	1709	Preoperative trajectory planning is important to minimize intracerebral hemorrhage after deep brain stimulation, in comparison with ventricle peritoneal shunt.
Wednesday, August 30	13:00 - 15:00	1710	Optimal topographic characteristics of focused ultrasound unilateral thalamotomy for tremor-dominant Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1711	Bilateral staged MRI-guided focused ultrasound subthalamotomy for Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1712	Microelectrode recording with subthalamic nuclei deep brain stimulation encompass neuro-electro physiological beta oscillations footmarks in Parkinson's cardinal motor symptoms sub-types
Wednesday, August 30	13:00 - 15:00	1713	Intra operative mer with stn-dbs in local and globally anesthetized Parkinson's analysis: a melancholic nostalgia group study
Wednesday, August 30	13:00 - 15:00	1714	At-home adaptive deep brain stimulation improves motor fluctuations and quality of life in patients with Parkinson's disease: a single-blind randomized study
Wednesday, August 30	13:00 - 15:00	1715	Ethnic and Gender Disparities in Access to Deep Brain Stimulation for Parkinson's Disease Among Participants in C-OPN
Wednesday, August 30	13:00 - 15:00	1717	"Grab-the-lock test " – A novel clinical test for identification of dorsolateral Subthalamic nucleus [STN] during deep brain stimulation [DBS]
Wednesday, August 30	13:00 - 15:00	1718	Utility and safety of same day discharge after Deep Brain Stimulator Electrode Implantation: a feasibility study
Wednesday, August 30	13:00 - 15:00	1719	MER length as a predictor of motor and non-motor outcomes of STN DBS in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1720	Deep brain stimulation and fusion technologies: a synthesis study

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1721	Differential Spatiotemporal Gait Effects with Frequency and Dopaminergic Modulation in STN-DBS
Wednesday, August 30	13:00 - 15:00	1722	Deep brain stimulation for movement disorders: Assessing disparities in access to care
Wednesday, August 30	13:00 - 15:00	1723	Does beta band activity correlate with electrode location within the STN in postoperative processed images?
Wednesday, August 30	13:00 - 15:00	1724	Efficacy of subthalamic nucleus deep brain stimulation in Parkinson's disease: A preliminary Thailand experience
Wednesday, August 30	13:00 - 15:00	1725	Postoperative change of local field potentials of subthalamic nucleus during and after period of microlesion effect of implantation of deep brain stimulation lead.
Wednesday, August 30	13:00 - 15:00	1726	Directional deep brain stimulation therapy in the long term
Wednesday, August 30	13:00 - 15:00	1727	Post-operative imaging findings in deep brain stimulation
Wednesday, August 30	13:00 - 15:00	1728	Advanced programming strategies in subthalamic DBS: Just a gimmick or well-established in clinical routine?
Wednesday, August 30	13:00 - 15:00	1729	Assessing the optimal pallidal target in deep brain stimulation for Parkinson's disease: A single-center retrospective review
Wednesday, August 30	13:00 - 15:00	1730	Preoperative motor deficits and depressive symptoms predict quality of life in patients with Parkinson's disease at different time points after surgery for subthalamic stimulation.
Wednesday, August 30	13:00 - 15:00	1731	Effects of Unilateral and Bilateral DBS of STN, GPi on Voice in PD Patients
Wednesday, August 30	13:00 - 15:00	1732	A retrospective comparison of functional and quality of life outcomes in DBS patients implanted via awake or asleep surgery: the Rush University Medical Center experience
Wednesday, August 30	13:00 - 15:00	1733	Local field potentials in the subthalamic nucleus of patients with Parkinson's disease - Effect of the deep brain stimulation
Wednesday, August 30	13:00 - 15:00	1734	Neuropsychological and quality of life outcome comparison after awake and asleep pallidal deep brain stimulation (DBS) surgery for Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1735	Deep brain stimulation for advanced Parkinson's disease: Initial experience in Varna, Bulgaria
Wednesday, August 30	13:00 - 15:00	1736	Spiral Tunneling Technique for passing electrode lead for Deep Brain Stimulation(DBS) surgery in Parkinson's disease(PD)
Wednesday, August 30	13:00 - 15:00	1737	Real-World Outcomes with Directional Deep Brain Stimulation (DBS) Systems: Awake versus Asleep Lead Placement
Wednesday, August 30	13:00 - 15:00	1738	Comparing Change in Motor and ADL Rating Scales after DBS in Parkinson's disease, Dystonia and Tremor
Wednesday, August 30	13:00 - 15:00	1739	AI-Guided Microelectrode Recording for GPi DBS in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1740	Comparative Analysis of Stepwise Unilateral and Simultaneous Bilateral Deep Brain Stimulator Electrode Placement for Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1741	Quantifying the value of multimodal MRI in outcomes prediction for STN DBS in PD
Wednesday, August 30	13:00 - 15:00	1742	Hypnosis for Deep Brain Stimulator Surgery
Wednesday, August 30	13:00 - 15:00	1744	Rapid cognitive decline and new-onset psychosis after GPi DBS in a severe GBA mutation carrier: a case demonstrating the importance of genetic screening pre-DBS
Wednesday, August 30	13:00 - 15:00	1745	Stepwise Dual-Target MR-guided Focused Ultrasound in A Patient with Advanced Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1746	Characterizing the neural response to electrical brain stimulation with spatiotemporal precision in mice.
Wednesday, August 30	13:00 - 15:00	1747	Mobile Brain / Body Imaging in early Parkinson's Disease: the Twin Brain project
Wednesday, August 30	13:00 - 15:00	1748	Predicting ALS progression using remote sensor-based assessments
Wednesday, August 30	13:00 - 15:00	1749	Continuous estimation of Parkinson's on-off states using wearable devices
Wednesday, August 30	13:00 - 15:00	1750	Detecting Changes in Parkinson's Motor Symptom Patterns Using Wearable Devices
Wednesday, August 30	13:00 - 15:00	1751	Text entry as a digital outcome in Parkinson's disease patients (TEXT-PD): results from two exploratory studies
Wednesday, August 30	13:00 - 15:00	1752	Using wearable wireless technology to understand the natural history of adrenomyeloneuropathy in both clinic and home settings: 1-year follow-up in the CYGNET study
Wednesday, August 30	13:00 - 15:00	1753	Mobile and electronic health-supported physical activity in Parkinson's disease: A scoping review
Wednesday, August 30	13:00 - 15:00	1754	Enhanced sensitivity to bradykinesia progression using digital health technologies in early Parkinson's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1755	Normative data for the Vietnamese smell identification test
Wednesday, August 30	13:00 - 15:00	1756	A new synchronization method between inertial signals and local field potentials
Wednesday, August 30	13:00 - 15:00	1757	How do people with Parkinson's disease experience self-optimization of treatment using digitally supported symptom monitoring?
Wednesday, August 30	13:00 - 15:00	1758	Predictive model for Identification of device-aided therapy (DAT) Candidates in Parkinson's Disease (DELIST-PD Study)
Wednesday, August 30	13:00 - 15:00	1759	A Novel Real Time Algorithm to Predict Freezing of Gait in Parkinson's Patients Using Wearable Mobility Sensors Data
Wednesday, August 30	13:00 - 15:00	1760	Teleprogramming Reduces the Time Needed to Optimize DBS Therapy: Results from the ROAM-DBS study
Wednesday, August 30	13:00 - 15:00	1761	Performance of commercial EEG wearable for sleep classification in Parkinson disease
Wednesday, August 30	13:00 - 15:00	1762	Quantification motor improvement from levodopa carbidopa infusion gel therapy in patients with Parkinson's disease using a wearable device.
Wednesday, August 30	13:00 - 15:00	1763	Telemedicine challenges in the management of patients with Parkinson's disease in Central Asia.
Wednesday, August 30	13:00 - 15:00	1765	WATCH-PD: Longitudinal Digital Assessments in Early Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1766	Comparision of objective Parkinson's disease monitoring systems and the interpretations of results
Wednesday, August 30	13:00 - 15:00	1767	Detection of freezing of gait in people with Parkinson's disease using novel deep learning approaches.
Wednesday, August 30	13:00 - 15:00	1768	Reliability and validity of automatedly generated vowel space metrics as biomarkers of articulatory impairment severity and progression in early Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1769	Actigraphy wear compliance across CNS disorders
Wednesday, August 30	13:00 - 15:00	1770	Words Spoken Daily: A Novel Measure of Cognition
Wednesday, August 30	13:00 - 15:00	1771	A framework to standardize gait study protocols in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1772	Is cognitive function related to daily life gait and turning in people with Parkinson's disease?
Wednesday, August 30	13:00 - 15:00	1773	Stability of beta oscillations during aDBS in Parkinson's disease: a methodology for reliable assessment
Wednesday, August 30	13:00 - 15:00	1774	Topical Botulinum-Toxin-like Alternatives: A Systematic Literature Review
Wednesday, August 30	13:00 - 15:00	1775	The predictive potential of circular walking in prodromal Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1776	Digital mobility sub-study in the Parkinson's Progressive Marker Initiative (PPMI) study.
Wednesday, August 30	13:00 - 15:00	1777	Association of real-world wearable mobility measures with Parkinson's disease severity and disease progression
Wednesday, August 30	13:00 - 15:00	1778	Co-designing Digital Technologies to improve Clinical Care in People with Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1779	An Open-Access Model for Parkinson's Disease Progression
Wednesday, August 30	13:00 - 15:00	1780	COPS: Continuous Observation of Parkinsonian Symptoms – A prospective data acquisition study using wearable accelerometry
Wednesday, August 30	13:00 - 15:00	1783	Is it safe to switch from constant voltage to constant current with a mixed Internal Pulse Generator in deep brain stimulation
Wednesday, August 30	13:00 - 15:00	1784	Normative values for the Instrumented Timed Up and Go test in Parkinsonian populations
Wednesday, August 30	13:00 - 15:00	1785	Analysis of a wearable sensor, STAT-on®, to detect motor complications in patients with Parkinson's disease (PDp)
Wednesday, August 30	13:00 - 15:00	1786	A cross-sectional study of telemedicine use during the COVID-19 pandemic in people with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1787	Referral patterns from primary care physicians to specialists among people with Parkinson's disease or a Parkinson's disease-related disorder
Wednesday, August 30	13:00 - 15:00	1788	Unsupervised multimodal digital assessment of fatigue and sleep disorders in Parkinson's disease: the IDEA-FAST study
Wednesday, August 30	13:00 - 15:00	1789	PD.ai – Detection of Parkinson's Disease with gait-based biomarkers using AI techniques
Wednesday, August 30	13:00 - 15:00	1790	Introduction of a Parkinson's Disease Virtual Ward Round

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1791	Evaluating continuous monitoring in Parkinson's disease through real-world, device-reported outcomes.
Wednesday, August 30	13:00 - 15:00	1792	Positive and negative myoclonus monitoring using ambulatory surface EMG and 3D accelerometry
Wednesday, August 30	13:00 - 15:00	1793	Sensor-based digital measurement of gait and wrist pronation-supination in clinically-defined classes of Parkinson's disease progression identified by unsupervised clustering
Wednesday, August 30	13:00 - 15:00	1794	A pilot study to prepare patients for doctor's consultation based on the NMS-Quest and a wearable medical device
Wednesday, August 30	13:00 - 15:00	1795	Automatic Detection of Parkinson's Disease by Voice Analysis
Wednesday, August 30	13:00 - 15:00	1796	Continuous algorithmic insights into PD motor symptoms and individual treatment response
Wednesday, August 30	13:00 - 15:00	1798	The added value of accelerometric monitoring during thalamotomy
Wednesday, August 30	13:00 - 15:00	1799	Real-life monitoring of Parkinson's disease tremor: does the non-tremor subtype really exist?
Wednesday, August 30	13:00 - 15:00	1800	Development and quantified evaluation of a continuous smartphone app-based monitoring approach to individualize Parkinson's disease management.
Wednesday, August 30	13:00 - 15:00	1801	Smartphone App-Based Stroop Test as a surrogate for impaired self-awareness in Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1802	Building and evaluating a speech biomarker from 2-seconds sustained phonation to detect and monitor Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1803	Real-life heart rate assessment: a digital biomarker for autonomic dysfunction in early Parkinson's disease?
Wednesday, August 30	13:00 - 15:00	1805	Touchscreen nQ application as a remote digital biomarker in Parkinson disease
Wednesday, August 30	13:00 - 15:00	1806	turning alterations detected by mobile health technology in idiopathic rem sleep behavioral disorders
Wednesday, August 30	13:00 - 15:00	1807	Curved Trajectories in Stereotactic Neurosurgery
Wednesday, August 30	13:00 - 15:00	1808	Contactless assessment of rigidity in Parkinson's disease using machine vision and machine learning
Wednesday, August 30	13:00 - 15:00	1809	Challenges in patient-physician communication during limited time appointments in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1810	Case report on the use of a High Frequency Vibrotactile Stimulation and Cueing Device over 4 months in a patient with Parkinson's Disease and refractory symptoms
Category: Allied Healthcare, Physical Therapy, Rehabilitation and Quality of Life/Caregiver Burden (1813 – 1930)			
Wednesday, August 30	13:00 - 15:00	1813	Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats
Wednesday, August 30	13:00 - 15:00	1814	Role of nanoparticles of berberine on oxidative stress in nigrostriatal tissue and neurobehavioral characteristics in rotenone induced animal model of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1817	Parkinson's disease and Spatiotemporal gait parameters: A Narrative Review of Effect of Climate Changes as a Mediating Effect
Wednesday, August 30	13:00 - 15:00	1818	Association between Stress and Bruxism in Egyptian University Female Students Throughout Their Final Exam Period
Wednesday, August 30	13:00 - 15:00	1819	Comparative Effects of Medical Treatment and Tension Deactivation Via Electromyography Biofeedback Intervention to Improve Maximum Mouth Opening in Individuals With Bruxism
Wednesday, August 30	13:00 - 15:00	1820	A baseline study for the first year of a diverse Parkinson's Disease interdisciplinary clinic
Wednesday, August 30	13:00 - 15:00	1821	Can a global measure of cognition be used to inform balance interventions in Parkinson's disease?
Wednesday, August 30	13:00 - 15:00	1822	Online education to promote compensation strategies for gait impairments in underserved Parkinson populations
Wednesday, August 30	13:00 - 15:00	1823	Screening risk of falls in Parkinson's disease population living in underserved areas
Wednesday, August 30	13:00 - 15:00	1824	A qualitative study exploring the feasibility of exergames among persons with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1825	Dyspnea and quality of life in Parkinson's: a mixed methods study
Wednesday, August 30	13:00 - 15:00	1826	Experiences of People with Parkinson's Disease use of a wearable technology for the management of drooling; qualitative insights from the Cue Band study
Wednesday, August 30	13:00 - 15:00	1827	How do recently diagnosed individuals with Parkinson's self-monitor their Parkinson's symptoms between consultations?
Wednesday, August 30	13:00 - 15:00	1828	Expiratory strength in Parkinson's disease patients? Does time matter?

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1829	Movement Disorders (MD) Specialist Nurse pilot project in Australia's Northern Territory (NT): One year of experience.
Wednesday, August 30	13:00 - 15:00	1830	Underutilization of Neurology and Rehabilitation Services among People with Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1831	The Value of Physician Assistant/Associates (PAs) in a Movement Disorder Clinic
Wednesday, August 30	13:00 - 15:00	1832	Relationship between sleep quality, fear of fall and falls history in people with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1833	The effect of exercise training on motor and non-motor symptoms in people with Essential Tremor; a feasibility pilot study
Wednesday, August 30	13:00 - 15:00	1834	Effects of an online 12-week Tai Chi intervention on gait and postural stability in individuals with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1835	Correlation of Functional Motor Assessments Used at Parkinson's disease by Physiotherapists in Clinical Practice
Wednesday, August 30	13:00 - 15:00	1836	A Need for Improving the Diet Quality of Individuals with Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1837	Review of NPO status on admitted PD patient outcomes
Wednesday, August 30	13:00 - 15:00	1838	PD-PRIDE: Healthcare experiences of people identifying as LGBTQ+ with Parkinson disease: A qualitative study preliminary analysis
Wednesday, August 30	13:00 - 15:00	1839	Certification for advanced practice providers working in movement disorders expands access to quality expert and specialized care.
Wednesday, August 30	13:00 - 15:00	1840	Ethical considerations in person-centered Parkinson's disease care: a cross-national comparison of patients' perspectives
Wednesday, August 30	13:00 - 15:00	1841	An Exploration of the Psychosocial Impact of Receiving Treatment at a Sialorrhea Clinic for People with Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1843	Quantitative analysis of speech diadochokinetic rate in hereditary spastic paraplegia SPG3A
Wednesday, August 30	13:00 - 15:00	1844	Combination of clinical and gait measures to classify fallers and non-fallers in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1845	Taking the driver's seat on Parkinson's care
Wednesday, August 30	13:00 - 15:00	1846	Intrarater and interrater reliability of the 3 meter backward walk test in individuals with Parkinson disease.
Wednesday, August 30	13:00 - 15:00	1847	Relationship between the Montreal Cognitive Assessment and clinical gait assessments in individuals with Parkinson disease
Wednesday, August 30	13:00 - 15:00	1848	Correlations between bradykinesia and acoustic speech variables in advanced Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1849	Bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease: preoperative predictors of speech worsening
Wednesday, August 30	13:00 - 15:00	1850	Short-term, intermittent exercise program improved the balance and gait in patients with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1851	The Effects of Consecutive and Integrated Postural-Cognitive Training on Dual-task Walking in Parkinson's Disease with Mild Cognitive Impairment: EEG Relative Power and Clinical Implication
Wednesday, August 30	13:00 - 15:00	1852	Cardio-respiratory fitness is associated with corticospinal excitability and motor learning in Parkinson's Disease.
Wednesday, August 30	13:00 - 15:00	1853	Feasibility and efficacy of a multidisciplinary telemedicine intervention program to reduce falls and gait impairment in Parkinson's disease (NCT04694443).
Wednesday, August 30	13:00 - 15:00	1854	Make-up for Parkinson's: a randomized control trial
Wednesday, August 30	13:00 - 15:00	1855	Technological visuo-cognitive training in Parkinson's disease: Preliminary findings from a pilot randomised controlled trial
Wednesday, August 30	13:00 - 15:00	1856	The association between compliance and the effects of home-based touchscreen training in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1857	Effectiveness of trampoline training on non-motor outcomes in people with Parkinson's: preliminary study results
Wednesday, August 30	13:00 - 15:00	1858	Narrative review of the efficacy of the efficacy of transcranial magnetic stimulation with patients with Parkinson disease.
Wednesday, August 30	13:00 - 15:00	1859	Rehabilitation robot-assisted gait training for Parkinson's disease: A systematic review and meta-analysis of its effects on lower extremity dyskinesia and motor function
Wednesday, August 30	13:00 - 15:00	1860	Effects and neural mechanisms of training involving rhythmic auditory stimulation on upper-limb movements in patients with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1861	An international consensus statement for rehabilitation care in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1862	Understanding rehabilitation care utilization in Parkinson's disease

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1863	Effectiveness of core muscle exercise training for Parkinson's disease patients with trunk side-bending
Wednesday, August 30	13:00 - 15:00	1864	The Effects of Motor Imagery Therapy in the rehabilitation of patients with Parkinson's Disease: A Systematic Review
Wednesday, August 30	13:00 - 15:00	1865	A systematic review of Action Observation Therapy for Parkinson's disease rehabilitation.
Wednesday, August 30	13:00 - 15:00	1866	The efficacy of transcutaneous tibial nerve stimulation for Parkinson's urinary problems: A Systematic review
Wednesday, August 30	13:00 - 15:00	1867	Validity and reliability of muscle peak power testing in persons with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1868	The association between perceived walking difficulties and gait speed in people with drug naïve/early PD
Wednesday, August 30	13:00 - 15:00	1869	Neurologic Music Therapy (NMT) and Non-Invasive Stimulation for Upper Extremity Performance in Patients with Corticobasal Syndrome (CBS)
Wednesday, August 30	13:00 - 15:00	1870	Prediction of turning characteristics parameters into Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1871	Effects of physical exercise interventions on cognitive function in Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials
Wednesday, August 30	13:00 - 15:00	1873	Does fatigue in Parkinson's disease impact one's physical function in daily live?
Wednesday, August 30	13:00 - 15:00	1874	Effectiveness of speech therapy in patients with Parkinson's disease – a randomized controlled trial
Wednesday, August 30	13:00 - 15:00	1875	Analysis of the relationship between acoustic measures and VHI score
Wednesday, August 30	13:00 - 15:00	1876	Novel application of the Timed Up and Go Scale as a reliable tool to measure functional improvement and fall prevention after inpatient Parkinson's Disease specific rehabilitation for
Wednesday, August 30	13:00 - 15:00	1877	Effects of ankle dorsiflexion training on anticipatory postural adjustments during gait initiation of patients with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1878	Association between Adherence to Physical Activity Guidelines and Health Literacy in Patients with Parkinson's Disease: An Online Web Survey
Wednesday, August 30	13:00 - 15:00	1879	Turning 360 degrees in standing - associations with perceived walking difficulties and comfortable gait speed in people with drug naïve/early Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1880	The effectiveness and usability of online rehabilitation for Parkinson's Disease patients
Wednesday, August 30	13:00 - 15:00	1881	A single session of aerobic exercise increase EEG gamma band in the motor and sensorimotor areas during usual walking in people with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1882	Parkinson's disease: cardiorespiratory fitness, respiratory muscle strength and lung capacity after a high-intensity Aquatic Physiotherapeutic Exercise Program (APEP/PEFA)
Wednesday, August 30	13:00 - 15:00	1883	Low Vision Occupational Therapy for Parkinson's Disease – A Pilot Study at the University of Alabama at Birmingham
Wednesday, August 30	13:00 - 15:00	1884	A non-expensive bidimensional assessment can detect subtle alterations in gait performance in people in the early stages of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1885	The Efficacy of Virtual Reality Interventions on Gait and Balance in Patients with Parkinson Disease. A systematic review of randomized clinical trials with meta-analysis.
Wednesday, August 30	13:00 - 15:00	1886	New wearable technology for quantification of freezing of gait in school going adolescent with pediatric movement disorders
Wednesday, August 30	13:00 - 15:00	1887	Use of the Dysphagia Handicap Index (DHI) patient reported outcomes measure in Parkinson disease and cervical dystonia
Wednesday, August 30	13:00 - 15:00	1888	Exercise based priming and virtual reality for optimizing neuroplasticity and balance in Parkinson's disease.
Wednesday, August 30	13:00 - 15:00	1889	Parkinson's disease and physiotherapy: perspectives in functional health education and innovation in digital media
Wednesday, August 30	13:00 - 15:00	1890	The effects of one session of dry needling on vital capacity in people with Parkinson's Disease
Wednesday, August 30	13:00 - 15:00	1891	High Intensity Interval Training for people with Parkinson's disease: individual response patterns of (non-)motor symptoms and blood-based biomarkers - a crossover single-case experimental design
Wednesday, August 30	13:00 - 15:00	1892	A novel motor-learning based dysphagia treatment approach in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1893	Effects of motor and cognitive complex training on obstacle-crossing ability in participants with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1894	Implementation and effects of telehealth exercise therapy on satisfaction and Mobility In persons with Parkinson's.
Wednesday, August 30	13:00 - 15:00	1896	Be aware of Involuntary Emotional Expressive Disorder: a neurological syndrome, not a mood disorder
Wednesday, August 30	13:00 - 15:00	1897	Protective potential of laughter yoga and clapping exercise on stress level and motor functions in Parkinson's disease patients with type 2 diabetes

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1899	Parkinson's disease management in the community
Wednesday, August 30	13:00 - 15:00	1900	Coping strategies in people with Parkinson disease (PwP)
Wednesday, August 30	13:00 - 15:00	1901	Validation of the EQ-5D-3L in Spinocerebellar Ataxia (SCA)
Wednesday, August 30	13:00 - 15:00	1902	Relationship of health-related quality of life (HRQoL) patterns with clinical diagnosis in patients with spinocerebellar ataxia (SCA) - A latent class analysis
Wednesday, August 30	13:00 - 15:00	1903	Was the deep brain stimulation surgery successful? Is it the same for the physician and the patient ?
Wednesday, August 30	13:00 - 15:00	1904	self-compassion, trait worry and sleep in parkinson's disease (PD) patients
Wednesday, August 30	13:00 - 15:00	1905	Patient perspectives on symptoms and functional impacts to inform a digital assessment of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1907	Gender inequities in people living with PD and their caregivers' burden in Mexican population
Wednesday, August 30	13:00 - 15:00	1908	Prevalence of urinary symptoms and its impact on life quality in patients living with parkinson disease in a mexican population
Wednesday, August 30	13:00 - 15:00	1909	Keeping patients out of care facilities--- clozapine rescues Parkinson's patients with troublesome psychosis unresponsive to quetiapine and pimavanserin.
Wednesday, August 30	13:00 - 15:00	1910	Financial impact of Parkinson's disease on women and men
Wednesday, August 30	13:00 - 15:00	1911	Comparative study of Non-Motor Symptoms and it's correlation with Quality of Life in Parkinson's disease and Atypical Parkinsonism
Wednesday, August 30	13:00 - 15:00	1912	Change in quality of Life, depression, and lived experiences of women with Parkinson's disease after deep drain stimulation
Wednesday, August 30	13:00 - 15:00	1913	Relationship between agricultural vulnerability to organic compound fungicides and herbicides and Parkinson's disease incidence in rural population in northern India
Wednesday, August 30	13:00 - 15:00	1914	Feasibility and acceptability of implementing dignity therapy as a supportive intervention for people with movement disorders.
Wednesday, August 30	13:00 - 15:00	1915	Development of a health-related quality-of-life (HR-QoL) questionnaire for hereditary spastic paraplegia (HSP) patients and caregivers.
Wednesday, August 30	13:00 - 15:00	1916	PARKinSOUND: Impact of participation in an orchestra in patients with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1917	Social and gender inequity on overall survival and access to deep brain stimulation in Parkinson disease patients in Colombia
Wednesday, August 30	13:00 - 15:00	1918	Burden and management of tardive dyskinesia (TD): a cross-sectional international survey study to assess the perceptions and experiences of patients with TD
Wednesday, August 30	13:00 - 15:00	1919	Health status of Lewy Body Dementia caregivers predicts psychological response to peer mentoring intervention
Wednesday, August 30	13:00 - 15:00	1920	Multi-stakeholder focus group study to develop recommendations of ways to improve treatment burden and capacity in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1921	Healthcare experiences of People with Parkinson's Disease (PwP) during COVID-19 pandemic
Wednesday, August 30	13:00 - 15:00	1922	Factors influencing health-related quality of life of patients with spinocerebellar ataxia
Wednesday, August 30	13:00 - 15:00	1923	Validity and responsiveness of the EQ-5D-3L in Friedreich-Ataxia
Wednesday, August 30	13:00 - 15:00	1924	Concealment of Parkinson's Disease: Prevalence and Impact on Health and Quality of Life
Wednesday, August 30	13:00 - 15:00	1925	Making the invisible visible: A qualitative interview study on the impact of young onset Parkinson's disease on (ex-)partners
Wednesday, August 30	13:00 - 15:00	1926	Neuropalliative communication curriculum: A review of the literature and needs assessment
Wednesday, August 30	13:00 - 15:00	1927	Caregiver burden in Parkinson disease: an updated scoping review
Wednesday, August 30	13:00 - 15:00	1928	Understanding Parkinson's Disease Patients' and Carepartners' Palliative Care Knowledge & Preferences
Wednesday, August 30	13:00 - 15:00	1929	Effects of a nurse-led Advance Care Planning and Care Coordination intervention in Parkinson's Disease – patient and family caregiver perspectives from a multicentre European study
Wednesday, August 30	13:00 - 15:00	1930	Palliative Care in Parkinson: a family caregiver's view. A PD-PAL Consortium initiative.
Category: Education, Other Topics (1931 – 1986)			
Wednesday, August 30	13:00 - 15:00	1931	Training an APRN in movement disorders: lessons learned

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1932	Development and Evaluation of a Digital Resource Library for Arkansans with Parkinson Disease and Their Caregivers
Wednesday, August 30	13:00 - 15:00	1933	A Parkinson's Manifesto for Europe
Wednesday, August 30	13:00 - 15:00	1934	Parkinson's Team Training is beneficial for new and established PD Centers
Wednesday, August 30	13:00 - 15:00	1935	Practices of neurologists in the management of Parkinson's disease patients in the Republic of Moldova
Wednesday, August 30	13:00 - 15:00	1936	Improving inpatient medication management in hospitalized Parkinson's patients
Wednesday, August 30	13:00 - 15:00	1937	IParkours : Role of the advanced practice nurse (APN) in the support/follow-up of parkinsonian patients.
Wednesday, August 30	13:00 - 15:00	1938	Pseudogout Mimicking Stiffness in Parkinson's Disease: A Case Report
Wednesday, August 30	13:00 - 15:00	1939	Age-associated changes in the striatal proteins in aging Asian-Indians
Wednesday, August 30	13:00 - 15:00	1940	The effect of anti-Parkinson's disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1941	Adequate hydration with personalized diet improves bowel function and mobility for people with Parkinson's (PwP's) on levodopa/carbidopa intestinal gel (LCIG) infusion therapy
Wednesday, August 30	13:00 - 15:00	1942	Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion
Wednesday, August 30	13:00 - 15:00	1943	The Quebec Parkinson Network (QPN): Interdisciplinary Collaboration in Parkinson's Disease and Related Disorders Research.
Wednesday, August 30	13:00 - 15:00	1944	Effect of the COVID-19 pandemic on gait and other motor and non-motor symptoms in people with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1945	Asian LRRK2 variants do not increase Likelihood Ratios derived from MDS prodromal Parkinson's Disease criteria in a community population
Wednesday, August 30	13:00 - 15:00	1946	Navigating Open Science in Canada with the Canadian Open Parkinson Network
Wednesday, August 30	13:00 - 15:00	1947	Measures of transcranial magnetic evoked potentials for prediction of response to ventriculoperitoneal shunt In normal pressure hydrocephalus
Wednesday, August 30	13:00 - 15:00	1948	Classification of Obstructive Sleep Apnea based on Statistical Features of the RR Interval using the Support Vector Machine Algorithm
Wednesday, August 30	13:00 - 15:00	1949	Serum levels of IL-1 β and interleukin 6 in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1950	Transforming Parkinson's Care in Africa: community engagement and involvement activities
Wednesday, August 30	13:00 - 15:00	1951	Predictors of death in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1952	From the Healthy Brain Ageing (HeBA) Cohort: Frequency of key risk factors for Parkinson in a European Cohort
Wednesday, August 30	13:00 - 15:00	1953	Needs assessment of patients with Parkinson's disease: a qualitative study
Wednesday, August 30	13:00 - 15:00	1954	Safety and performance of DBS primary cell IPG replacement: An interim report from the ADROIT study
Wednesday, August 30	13:00 - 15:00	1955	Integrating care coordination into telemedicine services provides a better patient experience than care coordination alone: Insights from a national neurodegenerative disease telemedicine program
Wednesday, August 30	13:00 - 15:00	1956	Education and the motor effects of dopamine loss in Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1957	The Healthy Brain Ageing (HeBA) Parkinson's disease risk survey: Study design and methods
Wednesday, August 30	13:00 - 15:00	1958	Characterization of gait variability of early Parkinson's disease and multiple system atrophy
Wednesday, August 30	13:00 - 15:00	1959	Towards smart glasses for improved care of individuals with Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1960	Variant frequencies in dystonia and Parkinson's disease genes cross phenotypic boundaries
Wednesday, August 30	13:00 - 15:00	1961	Validation and psychometric properties of the Thai version of the hemifacial spasm grading questionnaire (HFS score) for physician-assessed clinical involvement and patient-reported health-
Wednesday, August 30	13:00 - 15:00	1962	A retrospective comparison between EMG and US-guided botulinum injections for cervical dystonia
Wednesday, August 30	13:00 - 15:00	1963	From the Healthy Brain Ageing - HeBA - Cohort: Motivation for participating in the first online phase of HeBA
Wednesday, August 30	13:00 - 15:00	1964	Impact of culture on Impulse control disorders and correlation with levodopa-induced dyskinesia in Parkinson's disease in Egypt .

Presentation Date:	Presentation Time:	MDS Pub Number:	Title:
Wednesday, August 30	13:00 - 15:00	1965	Choroidal changes in Parkinson's disease: A longitudinal follow up study
Wednesday, August 30	13:00 - 15:00	1966	Evaluation of the effect of non-invasive therapies in Parkinson's Disease patients through the study of functional connectivity and Deep Learning techniques. (Preliminary results).
Wednesday, August 30	13:00 - 15:00	1967	Patients activation in people with Parkinson disease and its relation to personal factors
Wednesday, August 30	13:00 - 15:00	1968	Impact of Decreased Cognitive Function on the Risk of Falling in the Elderly
Wednesday, August 30	13:00 - 15:00	1969	SYNCHRONIZE: Real-world retrospective safety analysis in patients treated with onabotulinumtoxinA for more than one therapeutic indication
Wednesday, August 30	13:00 - 15:00	1970	Making Parkinson's care complete and global: an international survey of the "vitals" dashboard of Parkinson's disease
Wednesday, August 30	13:00 - 15:00	1971	Clinical Phenotypes and Imaging Localization of Movement Disorders after Acute Stroke
Wednesday, August 30	13:00 - 15:00	1972	Association between lifestyle and environmental factors with disease severity and age at onset in multi-ethnic Malaysian Parkinson's disease patients
Wednesday, August 30	13:00 - 15:00	1973	The spatial and spectral organization of thalamo-cortical connectivity in patients with essential tremor
Wednesday, August 30	13:00 - 15:00	1974	Effect of lower level laser therapy for neurogenic or non-neurogenic overactive bladder
Wednesday, August 30	13:00 - 15:00	1975	An European-Canadian multinational evaluation of access to care in Parkinson disease: a patient perspective
Wednesday, August 30	13:00 - 15:00	1976	Experience of Quality of Life in German Persons living with Parkinson's Disease: A Qualitative Exploration
Wednesday, August 30	13:00 - 15:00	1977	Stiff-person syndrome associated with anti-Yo1 antibodies: a case report
Wednesday, August 30	13:00 - 15:00	1978	Subacute Encephalopathy with Seizures in Alcohol Consumers (SESA) presenting as Focal Dyskinesias and Myoclonus
Wednesday, August 30	13:00 - 15:00	1979	Movement disorders in the setting of dengue infection in a rural medical teaching hospital in Gujarat, India
Wednesday, August 30	13:00 - 15:00	1980	Breast carcinoma presenting with anti-amphiphysin antibody-associated stiff-limb syndrome
Wednesday, August 30	13:00 - 15:00	1981	Meige Syndrome Following COVID Infection
Wednesday, August 30	13:00 - 15:00	1982	Tongue fasciculations and numbness: A case of calcifying pseudoneoplasm
Wednesday, August 30	13:00 - 15:00	1983	Complex movement disorder presentations of autoimmune encephalitis - recovery at 4 weeks versus 4 years
Wednesday, August 30	13:00 - 15:00	1984	Rapidly progressive fatal dystonia in an adult.
Wednesday, August 30	13:00 - 15:00	1985	Ataxia, deafness, aphonia associated with ANNA-1/"anti-Hu" and LUZP4 antibodies
Wednesday, August 30	13:00 - 15:00	1986	Case Report: Supranuclear Palsy and Increased Intraocular Pressure in Normal Pressure Hydrocephalus